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Georges Gilles de la Tourette was an individual of
great talent, subject to overexcitement and extraordinary
activity. He wrote books, research articles, communi-
cations, and historical papers in psychiatry and neurology,
but was well versed and interested in an even wider range
of subjects. Later in his life, a young paranoid woman who
was confined to a mental hospital shot him three times
while he was in a consulting room. One bullet hit him in
the head, and although the bullet was easily removed, it
was said he never fully recovered from his injury. Tourette
suffered from episodes of depression and mania in his last
years and died insane, most likely from syphilis.
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Gilles de la Tourette’s syndrome is a childhood-onset neuropsychiatric disorder
characterized by the presence of both multiple muscle movements and
vocalizations, referred to as motor and vocal tics. Tics vary greatly between
individuals with regard to severity and frequency. Also, tics show a typical waxing
and waning pattern over time within individuals. In addition to tics, many
individuals show associated behavioral abnormalities which may include
obsessions and compulsions, attention deficits, hyperactivity, impulsivity, and
social problems.
Once, tics were considered psychogenic phenomena. Together with nail biting
and bed watering, they were grouped among ‘child neurotic’ features.
Psychoanalysts linked motor and vocal tics to the repression of masturbatory
urges. Two early authors1 wrote that tics “always represent an expression of some
erotic desire, either the desire for physical gratification of a need for love or
affection, or for autoerotic pleasure.” According to these authors, eye blinks
should be read as symbolic for masturbation. In their view, the child learned early
on that a movement attracted attention, which made him willing to tolerate
ridicule and scorn, making tics difficult to treat. As a consequence, several forms
of psychotherapeutic treatments have been applied to tic disorder patients.
Because the involuntary movements were thought to represent the dramatization
of a conflict between instinctual desires and inhibitions, the tics themselves were
not considered to be the focus of treatment, but rather signs to be read on the
way to uncovering repressed psychosocial conflict.2
In modern views, psychological explanations for the presence of tics no
longer hold. Instead, the genetic background of tic disorders is well-established.
Also, much progress has been made in the field of neurochemistry and
neuroimaging. Evidence is available about the involvement of the basal ganglia
and related cortical structures in Tourette's syndrome. Furthermore,
abnormalities in neurotransmitter systems have been detailed. Notwithstanding
this progress, the exact pathogenesis of tic disorders remains largely unknown.
Some research findings suggest a central role for the involvement of
autoimmunity in the pathogenesis of tic disorders. Briefly, these seem to suggest
that infections may induce or reinforce tics and associated features in susceptible
individuals, possibly through the involvement of abnormal humoral immune
responses directed against self-tissue antigens. This possible role of immune
dysregulations in the pathogenesis of tic disorders is the central topic of the
present thesis.
Chapter 1 gives a review of research findings in favor of the involvement of
immune factors in tic disorders, and forms the theoretical framework of the
experiments described in this thesis. These experiments can be divided in a cross-
sectional (chapters 2 through 7) and a longitudinal part (chapters 8 through 10).
Apart from a study which investigates the social-behavioral problems of tic
disorder patients in relation to comorbid attention deficit/hyperactivity disorder
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and obsessive-compulsive disorder (chapter 2), the first, cross-sectional part
focuses on three laboratory assessments which may point to the involvement of
autoimmunity. First, a flow cytometry study (chapter 3) reports on overexpression
of the D8/17 surface marker on B lymphocytes in tic disorder patients, compared
to healthy subjects. D8/17 B cell overexpression is a putative susceptibility
marker of autoimmune sequelae in the aftermath of streptococcal infections. This
is followed by a reanalysis and alternative interpretation of the findings of this
flow cytometry study (chapter 4) and by a study on D8/17 B cell expression in a
contrast group, that is, patients with post-streptococcal arthritis (chapter 5). The
second laboratory parameter in the cross-sectional part of the experiments
constitutes the assessment of serum autoantibodies directed against brain self-
antigens, which may be a direct indicator of the involvement of autoimmunity.
Chapter 6 describes the results of this study in tic disorder patients, compared with
patients with autistic disorder, patients with obsessive-compulsive disorder, and
healthy subjects. The final cross-sectional laboratory measure involves the
metabolism of tryptophan through the kynurenine pathway (chapter 7). Pro-
inflammatory cytokines, most notably interferon-gamma, are known to stimulate the
enzyme indoleamine 2,3-dioxygenase, which promotes the breakdown of tryptophan
to kynurenine. This may lead to increased kynurenine levels, a well-established
marker of immune activation across a wide range of inflammatory conditions.
The longitudinal studies described in this thesis also look at three possible
factors. First, the association of infections with exacerbations of tic severity is
assessed in chapter 8. In contrast, the following chapter describes the possible influence
of small life events on the changing pattern of tic severity over time. Finally,
chapter 10 describes the effect of a therapeutic intervention, intravenously
administered immunoglobulins compared to a placebo condition.
The central question of this thesis is, whether or not immune factors play a role
in Tourette’s syndrome. An overall discussion of this issue is presented in chapter 11,
taking into account the various results of the experiments described in this thesis.
The next section briefly outlines the main concluding remarks, followed by a
summary in English and in Dutch.
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Abstract
We provide a review of recent research findings which support the involvement of
autoimmunity in childhood-onset tic disorders, in particular the presence of antineuronal
autoantibodies, D8/17 B lymphocyte overexpression, a marker of chorea associated with
streptococcal infection, and possible beneficial effects of immunomodulatory intervention.
One of the most controversial areas in this field is the validity of the proposed PANDAS
concept. Some researchers have delineated a putatively unique subgroup of patients from
the spectrum of illness encompassing Tourette’s syndrome and obsessive-compulsive
disorder, whose tics and obsessive-compulsive symptoms are shown to arise in response to
beta-hemolytic streptococcal infections. They designated it by the term pediatric
autoimmune neuropsychiatric disorders associated with streptococcal infections
(PANDAS). Herein, we additionally present pros and cons concerning the concept of
PANDAS. Finally, recommendations for future research directions are given.
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Introduction
Gilles de la Tourette's disorder, or Tourette's syndrome (TS), as it is mostly simply
referred to, is a neuropsychiatric disorder, characterized by the presence of both
motor and vocal tics. A tic is a sudden, rapid, recurrent, nonrhytmic, stereotyped
motor movement or vocalization (DSM-IV). Common examples of motor tics include
excessive eye blinking, nose twitching, head jerks, and tensing the abdomen, whereas
throat clearing, coughing, and sniffing are the most prevalent vocalizations. Tics
typically occur in bouts during the day,1 whereas the course of tics over a period of
months to years often waxes and wanes with regard to their severity.2 Furthermore,
the type of tics in an individual patient is typically changing, with some tics
disappearing and new ones appearing in the course of time. With increasing age,
however, symptoms tend to decrease in intensity and to show less variation over time
regarding both severity and type of tics.3 The age of onset of tics is mostly between
2 and 15 years with a median of 7.3 Facial tics are normally the initial symptom. Tics
are rather common in childhood, but are most often transient.4 Males are more
commonly affected than females.5 Movements generally decrease during sleep and
may be suppressed for short periods while the patient is awake.6 Transient tic
disorders are estimated to affect at least 5% of children between 7 and 11 years;
population studies estimate prevalence rates for full-blown TS between 2.9 and 5.2
cases per 10 000.5 Transient tic disorder, in which symptoms are required to last less
than 1 year, and chronic motor or chronic vocal tic disorder, in which only one type of
tics (either motor or vocal) is involved, are all thought to be etiologically closely related
to TS, thus making this DSM-IV based subclassification of tics into separate
categories rather artificial.
One interesting feature of TS is its well-known association with a wide range of
behavioral disorders and psychopathology.7 Attention deficit/hyperactivity disorder
(ADHD) is known to affect 50% of referred patients.8 Obsessive-compulsive
symptoms constitute another common cophenomenon of the spectrum of tic
disorders.9 Finally, many children show significant problems with social functioning.10
Currently, tics are diagnosed on clinical grounds alone. Though tic disorders are no
longer regarded as psychogenic, the pathogenesis is poorly understood. Circumstantial
evidence from neurochemical and imaging studies stresses the importance of basal
ganglia and cortico-striato-thalamo-cortical circuits.11
A high degree of heritability is characteristic of tic disorders. Several investigators
found that the pattern of vertical transmission within families fitted best to a mode of
inheritance of TS involving a single autosomal dominant locus with varying
penetrance. No such single gene defect has been found though, despite extensive
linkage studies covering most of the genome.12 Associations for markers within certain
chromosomal regions have been reported recently.13
Our lack of understanding of the pathophysiology of TS and associated
phenomena is reflected in the paucity of existing treatment options. They are all
purely symptomatic and consist largely of the use of various forms of psychotropic
medications, mostly antipsychotic agents.14 In some individual cases, however,
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medication does not show any effect on tic severity, whereas in many other cases,
the decrease of tic severity achieved by medication is only marginal and far from
sufficient. Besides, many patients suffer from troublesome medication side-effects,
such as sedation and weight gain. This unfavorable situation can be illustrated by
the fact that many patients, on long term, choose to live without medication,
despite the existence of debilitating tics.
What model of autoimmunity may be involved
in the pathogenesis of tic disorders?
Over the past decade, a significant amount of research has been conducted on the
role of autoimmunity in tic disorders. The proposed model of pathogenesis of tic
disorders in this research is analogous to Sydenham’s chorea.15 In genetically
predisposed individuals, tics and associated phenomena are thought to arise as a
consequence of the immunological response to infections with group A beta-
hemolytic streptococci (GABHS). Antibodies directed against the streptococci are
hypothesized to cross-react with structures of the central nervous system,
subsequently leading to damage to these structures, which eventually results in the
emergence of tics and associated features. This mechanism of autoimmunity is
supposed to be based on molecular mimicry between host and micro-organism.
What data point towards involvement of
autoimmunity?
Several clinical observations led to the hypothesis that Sydenham's chorea might be
a model for some types of childhood-onset OCD and tic disorders. First, it had
been noted that patients with Sydenham's chorea shared certain behavioral
characteristics with patients with OCD and/or tic disorders, such as emotional
lability, marked irritability, but also frank obsessive-compulsive symptoms.16
Second, a substantial number of children with OCD were reported to show
choreiform movements or tics.17 In addition, in some children with OCD and/or
tic disorders, an episodic course and/or abrupt onset of their symptoms seemed to
be temporally related to signs of GABHS infections.15 Following these
observations, case studies began to appear in the literature in which children with
OCD and/or tic disorders were described in whom a temporal relationship
between symptom onset or exacerbations, and GABHS or viral infections seemed
apparent.18-20
Researchers of the National Institute of Mental Health (NIMH) subsequently
proposed criteria to identify a putatively unique subgroup of patients from the
spectrum of illness encompassing TS and OCD whose tics and obsessive-
compulsive symptoms are shown to arise in response to beta-hemolytic
streptococcal infections. They designated it by the term pediatric autoimmune
neuropsychiatric disorders associated with streptococcal infections (PANDAS),19
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implicitly suggesting that in non-PANDAS cases autoimmunity would not be
involved. This concept is not without controversy, however, as will be addressed
later in this review. What percentage of children with TS and/or OCD would meet
criteria for PANDAS is unknown.
Thus, clinical observations might point to a role for infections preceding the
onset or exacerbations of tic or obsessive-compulsive disorders. Other clues for
such a relationship stem from laboratory work. Most importantly, autoantibodies
reacting with basal ganglia,21-26 increased serum levels of streptococcal
antibodies,27-29 as well as the presence of increased binding of an IgM monoclonal
antibody to B lymphocytes,22,30,31 a suggested susceptibility marker for the
development of rheumatic fever, have been reported in a majority of patients with
OCD and/or tic disorders. Other laboratory hints may come from limited findings
on tryptophan metabolism32-34 and cytokine profiles.35 Finally, rather fascinating is
the reported success of immunomodulatory interventions (plasmapheresis or
intravenous immunoglobulins).36 All these items will be discussed in the next
sections.
Studies demonstrating antineuronal anti-
bodies
A possible indicator of autoimmunity is the presence of autoantibodies directed
against components of the central nervous system. So far, several research groups
reported the increased presence of these antineuronal antibodies in sera from patients
with tic and/or OCD, compared to healthy controls.21-26 Results, however, have been
partially conflicting, and relatively high levels of antineuronal staining have been found
in sera from healthy control subjects. Kiessling and coworkers21 were the first to
assess antineuronal antibody status in children with recent onset of movement
disorders (TS, motor and/or vocal tics, chorea, or choreiform movements), compared
with a group of children referred for evaluation of ADHD, behavior disorders, and
learning disabilities who did not show signs of a movement disorder. They applied an
indirect immunofluorescence technique, with unfixed frozen human caudate nucleus
sections as antigenic substrate, using undiluted sera and fluorescein isothiocyanate-
labeled secondary antibody directed against human IgG, and found 44% of children
with a movement disorder to be strongly positive for antineuronal antibodies.
However, also 21% of the control group was strongly positive for antineuronal
antibodies. It is unlikely, that the behavioral symptoms of the control group explain
the positive antineuronal status in the controls, since two more studies applying the
same technique16,22 also found relatively high levels of antineuronal staining in healthy
controls, as will be addressed later. Unfortunately, no subsequent two-fold titrations of
positive sera were performed in this study, which could have been used to compare
titers between patients and controls.
Previously, in 46% of children with Sydenham's chorea, the presence of antibodies
reacting with caudate nuclei neurons had been reported.37 In that study, however,
which applied an indirect immunofluorescence technique similar to that in Kiessling's
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study, contrary to the latter study, none of the healthy control children showed
evidence of the presence of antineuronal antibodies. In contrast, two additional
studies, which, like Kiessling's work, adopted the method of indirect
immunofluorescence on human caudate nucleus sections as described by Husby,37
found relatively high percentages of positive staining using undiluted sera of healthy
controls: Swedo and colleagues16 reported positive antineuronal antibody titers in 50%
and Murphy22 in 24% of healthy control children. Unfortunately, in these studies, no
explicit data are available about the presence of intercurrent infectious illness or
autoimmune disorders in the control subjects. In both studies, the percentages of
positive antineuronal staining were consistently higher for the patient groups, being
91% for children with Sydenham's chorea in Swedo's study16 and 39% for children
with tic disorder and/or OCD in the report of Murphy.22 However, again, a
comparison of titers between diseased children and controls could not be made, as
serum dilutions were not performed.
To summarize, a major problem with previous studies reporting high levels of
antineuronal antibodies in patients with tic disorders is the relatively high level of,
possibly, nonspecific antineuronal staining in normal controls. Therefore, it would
have been important, if, in both patients and comparison subjects, also staining of
antibodies to other brain regions than the caudate nucleus would have been assessed,
in order to control for nonspecific antineuronal staining. A recent study, also applying
indirect immunofluorescence with unfixed frozen caudate sections, using undiluted
sera and fluorescein isothiocyanate-labeled anti-human IgG as secondary antibody,
was, however, able to detect antineuronal antibody staining in all patients with acute
chorea, whereas healthy control subjects showed a complete absence of antineuronal
antibodies.38 Contrary to the previous studies,16,21,22 which used fresh human brains
from adult victims of sudden or accidental death, this study used a fresh human brain
obtained from an autopsied stillborn cadaver, aged 34 weeks. It would be of interest
to apply the same methodology in TS patients.
Measuring levels of antineuronal antibodies more quantitatively, by applying an
enzyme-linked immunosorbent assay (ELISA) with human neural tissue from basal
ganglia as substrate, TS subjects were shown to have a significant increase in the mean
and median ELISA optical density (OD) levels of serum antibodies against putamen,
but not against caudate or globus pallidus, when compared with healthy controls.
Differences in magnitude of binding were, however, relatively low.23 These results
suggest that the putamen may be a major target site for antineuronal antibodies.
Two other studies did not use human neural tissue but an immortal cell line of
neural origin as substrate, and also applied ELISA assays. Though using the same
methodology, results were conflicting. When described originally, the assay was shown
to have the capability to differentiate between normal and TS populations, with a
sensitivity and specificity for TS of 79.1% and 61.2%, respectively.24 A later study,
however, did not find differences between children with TS and control children, due
to high OD values in controls in this study.25
Finally, a recent study assessed the presence of antineuronal antibodies in subjects
with TS and healthy controls with an indirect immunofluorescence assay on unfixed
frozen sections from rat brain striatum, and performed serum titrations to an end
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point by two-fold serial dilutions in order to quantify the levels of immunoreactivity.26
Again, there was much overlap in levels of immunoreactivity between patients and
controls. It is unclear, how to interpret this overlap between patients and controls. It
raises suspicions of methodological flaws, suggesting rather high levels of nonspecific
binding, albeit not necessarily, since autoantibodies in healthy subjects have repeatedly
been reported.39 Clearly, according to what criteria an individual's antineuronal
antibody assay should be regarded positive has insufficiently been operationalized as
yet.
Many questions remain regarding the significance, magnitude, and patho-
physiological meaning of serum reactivity with neuronal tissue in tic disorders. In
paraneoplastic syndromes (PNS) involving the central nervous system, the role of
antineuronal antibodies is much more established. First, in this area, the nature of
several neuronal antigens has been characterized. Furthermore, end-point titers for
positive identification of antibody, in general, are much higher than is the case in
movement disorders. Mostly, titers of > 1:500 will be regarded as positive in the field
of PNS, whereas most titers do not exceed 1:8 when movement disorders are
concerned.40 Given these apparently low titers in tic disorders, discriminating
differences from controls are fairly small. Correspondingly, confounds of nonspecific
binding form a great risk when studying antineuronal antibody status in patients with
tic disorders, paralleled by relatively high levels of positive reactivity in normal controls
reported so far.
To conclude, though several studies suggest the presence of autoantibodies
reacting with brain tissue in patients with OCD and/or tic disorders, some of these
raise concerns regarding methodology. Moreover, the presence of autoantibodies in
the serum of patients with tic disorders does not necessarily point to an autoimmune
basis of tic disorder. Autoantibodies are also found when tissue damage is caused by
trauma or infection. In other words, autoantibodies can result from, rather, than be
the cause of tissue damage, as has been reviewed elsewhere.41 One recent study,
however, elegantly suggested a pathogenic role for antineuronal antibodies for tic
disorders. Through the transfer of antineuronal antibodies of children with TS to the
striatum of rats, stereotypic movements and utterances could be induced in these
animals.42
Much remains to be investigated in this area, eg, how autoantibodies present in
sera are able to cross the blood-brain barrier, or whether IgG production takes place
inside the central nervous system. Simply measuring albumin and total IgG in serum
as well as in cerebrospinal fluid would give valuable information about IgG
production in the central nervous system and about the functional integrity of the
blood-brain barrier. Recently, basic principles of these measurements have been
adequately reviewed.43 Theoretically, in this respect, it would be also of interest, to
compare antineuronal antibodies instead of total IgG in both serum and cerobrospinal
fluid. Contrary to total IgG, however, we lack accurate quantitative methods of
measuring levels of antineuronal antibodies, as has been outlined in the previous
sections.
Also, the way in which antibodies against neuronal antigens might induce tics and
associated features is unknown. No evidence of antibody-associated inflammation or
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indications of autoantibody binding to functional cell-surface receptors in central
nervous tissue have been collected in the field of tic and related disorders. An animal
model as described above,42 or careful postmortem neuropathological examinations
may be fruitful future approaches in this respect.
Association with antistreptococcal antibody
titers
Conflicting results have also been reported on the issue whether increased levels of
antistreptococcal antibodies (antistreptolysin O and antideoxyribunuclease B) are
associated with TS. Two recent studies27,28 reported large differences between TS
cases and normal controls. Muller et al.27 found that 85% of the subjects with TS
versus 8% of normal controls had elevated antideoxyribunuclease B levels. The
same researchers subsequently showed the presence in TS patients of increased
titers against the streptococcal M12 and M19 proteins in TS patients as compared
with controls, while antibody titers against M1, M4, and M6 did not differ between
the TS and control groups.29 Also, Cardona et al.28 reported significantly higher
mean antistreptolysin titers in children with tics compared to control children, and
found a positive correlation between antistreptolysin titers and severity of tic
disorder as measured by the Yale Global Tic Severity Scale. Others, however,
reported less striking differences in this respect.23
Despite some inconsistency in these data, overall, a clear association is
noticeable between antistreptococcal antibody titers and tic disorders, further
strengthening the relationship between tic disorders and preceding streptococcal
infections. Longitudinal data, however, intending to link symptom fluctuations
over time to fluctuations of antistreptococcal antibody titers are highly needed. In
addition, though Muller et al.27 did not find increased antistreptococcal antibody
titers in a comparison group of patients with schizophrenia, it remains to be
systematically investigated whether elevated antistreptococcal antibody titers would
also be associated with other related neuropsychiatric disorders such as OCD,
autism spectrum disorders, and anorexia nervosa, or other mental disorders in
which mechanisms of autoimmunity sometimes have been suggested, such as
affective disorders.
Studies demonstrating elevated D8/17
expression on B lymphocytes, a marker of
rheumatic fever
One finding which somehow links tic disorders to rheumatic fever is the greater
than usual binding of a D8/17-specific monoclonal antibody to B lymphocytes,
reported in patient groups of both disorders.22 D8/17-specific monoclonal
antibody is a mouse monoclonal IgM antibody originally prepared from fusions of
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spleen cells from mice that had been repeatedly immunized with isolated human
B cells obtained from patients with rheumatic fever or rheumatic heart disease.
Elevated D8/17 B cell expression was originally investigated as a putative
susceptibility marker of rheumatic fever.44 Two independent research centers
reported elevated D8/17 expression on B cells in patients with tic disorders. In
these studies, B cells were incubated with the D8/17-specific monoclonal antibody
and an anti-mouse IgM specific conjugate, after which D8/17-positive cells were
counted by means of fluorescence microscopy.22,30 Using the same, somewhat
subjective method, elevated D8/17 B cell binding in autism has also been
reported.45 We recently demonstrated higher than usual D8/17 overexpression
compared to a control monoclonal antibody in patients with a tic disorder, by
means of flow cytometry, an objective rating method in which no operator
variability is involved.31 A significant minority of our patients (39.4%), however,
had levels of D8/17 expression within the range of that of our healthy comparison
subjects.
The exact meaning and pathogenetic significance of these findings is unknown.
The D8/17-specific monoclonal antibody has not only been found to bind to
B cell surface structures, but also to the cytoskeletal helical coil/coiled structures
myosin and tropomyosin, as well as to streptococcal M proteins, possibly
suggesting a substrate for structural homologies between host and streptococci.46
Given the specificity of elevated D8/17 B cell expression for poststreptococcal
disorders as reported after extensive studies with this antibody across different
autoimmune disease categories,47 elevated D8/17 B cell expression might point to
the involvement of poststreptococcal (auto)immunity in tic disorders. Whether,
however, the finding of elevated B cell expression in autistic subjects45 also implies
the involvement of poststreptococcal (auto)immunity in the pathophysiology of
autistic disorder, remains to be specifically investigated. In other words, the precise
meaning of elevated D8/17 expression remains obscure.
Altered tryptophan metabolism and data on
cytokines
One well-known and sensitive marker of cellular immune activation is the increased
degradation of tryptophan via the kynurenine pathway, leading to elevated plasma
levels of kynurenine and subsequent metabolites.48 Upregulation of the kynurenine
pathway can be induced through increased activity of indoleamine 2,3-dioxygenase
(IDO), an enzyme active in extra-hepatic tissue including brain, which is sensitive to
interferon-gamma, a major cytokine of cellular immunity.49
Indeed, in one study, involving only seven patients with a tic disorder, the serum
kynurenine level was found to be clearly increased in all seven patients, whereas serum
tryptophan was normal,32 thus, possibly reflecting immune activation. In a subsequent
larger scale study,33 involving 72 TS patients and 46 matched controls, again, plasma
kynurenine levels were found to be significantly elevated. Interestingly, both
studies32,33 reported a significant positive correlation in TS patients between levels of
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kynurenine and neopterin. This finding further supports involvement of
(auto)immunity, given the fact that neopterin is a well-known marker of cellular
immunity, which is, like IDO activity, induced by cytokines. We know of one other
independent report of increased plasma kynurenine,34 further strengthening the
significance of this finding.
Also, significantly decreased serum tryptophan levels of TS patients have been
reported in two large-scale studies,50,51 which would be compatible with increased
turnover of tryptophan along the kynurenine pathway. However, cerebrospinal fluid
tryptophan levels were found to be normal in a different study.52 Interestingly,
conversion of tryptophan to kynurenine can be triggered by GABHS, as has been
recently shown in vitro.53 In that study, streptococcal erythrogenic toxins, exposed to a
peripheral blood mononuclear cell culture were demonstrated to stimulate tryptophan
degradation to kynurenine.
An alternative explanation for increased plasma kynurenine, other than through
immune based IDO activation, would be activation of cortisol-inducible tryptophan
dioxygenase (TDO), possibly reflecting heightened stress response.54 However,
contrary to neopterin, cortisol was not found to show a correlation with kynurenine.33
Surprisingly, the studies reporting on elevated plasma kynurenine32-34 did not yield
elevated levels of quinolinic acid and kynurenic acid, two further metabolites along the
kynurenine pathway.55 Increased levels of quinolinic acid are known to be correlated
with different immune-based neurologic conditions, among others the AIDS
dementia complex.56,57 When present in higher than usual levels in brain tissue,
quinolinic acid is toxic to neurons, leading to a loss of neuronal cell density.
Cerebrospinal fluid levels of quinolinic acid are closely associated with severity of
neurologic damage in inflammatory brain disease.56,58 Therefore, it would be of
interest, to study kynurenine pathway metabolites in cerebrospinal fluid of TS patients.
Precisely how an altered metabolism of tryptophan might contribute to the
pathogenesis of tics is not clear. It can be an epiphenomenon, merely reflecting a state
of immune activation. Another possibility is a direct toxic effect of kynurenine or one
of its metabolites in the basal ganglia. Some authors found that kynurenine increases
tic-like behavior in an animal model of TS: in mice, head-shakes which had been
induced by the 5-hydroxytryptamine receptor agonist dimethoxy-iodophenyl-
aminopropane were potentiated by administration of kynurenine.59 A third possibility
would be that reduced levels of tryptophan could lead to reduced synthesis of
serotonin, causing pertuberations in serotonergic transmission. The last two
possibilities are not mutually exclusive.
Clearly, however, more data are needed concerning altered tryptophan metabolism
in patients with tic and related disorders, to allow for more definite conclusions.
Unfortunately, studies which investigated cytokines in pediatric neuropsychiatric
disease are scarce. Patients with OCD were reported in one study to show a relative
preponderance in cerebrospinal fluid of type 1 cytokines, notably interleukine-2,
suggesting the involvement of cell-mediated immunity.35 This could be consistent
with a role for streptococcal infection, through the involvement of streptococcal
erythrogenic toxins, which can act as superantigens and are known to induce type 1
cytokines.53,60
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Cytokines are proteins made by cells that affect the behavior of other cells. One
function of cytokines is to shape the type of adaptive immunity in response to a
pathogen, by determining the fate of naive CD4 T cells. Proliferating CD4 T cells
can differentiate into type 1 CD4 T cells (Th1 cells) or type 2 CD4 T cells (Th2 cells),
which mainly depends on the type of cytokines produced in response to pathogens by
cells of the innate nonadaptive immune system. Th1 cells are involved in activating
macrophages, resulting in cell-mediated immunity, whereas Th2 cells have their main
function in stimulating B cells to become antibody producing plasma cells.
Given the known IDO induction capacities of interferon-gamma, it would be of
interest to study cytokine profiles in patients with tic disorders. At present, no such
studies are available.
Application of immunomodulatory interven-
tions in tic disorders
One attractive consequence of the accumulating evidence supporting the
involvement of autoimmunity in the pathophysiology of tic disorders is the
development of new treatment options, targeting on the supposed pathophysiology
instead of being purely symptomatic. The existing literature concerning
immunomodulatory therapy for TS and related disorders is still surprisingly scarce,
and is confined to a handful of case studies and one placebo-controlled study.
A small number of case studies reported improvement in tic severity after
immunosuppression with corticosteroids.61-63 Other case studies in the literature
reported dramatic symptom improvement in children fulfilling criteria for
PANDAS with either plasmapheresis,18-20 or intravenous immunoglobulin
(IVIG).20,64,65 In some of these case studies, after succesful plasmapheresis,
attempts have been made to prevent new GABHS infections with penicillin
prophylaxis.20
We know of only one placebo-controlled study on the efficacy of
immunomodulatory therapy in patients with TS/OCD.36 In that study, a total number
of 30 children meeting PANDAS criteria, were randomly assigned to either
plasmapheresis, IVIG, or a placebo condition (saline solution given in the same
manner as IVIG), and subsequently each patient was given a regimen of penicillin
prophylaxis. Symptom severity was rated at baseline and at 1 month and 12 months
after treatment by use of standard assessment scales for OCD, tics, anxiety,
depression, and global functioning. At 1 month after treatment the IVIG/placebo
masking was broken. Then, the IVIG and plasma exchange groups showed striking
improvements in severity of OCD symptoms, anxiety, and overall functioning. Tic
symptoms were significantly improved by plasma exchange only. The children in the
placebo condition did not show any amelioration. Interestingly, these improvements
were maintained at 1 year after treatment for both plasmapheresis and IVIG. Though
these results are intriguing, the study of Perlmutter and colleagues has some serious
drawbacks. At baseline, tic severity in the plasma exchange group was significantly
higher than in the IVIG and sham-IVIG groups, which makes it hard to evaluate the
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effect of IVIG on tic severity. Blinding of the treatment groups was already broken at
1 month after treatment. In fact, the study lacks an acceptable sustained placebo
condition. Another serious drawback is the limited number of symptom rating
moments, both before and after treatment. As a consequence, we lack knowledge of
the way of natural symptom fluctuation in the groups versus the possible effect of
intervention.
Perlmutter and colleagues did not use laboratory measures in their assessment after
treatment, so from Perlmutter’s data, we cannot gain insight in possible treatment
mechanisms. More specifically, baseline and post-treatment levels of antineuronal
antibodies and percentages of D8/17-positive B lymphocytes would have been of
interest. Two more problems are the small number of patients in each treatment arm
and the confounding role of the use of penicillin.
Certainly, further, larger scale studies on the effectiveness of immune-based
therapies in well-characterized patients with tic disorders would be of great interest.
How valuable is the PANDAS concept?
Many problems are associated with the concept of PANDAS, both
methodologically and fundamentally. The diagnostic criteria for PANDAS are not
easy to apply. Especially, it is hard to demonstrate a temporal association between
GABHS infection and symptom onset or exacerbations. In fact, as far as such an
association in tic disorder or OCD exists, no knowledge is available of the nature
of this association. Interestingly, in Sydenham's chorea, a latent period between
onset of symptoms and the preceding GABHS infection as long as 6 months is not
uncommon.66 Streptococcal infections are fairly common in children in general,67
as are remissions and exacerbations in children with tic disorders.68 Another
criterion for PANDAS, the presence of an episodic course of symptom severity,
with explosive exacerbations and remissions, has insufficiently been opera-
tionalized. An episodic course of symptoms is characteristic of pediatric tic and
OCD symptoms in general, but it is hard to say when exacerbations can exactly be
called explosive.
The significance and validity of PANDAS remains to be established, since we
lack direct comparisons between TS subjects who do, and TS subjects who do not
meet criteria for PANDAS. Comparative studies in this respect should include
comprehensive clinical and serological features in relation to response to treatment.
Besides, much of the evidence supporting a role for autoimmunity in tic disorders
in general has been based on unselected subjects. Findings in unselected cases have
been similar in magnitude as in cases fulfilling criteria for PANDAS. All of the
findings supporting autoimmunity as outlined in the previous sections are equally
valid for unselected TS patients. These include the D8/17 B cell overexpression22,31
and levels of increased antineuronal autoantibodies,24 both of which are the most
robust indicators of a role for autoimmunity. There is, however, one major
exception: researchers at the NIMH recently conducted an open trial of plasma
exchange in five patients with non-PANDAS OCD, after which none showed
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significant improvement.69 To fully investigate the usefulness of the proposed
PANDAS concept, more studies comparing TS subjects fulfilling the PANDAS
criteria with non-PANDAS subjects will have to be performed. At present, it suffices
to state that PANDAS probably simply represents those patients who feature the
most obvious relationship with GABHS infections.
Apart from the point whether or not PANDAS is a useful concept, one may
question, what type of symptoms should be included in the spectrum of tic and
related disorders. The PANDAS criteria simply require the presence of OCD and/or
a tic disorder as the first criterion,70 thus, lumping together two types of disorders
which are generally regarded distinct in phenomenology and presumed etiology.71
Only a subgroup of pediatric OCD may be etiologically related to tic disorders,
characterized by a family history of tics, a more familial subtype in general, male
preponderance, association with disruptive behavior and developmental disorders,
and a less striking association with mood disorders.72 The predominant pheno-
menology of obsessions/compulsions also differs between tic-related and non-tic-
related OCD. Presence of hoarding/symmetry and sexual and aggressive symptoms
predominates in the former, whereas in non-tic-related OCD, symptoms of
contamination/checking prevail.73 In tic-related OCD, compulsions do not
generally appear to be anxiety-driven, but rather, could be phenomenologically
regarded as complex tic behaviors. It is well-known that so-called mental tics form
a part of tic symptomatology, and it is our clinical impression that in many cases,
certain obsessions and compulsions could be better conceptualized as mental and
complex tics, respectively. Thus, it may well be that the presence of tics, or, more
general, a movement disorder, in contrast to anxiety-driven obsessions and
compulsions, forms the distinctive feature of those neuropsychiatric disorders
which may be related to autoimmunity. Our preliminary, unpublished data on
D8/17 B cell overexpression in OCD suggest, that only tic-related OCD shows
increased expression of this marker of rheumatic fever.
In conclusion, the concept of PANDAS is ill-defined, is not supported by
unique immunologic findings which have not been reported in unselected patients,
and is phenomenologically unsound. It would be better to define homogeneous
subgroups by means of both clinical and laboratory characteristics. Presence of
antineuronal antibodies, or levels of D8/17 B cell overexpression might be two
candidate approaches.
Conclusions and future directions
A growing body of research data indicates the involvement of autoimmunity in the
pathogenesis of at least a subgroup of patients with tic and related disorders. The
most fascinating data include the work on antineuronal autoantibodies,21-26
especially regarding their potential in generating disease in an animal model,42 the
association with B lymphocyte D8/17 expression,22,30,31 and the promising data
concerning immunomodulatory approaches36 in a disorder which is otherwise hard
to manage. Given the economic costs and the invasiveness of these interventions,
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future research should focus on the identification of patients in whom
autoimmunity may be involved, and who may subsequently profit from
immunomodulatory treatments.
Much more work remains to be done in this field, however. The
characterization of the antigen recognized by the D8/17-specific monoclonal
antibody as well as the characterization of the brain antigenic structures recognized
by the antineuronal antibodies awaits further study. Western blot analyses which
can identify antibodies against specific antigenic structures have been inconclusive
so far.23 Postmortem studies in search of inflammatory alterations warrant further
attention.
Furthermore, large-scale longitudinal data are needed to investigate the role of
infections with regard to symptom fluctuation. Many areas remain neglected. Just a
few studies examined the human leukocyte antigen (HLA) system.74-76 Since many
human autoimmune diseases show HLA-linked disease associations, studying HLA-
associations would be of great interest in homogeneous, immune-based subgroups of
tic disorders. Also, we lack imaging studies aimed at visualizing possible blood-brain
barrier ruptures. Of special interest in this regard is the report by Kienzle and
coworkers77 demonstrating focal blood-brain barrier disruption confined to the head
of the caudate nucleus in two patients with Sydenham's chorea during the active phase
of the disease, by magnetic resonance imaging after intravenous administration of
gadopentetate dimeglumine. Interestingly, when repeating the procedure in these
patients after symptoms had greatly diminished, leakage of contrast was absent.
Ultimately, unraveling the genetic background of tic and related disorders will
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Abstract
Objective: To investigate social and behavior problems related to attention
deficit/hyperactivity disorder (ADHD), severity of obsessions and compulsions, and tic
severity in children with a tic disorder.
Methods: Parents of 58 clinically referred children with a tic disorder with and without
different forms of ADHD filled out the Child Behavior Checklist (CBCL) and the
Children’s Social Behavior Questionnaire, a novel parent questionnaire covering a broad
range of behavior problems as seen in children with milder variants of pervasive
developmental disorders. Comparisons were made between tic disorder patients with
primarily hyperactive-impulsive ADHD, tic disorder patients with primarily inattentive
ADHD, and tic disorder patients without ADHD. Also, part correlations of subscale
scores of the questionnaires with measures of ADHD severity, severity of obsessions and
compulsions, and tic severity, respectively, controlling for the predictive value of the other two
measures on the outcome of the questionnaires were executed.
Results: Tic disorder patients with primarily hyperactive-impulsive ADHD had the
highest scores on the parent questionnaires, tic disorder patients with primarily inattentive
ADHD medium scores, and tic disorder patients without ADHD the lowest. On a
considerable number of subscales, significant part correlations with ADHD severity, but
not tic severity were obtained. Severity of obsessions and compulsions was independently
correlated with the CBCL subscale thought problems, but not with most other subscales.
There was no significant correlation between tic severity and ADHD severity.
Conclusion: In patients with a tic disorder, it is the presence and severity of ADHD
that is the main predictor of associated behavior and social problems.
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Introduction
Though solely defined by the presence of recurrent motor movements and
vocalizations, Tourette's disorder (TD) and other tic disorders are well-known to
be associated with a wide range of psychopathology.1 Often, behavioral abnor-
malities and problems in social and emotional adjustment of patients with a tic
disorder are far more disabling than the core tic symptoms, thus, constituting a
major challenge to treatment. With regard to the association of tic disorders with
single (DSM-IV based) categorical entities of mental disorders, the available
studies show considerable agreement. Many referred children have behavioral
features of inattention, hyperactivity, and impulsivity, severe enough to justify a
separate classification of attention deficit/hyperactivity disorder (ADHD).2 The
frequent presence of obsessive-compulsive disorder (OCD) in patients with a tic
disorder is also apparent across different centers.3-5 Some researchers furthermore
reported on an association with mood and anxiety disorders.6,7
Another clinically well-known feature of many referred patients with a tic
disorder constitutes their marked problems in social interaction, an associated
feature that cannot easily be captured in DSM-IV based categories. There is a
relative lack of studies specifically investigating problems in social functioning of
patients with tic disorders. Champion et al.8 reported more than 40% of patients
with TD to have problems in dating and making and keeping friends. Stokes and
colleagues9 used the Pupil Evaluation Inventory, a sociometric questionnaire
completed by the child’s classmates, and found TD patients to be significantly more
withdrawn, more aggressive, and less popular than their classmates. Another study10
described the frequent occurrence of socially inappropriate behavior in patients
with TD, such as insulting and inappropriately commenting on others. Singer and
Rosenberg,11 using the parent form of the Child Behavior Checklist (CBCL)12
identified problems with obsessive-compulsive behavior, aggressiveness,
hyperactivity, immaturity, withdrawal, and somatic complains in patients with TD.
In that study, tic severity was not a statistically significant predictor of behavioral
disturbance. A subsequent study,13 also using the CBCL, did find a relationship
between the severity of tics and behavioral problems.
The influence of co-occurring ADHD, however, is not well-corrected for in
these studies. Social disability is a well-known phenomenon in patients with
ADHD.14 Given the frequent co-occurrence of ADHD and tic disorders, it is
essential to study social behavior independently from the presence of ADHD, in
order to disentangle the impact of ADHD. In one study that specified ADHD-
status of children with TD, measures of peer relationships were not found to be
related to tic severity. Instead, the co-occurrence of ADHD did turn out to be an
important indicator of poor peer relationships in that study.15 In another study,16
using the CBCL and the Vineland Adaptive Behavior Scales, children with TD
without ADHD were not significantly different on most measures of externalizing
behaviors and social adaptation, as opposed to children with both TD and ADHD.
The latter were characterized by significant behavior problems and poor social
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adaptation. Thus, existing studies suggest that much of the social and behavioral
maladaptation reported in earlier studies in children with TD is ADHD-specific.
The purpose of the present study was to investigate the role of ADHD versus
tic and OCD severity in social and behavior problems of children with a tic disorder.
We determined the association of subtypes of ADHD, as well as the number of
ADHD symptoms compared to tic severity and severity of obsessions and com-
pulsions, with social and behavioral functioning of patients with a tic disorder, by
using the CBCL as well as the Children’s Social Behavior Questionnaire (CSBQ).
First, we made comparisons on these parent rating scales between tic disorder
patients with primarily hyperactive-impulsive ADHD, tic disorder patients with
primarily inattentive ADHD, and tic disorder patients without ADHD. In a second
analysis, we measured the unique relative contribution of severity of tics, severity of
obsessions and compulsions, and the number of ADHD symptoms to the
behavioral and social problems of patients with a tic disorder.
The CSBQ is a novel parent questionnaire, containing items referring to
behavior problems as seen in children with milder variants of pervasive
developmental disorders and covering social interaction, communication,
stereotyped behaviors, motor behavior, attention, affect regulation, sensory
abnormalities, and children's understanding of social cues.17 Previous research
demonstrated the good psychometric qualities of the CSBQ with respect to both
reliability and validity.18 Also, the CSBQ has been shown to be a sensitive
instrument to assess social problems in children with developmental problems
including ADHD.19
Based on previous studies, we hypothesize that it is not the severity of tics, but
the presence of ADHD and the number of ADHD symptoms that constitutes the




Patients were recruited from two sources, either from members of the TD patients’
association in the Netherlands or from patients who had previously (from 1989
through 1999) been referred to the outpatient clinic of the Child and Adolescent
Psychiatry Center in Groningen, the Netherlands, and who had subsequently
received a clinical diagnosis of a tic disorder. Parents of both groups received a
written invitation to participate in the study. This letter fully described the aims and
background of the study. Unfortunately, it cannot be said what percentage of
subjects of both sources were willing to participate in the study. First, we did not a
priori know how many members of the TD patients’ association were between 4
and 18 years of age (the association has many adult members), so we do not know
how many subjects in the desired age range we actually did approach. In addition, we
were not sure how many addresses of former patients from our outpatient clinic
were still correct, when we tried to contact them. Finally, some parents will have
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received two letters, as far as they were both known to our clinic and the patients’
association. However, to give an impression of response rates, of 461 letters sent to
parents of patients under the age of 18 with a clinical diagnosis of a tic disorder from
our outpatient clinic, 146 (or 32%) were willing to participate. In addition, 22 parents
of subjects younger than 18 from the patients’ association showed their willingness.
Those parents who wanted to participate in the present study, were subsequently
mailed a booklet containing parent questionnaires which had to be filled out prior to
a scheduled meeting of the patient and their parents with one of the clinical
investigators of the study, all experienced clinicians in the field of tic disorders.
Only patients between 4 and 18 years old who met Tourette’s Syndrome
Research Criteria for a definite tic disorder entered the study. According to these last
criteria, observable tics had to be present during the clinical interview to allow for
study entry. Of all 168 patients who originally were willing to participate and who
showed up on the clinical interview, 58 were judged to have a definite tic disorder,
and, thus, entered the study (five from the patients’ association and 53 from our
outpatient clinic). The remaining 110 patients either did not unequivocally
demonstrate tics during the clinical interview, or had overgrown their tics. Forty-
three of the participating patients met DSM-IV criteria for TD, the remaining 15
had a DSM-IV classification of chronic motor tic disorder. All five patients from the
TD patients’ association had in the past been referred to a mental health service.
Thus, our final sample exclusively consisted of clinically referred patients. The only
exclusion criteria were an existing clinical diagnosis of autistic disorder or a known
IQ below 70. None of the subjects who were willing to participate in the study
fulfilled one or both of these exclusion criteria.
Subject characteristics
A total number of 58 patients with a definite tic disorder participated (43 male, 15
female), ranging in age from 5 to 16 years (mean=11.4, SD=2.6). To assess the tic
severity of the patients, we used the Yale Global Tic Severity Scale (YGTSS),
consisting of separate scales for motor and vocal tics complemented with a
separate rating of impairment. The mean total YGTSS score for the patients was
35.7 (SD=20.6, median=34.5, range=5-81), with a mean motor score of 11.7
(SD=4.0, median=11.0, range=4-21), a mean vocal score of 7.3 (SD=5.7,
median=8.0, range=0-22), and a mean impairment score of 16.7 (SD=15.2,
median=20.0, range=0-50). Since the impairment score of the YGTSS focuses on
the impact of the tic disorder on the individual and does not measure tic severity
per se, we decided to use the sum of the motor and vocal tic score as measure of
objective tic severity. Mean objective tic severity for the patients was 19.0
(SD=6.6, median=18.0, range=5-41).
The children’s Yale-Brown Obsessive Compulsive Scale (CYBOCS)20 was
used to measure severity of obsessions and compulsions. The mean obsessive
score of the patients was 2.0 (SD=3.8, median=0.0, range=0-13), whereas the
mean compulsive score was 3.0 (SD=4.8, median=0.0, range=0-16). Mean total
CYBOCS score was 5.0 (SD=7.6, median=0.0, range=0-26).
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Thirty-eight of the patients were using psychotropic medication, either various
antipsychotic agents (N=17), clonidine (N=7), psychostimulants (N=3), a selective
serotonin reuptake inhibitor (N=1), combinations of antipsychotic agents and
clonidine (N=6), combinations of antipsychotic agents and psychostimulants (N=2),
or combinations of antipsychotic agents and a selective serotonin reuptake inhibitor
(N=2); 20 patients were free of medication.
To determine ADHD-status of the patients with a definite tic disorder, we made
use of the ADHD part of the parent version of the Dutch translation of the
Diagnostic Interview Schedule (DISC-P), which we administered in the absence of
the child. This DSM-IV based semi-structured interview assesses whether or not a
child fulfils each separate DSM-IV criterion for ADHD, thus resulting in a diagnosis
of no ADHD, ADHD combined type, ADHD predominantly inattentive type, or
ADHD predominantly hyperactive-impulsive type. The DISC-P algorithm only
allows for a classification of an ADHD subtype, if significant symptoms are manifest
in two environments, including home and school. We decided to combine ADHD
combined type and ADHD predominantly hyperactive-impulsive type to one single
diagnosis of ADHD predominantly hyperactive-impulsive type. In addition, we used
the number of positively scored ADHD criteria, as yielded by the DISC-P as a
measure of ADHD severity, irrespective of whether or not subjects fulfilled criteria
for one of the ADHD subtypes. Of the 58 patients with a tic disorder 25 (or, 43%)
received a diagnosis of no ADHD (mean ADHD severity=4.4; SD=3.3;
range=0-11), 18 (or, 31%) of ADHD predominantly hyperactive-impulsive type (5
true ADHD predominantly hyperactive-impulsive type, and 13 ADHD combined
type), with a mean ADHD severity of 14.7 (SD=3.4; range=7-18), and 15 (or, 26%)
a diagnosis of ADHD predominantly inattentive type (mean ADHD severity=10.1;
SD=2.0; range=7-13). Table 1 summarizes data regarding gender, age, medication
status, tic severity, type of tic disorder, and severity of ADHD for these categories.
Instruments
Prior to the clinical interview, parents were asked to fill out two parent
questionnaires, the CSBQ and the CBCL. All parents of participating patients did
complete both questionnaires.
The CSBQ contains 96 items to each of which the parent is asked to respond by
indicating whether it does not describe the child (score 0), infrequently describes the
child (score 1), or clearly applies to the child (score 2). Parents were asked to base
their answers solely on the child’s behavior during the last 2 months. On the basis of
factor analysis of previously obtained data on a large number of children, five scales
have been constructed, together using 66 of the 96 items. These scales have been
designated acting-out (scale 1, containing 14 items), social contact problems (scale 2,
13 items), social insight problems (scale 3, 16 items), anxious/rigid (scale 4, 16
items), and stereotypical scale (scale 5, seven items). The CSBQ differentiates
between clinical groups and has a good inter-rater and test-retest reliability.18 The
CBCL contains 122 items to which parents have to respond in a way similar to
the CSBQ; the CBCL can be divided into eight different scales.
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Table 1. Data regarding age, tic severity, severity of ADHD, type of tic disorder, gender,










Mean SD Mean SD Mean SD
Age 10.78 2.56 11.40 2.33 11.20 3.76
Total YGTSS 42.89 20.44 30.73 22.95 33.52 18.62
Motor YGTSS 13.00 3.68 10.80 4.54 11.20 3.76
Vocal YGTSS 8.78 5.14 7.27 6.01 6.32 5.89
Impairment YGTSS 21.11 16.41 12.67 15.80 16.00 13.54
Objective tic severity 21.78 8.02 18.07 9.81 17.52 8.56
ADHD severity 14.7 3.4 10.1 2.0 4.4 3.3
Type of tic disorder N % N % N %
TD 16/18 89 11/15 73 16/25 64
CMT 2/18 11 4/15 27 9/25 36
Gender
male 13/18 72 12/15 80 18/25 72
female 5/18 28 3/15 20 7/25 28
Medication Status
medication 13/18 72 13/15 87 12/25 48
no medication 5/18 28 2/15 13 13/25 52
ADHD=attention deficit/hyperactivity disorder; YGTSS=Yale Global Tic Severity Scale;
TD=Tourette’s disorder; CMT=chronic motor tic disorder
Data analysis
We used two separate multiple analyses of covariance (MANCOVA) to test for
differences on the CSBQ and CBCL subscales, respectively, between patients with a
tic disorder stratified by ADHD-status and between male and female patients,
while using age as a covariate. This was followed by univariate analyses of
covariance (ANCOVA), controlling for age, and by pairwise comparisons between
the tic disorder groups by means of a Mann-Whitney U Wilcoxon Rank Sum W Test
in case of a significant ANCOVA.
Within the patients with a tic disorder as a whole, scores on the subscales of the
CSBQ and the CBCL were correlated with measures of ADHD, total CYBOCS
scores, and objective tic severity, using Pearson's correlation test. Also, part
correlations of the subscales of the questionnaires with ADHD severity, objective tic
severity, and severity of obsessions and compulsions separately, each time
controlling for the predictive value of the other two measures on the outcome of the
questionnaires, were executed. Finally, Pearson's correlation test was used to assess
the possible correlation between ADHD severity and objective tic severity, as well as
between ADHD severity and CYBOCS scores. All tests of significance used the
0.05 level of significance and were two-tailed.
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Results
We compared scores on subscales of the two parent questionnaires between tic
disorder patients stratified by ADHD-status and sex, while controlling for the
possible effect of age. Regarding CSBQ subscales, we found a significant effect of
ADHD-status (Pillai’s Trace, F=3.00, p=0.003), but failed to find an effect of age
(Pillai’s Trace, F=1.45, p=0.225) and sex (Pillai’s Trace, F=1.57, p=0.189). With
regard to the CBCL subscales, we also encountered a significant effect of ADHD-
status (Pillai’s Trace, F=2.19, p=0.010), which was absent for the effect of age
(Pillai’s Trace, F=1.58, p=0.157) and sex (Pillai’s Trace, F=0.91, p=0.530).
Subsequent ANCOVAS with regard to ADHD-status, while controlling for age,
were significant for the CSBQ subscales acting out, social insight problems, and the
stereotypical subscale, but failed to reach significance for the social contact
problems and anxious/rigid subscales. Also, significant subgroup differences were
found with regard to the CBCL subscales attention problems, social problems, as
well as the aggressive and delinquent subscales. Of note, patients with a tic disorder
with comorbid ADHD hyperactive-impulsive type showed the highest scores on the
parent questionnaires, with tic disorder patients with ADHD inattentive type
yielding medium scores and tic disorder patients without ADHD consistently having
the lowest scores (table 2).
Significance levels of post-hoc pairwise comparisons between the different tic
disorder groups are given in table 3. These comparisons demonstrate significant
differences between tic disorder patients without ADHD and tic disorder patients
with ADHD hyperactive-impulsive type on a considerable number of CSBQ and
CBCL subscales, including the CSBQ social insight subscale. Furthermore, table 4
gives an overview of correlation coefficients of ADHD severity, severity of
obsessions and compulsions, and tic severity with the different subscales of the
parent questionnaires. Also, part correlations of the subscales of the questionnaires
with ADHD severity, severity of obsessions and compulsions, and tic severity
measures, controlling for the predictive value of the other two measures on the
outcome of the questionnaires are represented. ADHD and OCD severity, in
contrast to tic severity, correlate with most of the subscales. No correlation,
however, was detected between ADHD severity and the CSBQ subscale social
contact problems. Finally, no significant correlation was found between ADHD
severity and objective tic severity (r=0.22, p=0.103). In contrast, severity of
obsessions and compulsions significantly correlated with both tic severity (r=0.39,
p=0.004) and ADHD severity (r=0.57, p<0.001).
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Table 2. Scores on (sub)scales of the CSBQ and CBCL across patient groups. F-values











Mean SD Mean SD Mean SD F P
CSBQ subscales
acting out 17.11 5.53 11.13 5.21 7.60 4.75 15.3 <.001
social contact problems 6.17 4.55 5.00 4.42 4.84 4.61 1.39 n.s.
social insight problems 13.89 7.10 11.67 6.52 7.48 5.39 4.04 .024
anxious/rigid scale 11.06 8.00 6.40 4.26 6.04 6.12 3.16 n.s.
stereotypical scale 4.44 3.36 2.60 2.23 1.58 1.69 4.31 .019
CBCL subscales
attention problems 11.11 4.19 10.67 4.34 6.08 3.93 7.51 .002
social problems 6.00 3.27 5.20 2.91 2.56 2.33 5.03 .011
thought problems 3.78 3.80 3.14 2.93 1.54 2.92 2.80 n.s.
sexual problems 1.06 1.83 0.13 0.35 0.36 0.70 2.91 n.s.
aggressive 17.78 8.21 13.93 6.50 8.54 6.43 9.07 <.001
delinquent 3.72 3.54 4.20 4.48 1.08 1.41 5.17 .009
anxious/depressive 9.17 6.95 7.53 4.36 5.56 5.78 2.99 n.s.
somatic 3.83 3.49 3.62 3.45 3.92 3.61 0.51 n.s.
withdrawn 4.22 3.81 4.80 2.57 3.52 2.76 1.21 n.s.
ADHD=attention deficit/hyperactivity disorder; CSBQ=children’s social behavior questionnaire;
CBCL=childhood behavior checklist; n.s.=not significant
Table 3. Significance levels of post-hoc pairwise comparisons (Mann-Whitney U Wilcoxon

















acting out n.s. <.001  n.s.
social insight n.s. .003  n.s.
stereotypical scale n.s. .003  n.s.
CBCL subscales
attention problems n.s. .001 .002
social problems n.s. .001 .009
aggressive n.s. .003  n.s.
delinquent n.s. .005 .008
ADHD=attention deficit/hyperactivity disorder; CSBQ=children’s social behavior questionnaire;
CBCL=childhood behavior checklist; n.s.=not significant
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Table 4. Part correlations of the scales of the questionnaires with either ADHD severity,
severity of obsessions and compulsions (OCD severity), or tic severity, controlling for
the predictive value of OCD, tic, and ADHD severity, respectively, on the outcome of
the questionnaires. Also, uncontrolled correlation coefficients are given (first columns).

















acting out .71 .61 .40
social contact problems
social insight problems .58 .50 .33
anxious/rigid scale .43 .40 .57 .31
stereotypical scale .39 .42 .48
CBCL subscales
attention problems .62 .52 .38
social problems .59 .45 .44
thought problems .39 .46 .72 .49
sexual problems .30





ADHD=attention deficit/hyperactivity disorder; OCD=obsessive-compulsive disorder;
CSBQ=children’s social behavior questionnaire; CBCL=childhood behavior checklist;
Discussion
The overall high scores on the CSBQ and CBCL subscales of the tic disorder
patients, when compared to what was previously found in healthy control subjects
who had never been in contact with mental health services,18 demonstrates the
significance and magnitude of behavior and social problems of clinically referred
children and adolescents with a tic disorder and is an indication of the broad range
of possibly associated problems in referred tic disorders. In accordance with
previous studies,2 more than half of our patients with a tic disorder fulfilled criteria
for ADHD. A first indicator of the importance of ADHD for behavioral and social
problems in children with a tic disorder yields a comparison of parent rating scores
between tic disorder patients with ADHD primarily hyperactive-impulsive type, tic
disorder patients with ADHD primarily inattentive type, and tic disorder patients
without ADHD. In addition, the results of the correlations between tic and ADHD
severity, respectively, with the parent questionnaires, clearly demonstrate that it is the
severity of ADHD, and not the severity of the tics per se, which determines the
magnitude of many associated features. This study specifically examined the
contribution of tic symptom severity versus ADHD severity and severity of
obsessions and compulsions, to the outcomes of the parent rating scales. Future
studies should address the contribution of other comorbid disorders such as mood
and anxiety disorders to social-behavioral functioning in children and adolescents
with a tic disorder, which may play a role alongside ADHD and OCD. However,
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irrespective of the role of these other comorbidities, the present data unequivocally
indicate an absent association of indices of social functioning and behavior
problems with tic severity.
The existing association between severity of tics and the stereotypical and
anxious/rigid subscale of the CSBQ seems to reflect the incorporation of items that
measure repeated motor movements and obsessive thoughts, respectively, in these
CSBQ subscales. The positive correlation between tic severity and the CBCL
subscale thought problems is largely due to obsessive-compulsive symptoms, as
evidenced by the clear correlation of this subscale with severity of obsessions and
compulsions, and the absent correlation with tic severity when controlling for
ADHD and CYBOCS scores. Thus, association with obsessive-compulsive
symptoms seems to be tic-specific. In contrast, independently from the severity of
the tic disorder, the degree of comorbid ADHD predicts the presence of associated
features that are well beyond the defining symptoms of ADHD. A striking example
is the association with the CSBQ subscale social insight problems. Parents respond
to items like ‘does not fully understand what is being said to him/her, i.e. tends to
miss the point’, ‘is exceptionally naive; believes anything you say’, ‘does not
understand jokes’, or ‘frequently says things which are not relevant to the
conversation’. These social insight problems, albeit no part of formal DSM-IV
symptomatology, nonetheless constitute an important problem area in clinical
practice, given the substantial impact for both patients and their parents of social
dysfunctioning on such diverse areas like self-esteem, school functioning, and
managing the children at home. Previous experience with the CSBQ indicates
similar ADHD-associated social problems in ADHD cases without tics,19 which
makes it unlikely that these are specifically linked to ADHD in tic disorder patients.
However, future studies should compare the relative contribution of ADHD
symptoms to social functioning in patients with ADHD with and without tics.
The exact relationship between tic disorders and associated mental disorders is
an issue of considerable controversy. There has been much debate about the
‘broadness’ of the phenotypic expression of the gene(s) responsible for tic
disorders. Comings and Comings21 concluded on the basis of their extensive family
studies a wide range of behavioral disorders, including ADHD, to be an integral
part of tic spectrum disorders, whereas the researchers of the Yale Child Study
Center presented evidence against a simple genetic relationship between tic
disorders and ADHD.22 Of particular note is the absent correlation between
ADHD and tic severity in our data. This finding speaks against the view of TD as a
broad disorder in which behavioral problems form an intrinsic part of the disorder.
Even though some of the reported attentional symptoms might represent executive
dysfunction,23 they still do not appear to correlate with tic severity.
Other authors pointed to the possibility of an association of tic disorders with
pervasive developmental disorders (PDD). Social contact problems, as evidenced
by little or no need for contact with others, form the clinical hallmark of PDD. In
the literature, several coincident cases of TD and PDD have been described.20,24,25
In addition, Comings and Comings26 presented a number of cases of TD probands
with autistic relatives and expressed the opinion that some cases of PDD are due to
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the TD gene(s). Indeed, in the present study, compared to healthy controls, the tic
disorder patients obtained higher scores on both scale 2 of the CSBQ, designated
social contact problems, as well as on the CBCL withdrawn subscale. However,
these subscales did not correlate with tic severity. This speaks against a direct
relationship between tic disorders and PDD. Stern et al.24 state that in their TD
clinic, no striking impression of even an anecdotal association of TD with PDD
exists and suggest an alternative explanation, namely a TD/tic phenocopy in those
PDD who present with tics. Our correlation results seem to support the view of
the latter authors.
In conclusion, the results of the present study confirm that clinically referred
patients with tic disorders show a wide range of behavioral and social problems. No
support, however, was found for a direct link of these associated features with tic
disorders. Our finding that, apart from obsessions and compulsions, these associated
features seem secondary to comorbid ADHD, is remarkably consistent with a
previous report that assessed neuropsychiatric correlates in children with TD with
and without ADHD27 as well as with a recent study reporting that it is the comorbid
ADHD, in contrast with tic severity, that is highly associated with disruptive
behavior and functional impairment in children with TD.28
In the present study, we relied on patients with a tic disorder that had been
referred to an outpatient clinic for child and adolescent psychiatry. Ascertainment
bias may thus have influenced our study results. The results should be viewed with
caution, since it may well be that our patients had been referred to mental health
services due to behavioral problems, rather than because of their tics. However,
even against this background, we found evidence against an intrinsic relationship
between tic disorders and associated phenomena, including ADHD.
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Abstract
Objective: Elevated D8/17 expression on B lymphocytes is a known susceptibility
marker of rheumatic fever. Previous studies have reported higher than usual D8/17
expression on B lymphocytes of patients with tic disorders. The purpose of this study was to
assess D8/17 expression on B lymphocytes of tic disorder patients by using an objective
method in which no operator variability was involved.
Methods: D8/17 expression on B lymphocytes was assessed with flow cytometry by using
an immunoglobulin M (IgM) monoclonal D8/17-specific antibody in an unselected group
of Dutch patients with tic disorders (N=33) and healthy volunteers (N=20). Binding of
this monoclonal antibody was compared with binding of an irrelevant IgM monoclonal
antibody, and the shift in mean fluorescence intensity of the D8/17-specific antibody
compared to that of the irrelevant IgM monoclonal antibody was used as a measure of
D8/17 overexpression. For the patients, Yale Global Tic Severity Scale scores were used to
assess disease severity.
Results: D8/17 overexpression in the patient group (mean=16.8 arbitrary units,
SD=30.5) was significantly higher than in the comparison group (mean=3.2, SD=3.0).
A significant minority of the patients (N=13, 39.4%), however, had their levels of
D8/17 overexpression within the range of that of the healthy comparison subjects. Flow
cytometric analysis did not indicate a separate subpopulation of D8/17-positive B cells.
Conclusion: These data confirm the utility of D8/17 B cell overexpression as a
peripheral blood marker in patients with tic disorders and are compatible with a
streptococcus-related pathogenesis for at least a subgroup of patients with tic disorders.
Chapter 3 49
Introduction
The pathogenesis of childhood-onset tic disorders is not well understood. In
addition to genetic factors, autoimmunity may be involved in these disorders.1
Sydenham's chorea has been postulated as a medical model for tic disorders.2 A
possible indicator of autoimmunity is the greater than usual binding of a D8/17-
specific monoclonal antibody to B lymphocytes.3-4 D8/17-specific monoclonal
antibody is a mouse immunoglobulin M (IgM) monoclonal antibody originally
prepared from fusions of spleen cells from mice that had been repeatedly
immunized with isolated human B cells obtained from patients with rheumatic fever
or rheumatic heart disease.5 D8/17-specific monoclonal antibody has been reported
to bind to a small percentage of B lymphocytes in normal comparison subjects
(averaging 5%-7%), but in patients with rheumatic fever, the percentage of D8/17-
positive B lymphocytes was found to be much higher (mean=33.5%).5 It has been
proposed that an individual could be classified as “D8/17-positive” when his D8/17
B cell expression exceeded the mean plus one standard deviation of that of the
healthy comparison subjects (that is, 12%). The D8/17-positive status has been
suggested as a susceptibility marker for rheumatic fever, a well-known complication
of infections with group A beta-hemolytic streptococci; 60%-100% of the subjects
with rheumatic fever studied so far have been reported to be D8/17-positive.6-11
Two research centers reported elevated D8/17 expression on B cells in patients
with tic disorders. A National Institute of Mental Health group4 investigated 27
children who fulfilled the criteria for pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections (PANDAS), nine children with
Sydenham's chorea, and 24 healthy comparison subjects. The children with
PANDAS represent a separate subgroup of patients from the spectrum of illness
encompassing Tourette’s syndrome and obsessive-compulsive disorder (OCD),
whose tics and obsessive-compulsive symptoms are shown to arise in response to
beta-hemolytic streptococcal infections. They found that 85% of the children with
PANDAS, 89% of the children with Sydenham’s chorea, and only 17% of the
comparison subjects were D8/17-positive.4 Murphy et al.3 compared 31 patients
with childhood-onset OCD, Tourette’s syndrome, or chronic tic disorders with 21
healthy comparison subjects and found that all patients and only one comparison
subject were D8/17-positive. They suggested that D8/17-positivity may serve as a
susceptibility marker for the development of tics or obsessive-compulsive
symptoms.
In both studies, D8/17 expression on B cells was assessed by indirect
immunofluorescence, after which D8/17-positive cells were scored by means of
fluorescence microscopy. In the study of Murphy et al.,3 the investigators were
not always completely blind to the subject’s disease status. Given the subjective
nature of the use of indirect immunofluorescence, we intended to improve the
methodology of assessing D8/17 B cell expression by applying a method in
which no operator variability was involved, and controlling for nonspecific
binding.
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We report here on D8/17 expression on B lymphocytes in an unselected
group of Dutch patients with tic disorders and in a group of healthy volunteers
by means of flow cytometry. In addition, we correlated D8/17 expression with
disease severity as measured by the Yale Global Tic Severity Scale.12
Methods
Subjects
Two groups of subjects were chosen for the study: healthy volunteers and patients
with a definite tic disorder per the Tourette’s Syndrome Research Criteria.13
According to these criteria, observable tics must be present during the clinical
interview to allow for study entry. The aim and procedure of the study were fully
explained to the subjects before written consent was requested. If the subjects were
under 18, the parents were informed as well, and the written informed consent of
the parents and the subject's assent were obtained.
None of the comparison subjects or their families was reported to show
symptoms of a tic disorder or any other neuropsychiatric disorder. Another
exclusion criterion for the comparison group was any known history or family
history of an autoimmune disorder, including a history of rheumatic fever. Twenty
healthy volunteers entered the study (13 male, seven female), ranging in age from 8
to 32 years (mean=13.9, SD=5.0).
The patients were recruited from the outpatient clinic of the Child and
Adolescent Psychiatry Center or from members of the Tourette’s syndrome
patients’ association in the Netherlands. None of the patients reported a history of
autoimmune disorder, including a history of rheumatic fever. Thirty-three patients
entered the study (19 male, 14 female), ranging in age from 6 to 59 years
(mean=20.6, SD=14.5). The presence of psychiatric disorders other than autism was
not an exclusion criterion. Psychiatric screening was performed by two of the
authors, an experienced physician in the field of tic disorders (P.J.H.) and a board-
certified child psychiatrist (P.W.T.). Blood was sampled from the subjects within a
week of the psychiatric screening.
To assess tic severity, we used the Yale Global Tic Severity Scale,12 which
consists of separate scales for motor and vocal tics complemented with a separate
rating of impairment. The mean total Yale Global Tic Severity Scale score for the
patients was 37.81 (SD=24.33, range=5-93), with a mean motor score of 13.44
(SD=5.09, range=5-24), a mean vocal score of 6.88 (SD=6.41, range=0-22), and a
mean impairment score of 17.5 (SD=16.1, range=0-50). Ten of the patients were
taking psychotropic medication, either clonidine (N=3) or various antipsychotic
agents (N=7); 23 were free of medication.
Immunology
Both groups were assessed for D8/17 B cell expression by an examiner (J.B.) who
was blind to subject status. Blood was collected in acid citrate dextran tubes (acid
citrate dextran solution B tubes, Terumo Europe, Leuven, Belgium), and the blood-
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staining procedure was carried out on fresh cells. Flow cytometric analysis was
performed within 24 hours.
Staining was performed by adding 30 µl of an irrelevant IgM monoclonal
antibody, MOC32, directed against neuroendocrine antigens of epithelial origin of
small cell lung cancer cells (tube A) or 30 µl of the D8/17-specific monoclonal
antibody (tube B), to 100 µl of whole blood. Both the D8/17-specific monoclonal
antibody and MOC32 were available in a concentration of 150 µg/ml and were used
in an undiluted form. After incubation for 1 hour at 4° C, the suspension was
washed with 2 ml of phosphate-buffered saline with 0.5% bovine serum albumin
(Sigma Aldrich, Zwijndrecht, the Netherlands) and centrifuged at 2 500 rpm for 2
minutes. To both pellets, 5 µl of phycoerythrin-conjugated CD19 (IQP, Groningen,
the Netherlands) as well as 5 µl of fluorescein isothiocyanate-conjugated goat anti-
mouse IgM (SBA, Birmingham, Ala.) was added for half an hour at room
temperature. Phycoerythrin-conjugated CD19 was used as a marker of the total
B cell subpopulation, whereas the fluorescein isothiocyanate-conjugated goat anti-
mouse IgM was able to detect binding of the D8/17-specific monoclonal antibody
and of the irrelevant monoclonal antibody, respectively. After incubation, the cells
were lysed with 3 ml of fluorescence-activated cell sorter lysing solution (BD,
Leiden, the Netherlands) for 10 minutes, centrifuged, and washed. The pellets were
resuspended in 100 µl of phosphate-buffered saline with 0.5% bovine serum
albumin and stored at 4° C until measured on a FACSstar (Becton Dickinson,
Woerden, the Netherlands).
Measuring was performed by placing a gate around the CD19-positive B cells
and counting 2 000 cells. As shown in figure 1, intersecting perpendicular lines were
placed to define the R2 quadrant with the comparison IgM monoclonal antibody at
1% (top row) in order to examine D8/17-positive B cells (bottom row).
Overexpression of D8/17 B cells was calculated by subtracting the mean
fluorescence intensity of the comparison monoclonal antibody from the mean
fluorescence intensity of the D8/17-specific monoclonal antibody. Negative values
of this shift in mean fluorescence intensity were set at 0. Individuals were classified
as D8/17-negative (<95th percentile of the D8/17 B cell overexpression of the
comparison subjects) or D8/17-positive (>95th percentile of the D8/17 B cell
overexpression of the comparison subjects).
Data analysis
We used the Mann-Whitney U test to test differences between the D8/17 B cell
overexpression of patients and of comparison subjects. To rule out medication
effects, we also tested differences between D8/17 B cell overexpression of patients
who were not taking medication and of healthy comparison subjects, by means of
the Mann-Whitney U test. Spearman’s rank correlation test was used to assess the
relationship between D8/17 overexpression and the total as well as motor and
phonic scores of the Yale Global Tic Severity Scale.12
To assess the relationship between D8/17 B cell overexpression and patient age,
we used Spearman’s rank correlation test. To investigate possible differences
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between D8/17 B cell overexpression and sex in patients, we used the Mann-
Whitney U test. All tests of significance used the 0.05 level of significance and were
two-tailed.
Results
We assessed D8/17 overexpression on B cells by means of flow cytometry in
subjects with tic disorders and a healthy comparison group. Figure 1 (lower right
corner) shows a typical flow cytometric picture of a D8/17-positive patient with a
relatively large overexpression of D8/17 compared to the binding of the irrelevant
monoclonal antibody. Also, the results obtained with a comparison subject are
shown, demonstrating a slight overexpression of D8/17. Figure 1 shows that the
population of B cells stained with D8/17-specific monoclonal antibody is fairly
homogeneous: no separate subpopulation of D8/17-positive cells can be
distinguished, despite the marked shift in mean fluorescence intensity of the D8/17-
specific antibody compared to the expression of the comparison monoclonal
antibody.
Median D8/17 B cell overexpression was significantly (Mann-Whitney U=121.0,
df=51, p<0.001) higher in the patient group (mean=16.8 arbitrary units, SD=30.5,
median=11.6, range=0-179.6) than in the comparison group (mean=3.2, SD=3.0,
median=2.8, range=0-10.1). For the total group, the median shift in mean
fluorescence intensity was 6.3 (arbitrary units) (mean=11.8, SD=24.9,
range=0-179.6). Figure 2 shows D8/17 overexpression on B cells in the total
group, in tic disorder patients, and in comparison subjects. A comparison of the
patient group that was not taking medication (mean=10.6, SD=7.0, median=10.6)
with the healthy comparison subjects also revealed significant differences in
D8/17 B cell overexpression (Mann-Whitney U=97.5, df=41, p=0.001).
When the cutoff point for an individual’s D8/17-positivity was set at 10.0 (at the
95th percentile of the D8/17 B cell overexpression of the comparison subjects), one
(5%) of the comparison subjects was D8/17-positive, whereas 20 (60.6%) of the
patients were D8/17-positive.
Furthermore, we tested whether the level of D8/17 overexpression correlated
with the severity of the tic disorder. There was no statistically significant positive
correlation between the level of D8/17 expression and the severity of tics as
measured by the motor (r=0.24, df=31, p=0.18), phonic (r=-0.20, df=31,
p=0.25), or total (r=0.16, df=31, p=0.37) score on the Yale Global Tic Severity
Scale. There was no correlation between D8/17 expression and age. The mean
D8/17 expression of the male patients did not differ from that of the female
patients (Mann-Whitney U=117.0, df=31, p=0.58).
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Figure 1. Flow cytometric analysis of D8/17 expression on B lymphocytes in a healthy
comparison subject and in a tic disorder patient with higher than normal D8/17
expression.*
*Each dot represents one cell. Both axes refer to fluorescence intensity reflecting the magnitude of the
respective antibody binding (D8/17-specific monoclonal antibody, MOC32, or CD19) of each cell. The
top two panels show expression on the B cells of an irrelevant monoclonal antibody (MOC32). The two
bottom panels show expression of D8/17-specific monoclonal antibody, showing that the cell
population is fairly homogeneous. Therefore, measurement of cells gated to the R2 quadrant is not
entirely precise, indicating measurement of shift in mean fluorescence intensity is a more accurate
measure of D8/17 B cell overexpression. The area of specific binding is defined as the area in which
less than 1% of the B cells bind to the irrelevant monoclonal antibody MOC32.
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A significant minority of patients (N=13, 39.4%), however, had levels of D8/17
overexpression that fell within the range of that of the healthy comparison subjects.
In this respect, our results differ from those of Murphy et al.3 who reported, using a
different method, that all of their 31 patients had elevated levels of D8/17
expression. However, a recent study in an Afrikaner population in South Africa14
also reported an overlap in D8/17 expression between healthy comparison subjects
and OCD patients. Ten out of 11 patients with OCD and 14 out of 22 comparison
subjects were reported to be D8/17-positive (defined as having 12% or more
D8/17-positive B lymphocytes) in that study as determined by immunofluorescence
microscopy. If the cutoff point for D8/17-positivity in that study had been defined
as the 95th percentile for the comparison subjects, the results would have been
virtually identical to our data.
The present study is, to our knowledge, the first using flow cytometry with a
comparison IgM monoclonal antibody for assessing D8/17 expression on
B lymphocytes. Flow cytometry is an objective method in which no operator
Figure 2. Levels of overexpression of
D8/17 antigen on B lymphocytes in 20
healthy comparison subjects, 33 tic
disorder patients, and the total group.*
*Shift in mean fluorescence intensity of the
D8/17-specific antibody compared to that of the
irrelevant immunoglobulin M (IgM) monoclonal
antibody. Horizontal lines represent median
values.
Discussion
As a group, the patients with a tic
disorder showed significantly
higher D8/17 overexpression on
B lymphocytes than did the healthy
volunteers, thus confirming the
findings of earlier reports.
However, no support could be
found for the distinction of a
separate subpopulation of D8/17-
positive B cells. Given this finding,
it is unclear how D8/17-positive
B cells could be distinguished and
counted manually by means of
indirect immunofluorescence, as
described in the reports of Murphy
et al.3 and Swedo et al.4
Apparently, contrary to earlier
concepts (e.g., reference 5), D8/17-
positive patients do not show an
elevated number of D8/17-positive
B cells but, rather, show elevated
D8/17 expression on the B cell
population as a whole, which can
accurately be measured by calcula-
tion of the shift in mean fluore-
scence intensity of the D8/17-speci-
fic antibody compared to that of the
irrelevant IgM monoclonal antibody.
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variability is involveld that allows for analysis of many more cells than is possible by
counting D8/17-positive cells by using a fluorescence microscope. Previously,
Chapman and coworkers15 also described a flow cytometric assay for assessing
D8/17 B cell expression in patients with Tourette’s syndrome or OCD, but their
method clearly differed from ours, since they did not control binding of the D8/17-
specific monoclonal antibody for nonspecific binding by using an irrelevant
monoclonal antibody. Therefore, they measured a percentage of D8/17-positive
B cells instead of using a shift in mean fluorescence intensity of the D8/17-specific
antibody compared to that of the irrelevant IgM monoclonal antibody as a measure
of D8/17 overexpression. Chapman and coworkers compared the results of their
flow cytometric assay with the results of cell counting using immunofluorescence
microscopy and found a significant but not perfect correlation (r=0.82). In their
study, D8/17 B cell expression of patients and comparison subjects also clearly
overlapped, irrespective of the method of assessment. Those data are in accordance
with our data, but they clearly differ from the earlier reports of Swedo et al.4 and
Murphy et al.3
The characterization of the antigen recognized by the D8/17-specific
monoclonal antibody as well as the pathogenetic meaning of D8/17
B lymphocyte overexpression awaits further study. The D8/17-specific
monoclonal antibody has not only been found to bind to B cell surface structures,
but also to diverse tissue sites in humans such as the myocardium, smooth
muscle, skeletal muscle, and epithelium cells. The monoclonal antibody appears
to bind to the cytoskeletal helical coil/coiled structures myosin and tropomyosin.
It is of interest that the D8/17-specific monoclonal antibody was also found to
bind to streptococcal M proteins.16 Because of such cross-reactivities, structural
similarities may exist between the cytoskeletal proteins myosin and tropomyosin,
surface antigens present on a subset of B cells, and streptococcal M proteins. It is
unclear how these findings relate to the model of molecular mimicry that is
thought to lead to the symptom complex of rheumatic fever. However, elevated
D8/17 expression may point to an individual’s susceptibility to experience
autoimmune complications in the aftermath of streptococcal infections.
Apparently, some individuals with increased D8/17 expression develop
rheumatic fever, whereas others are prone to the emergence of tic disorders. On
the other hand, there are considerable numbers of patients with tic disorders who
show D8/17 expression in the normal range. It is not known whether D8/17-
positive patients with Tourette’s syndrome represent a distinct subgroup within
the spectrum of tic disorders in which autoimmunity may be involved, or whether
alternative disease mechanisms may be involved in D8/17-negative patients with
tic disorders. Carefully comparing D8/17-positive with D8/17-negative patients,
both clinically and serologically, as well as with regard to treatment response,
should identify possible differences between these patients.
The specificity of D8/17-positivity for child neuropsychiatric disorders remains
to be elucidated, since elevated D8/17 B cell binding in autism has also been
reported.17 In this group, a positive correlation was found between the percentage of
D8/17-positive B cells and repetitive behavior, the hallmark of tic disorders. We
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found no correlation between D8/17 B cell expression and tic severity as measured
by the Yale Global Tic Severity Scale. In contrast to those of autism, the symptoms
of tic disorders are liable to fluctuate, which can possibly obscure this correlation in
patients with tic disorders, since it is not known whether percentages of D8/17
expression reflect such fluctuations.
Furthermore, the ethnic background of the patient sample might be a relevant
factor. For example, 90%-100% of the rheumatic fever patients in the United States
(of unspecified ethnic origin) were found to have elevated D8/17 B cell expression,
whereas it was found in only 66% of the rheumatic fever subjects in India.18 Specific
regional susceptibility markers for the latter population have been found.19 It is
therefore of interest to investigate whether different susceptibility markers also exist
in tic disorder patients across different regions. To our knowledge, the present study
is the first report on D8/17 B cell overexpression in Western Europe. Clearly, more
data are needed concerning D8/17 B cell expression in healthy comparison subjects
across different population groups with the use of objective measures.
Much work remains to be done in order to elucidate the role of autoimmunity in
tic disorders, especially with regard to the role of previously reported auto-
antibodies.20-22 To further investigate the usefulness of the proposed concept of
PANDAS, studies comparing Tourette’s syndrome subjects who fulfill the criteria
for PANDAS with non-PANDAS subjects must be performed.
To conclude, the present finding of elevated D8/17 B cell overexpression by
an objective method in a psychiatric population is highly intriguing. Elevated
D8/17 B cell expression might not only serve as an objective blood marker for at
least a subgroup of the tic disorder spectrum, but moreover, it points towards a
streptococcus-related pathogenesis with potentially promising implications for
further fruitful research, possibly leading to more effective future interventions.
Apart from providing insight in the possible pathophysiology, a blood marker
may stimulate research in other fields. For example, if elevated D8/17 B cell
expression is a reliable and stable marker in a subgroup of patients, it could
facilitate the composition of homogeneous subgroups for genetic studies.
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Chapter 4  Increased expression of Fc-µ?60
 To the editor
Several groups have independently reported elevated D8/17 expression on
B lymphocytes in patients with a tic or related disorder, making this a promising
peripheral blood marker for these conditions.1 However, concerns regarding
insufficient sensitivity of the D8/17 assay have recently been raised.2 This
prompted us to reanalyze the data of our published study on D8/17 B cell
expression in tic disorder patients compared with healthy subjects.1 Our study
was the only study reported so far that used both flow cytometry and a
comparison immunoglobulin M (IgM) monoclonal antibody. For this purpose, we
used MOC32, an IgM monoclonal antibody that is directed against a
neuroendocrine antigen of epithelial origin of small cell lung cancer cells. In contrast
to previous studies, we did not assess a percentage of D8/17-positive B cells, since
our flow cytometric analysis did not indicate a separate subpopulation of D8/17-
positive B cells. Instead, we calculated D8/17 B cell overexpression, by subtracting
the mean fluorescence intensity (MFI) produced by MOC32 from the MFI
produced by the D8/17-specific monoclonal antibody. At reanalysis of our
published data, there appeared to be an unexpected, close correlationship between
the MFI produced by the irrelevant IgM, MOC32, and that by the D8/17-specific
IgM, both in the 33 tic disorder patients (Pearson’s r=0.730, df=31, p<0.001), the 20
healthy comparison subjects (r=0.839, df=18, p<0.001), and the group as a whole
(r=0.753, df=51, p<0.001). Also, the median MFI produced by MOC32 appeared to
be significantly (Mann-Whitney U=125.0, df=51, p<0.001) higher in the 33 tic
disorder patients (median=13.3 arbitrary units) than in the 20 healthy controls
(median=8.9), as was the case with the median MFI produced by the D8/17-specific
antibody (median in patients=23.9, median in controls=13.4, Mann-Whitney
U=89.5, df=51, p<0.001). These results could suggest that, at least in part, we did
not detect D8/17 overexpression on B cells in tic disorder patients compared to
healthy controls, but rather, increased expression of receptors for the constant parts
of IgM molecules (Fc-µ) on B cells, so explaining increased binding of both the
D8/17-specific monoclonal antibody, and the irrelevant monoclonal antibody
(MOC32). This may be due to a more general state of immune activation. Thus,
these results may suggest that tic disorder patients do not express a specific, possibly
genetic, susceptibility marker for experiencing autoimmune sequelae in the aftermath
of streptococcal infections, but at best show evidence of increased immune activity.
Perhaps, previous positive reports were due to a nonspecific increase of the
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To the editor
The last decennium has witnessed a resurgence of reactive arthritis secondary to
infection with beta-hemolytic group A streptococci (GAS).1 Nowadays, post-
streptococcal reactive arthritis (PSRA) is recognized as a clinical syndrome
distinct from the classic acute rheumatic fever (ARF).2–5 The major differences
between ARF and PSRA are the predominant age of occurrence and the relative
risk of developing carditis. Genetic studies reveal differences in the association of
HLA DRB1*01 and HLA DRB1*16 with ARF versus PSRA.6 These HLA alleles
may represent an individual’s genetic susceptibility factor for developing a
humoral hyper-responsiveness secondary to GAS: the elevated D8/17 binding to
B lymphocytes in vitro occurs with a high frequency (63%–100%) in ARF and has
therefore been proposed as a susceptibility marker for ARF.7–10 Here we report
preliminary data on the binding of monoclonal antibody D8/17 to B lymphocytes
in a series of Dutch PSRA patients.
We performed a systematic prospective observational study of eight
consecutive patients at a Dutch outpatient department of rheumatology who pre-
sented with arthritis after streptococcal pharyngitis in the Dutch region of
Friesland between May 1998 and May 1999. In all patients, antistreptolysine O
(ASO) and antideoxyribonuclease B (antiDNAse B) titers were measured
simultaneously and monitored sequentially at presentation, and 6 weeks and 3 and
6 months after the primary throat infection. A significant rise and fall of ASO
and/or antiDNAse B titers was required prior to inclusion, as described
previously.5 Patients were included only if PSRA was diagnosed according to
accepted criteria.1–5
All PSRA patients were assessed for B cell expression of D8/17, except one
whose blood sample was lost. Blood was collected in acid citrate dextran tubes
(ACD solution B tubes; Terumo Europe, Leuven, Belgium) and the whole-blood
staining procedure was done the same day. Fluorescence-activated cell sorting
(FACS) was performed within 24 h. Staining was done by adding 30 µl of
immunoglobulin (Ig) M monoclonal antibody (tube A) or 30 µl of the D8/17
antibody (a generous gift from Dr. J.B. Zabriskie, The Rockefeller University,
New York, USA) (tube B) to 100 µl of whole blood. After incubation for 1 hour
at 4° C, the suspension was washed with 2 ml phosphate-buffered saline (PBS)
with 0.5% bovine serum albumin (Sigma Aldrich, Zwijndrecht, the Netherlands)
and centrifuged at 2500 rpm for 2 minutes. To both pellets, 5 µl CD19-PE (IQP,
Groningen, the Netherlands) and 5 µl goat-anti-mouse-IgM-FITC (Southern
Biotechnology Associates, Birmingham, AL, USA) bovine serum albumin (Sigma
Aldrich, Zwijndrecht, the Netherlands) were added for half an hour at room
temperature. After incubation, the red cells were lysed with 2 ml FACS lysing
solution (Becton Dickinson, Leiden, The Netherlands) for 10 minutes,
centrifuged, and washed. The pellet was resuspended in 100 µl PBS with 0.5%
bovine serum albumin and stored at 4° C until measured on the FACSstar
(Woerden, the Netherlands). Measuring was done by placing a gate round the
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CD19-positive B cells; 2 000 cells were counted. The results for D8/17-positive
B cells obtained by FACS analysis were classified as negative when expression
was <8.0% (<P95 as determined in a control group) and as positive when
expression was >8.0% (>P95 D8/17).
Eight Dutch patients [female/male ratio 7/1; mean (S.D.) age 32 (12) yr] with
arthritis were included (complete data sets for seven patients are shown in Table
1). A positive throat culture with GAS was obtained in only three patients.
Arthritis was present in all patients; the mean (S.E.M.) number of affected joints
was 7.9 (2.6). No manifestations of carditis, conduction block, or erythema were
observed. Transient cholestatic hepatitis was found in one and uveitis in two
patients. Prophylaxis by monthly treatment with penicillin was advised for all
patients in whom a primary GAS infection was suspected. All patients showed
full recovery within a 1-year follow-up period, which was uneventful. The binding
of monoclonal antibody D8/17 to B lymphocytes was assessed. The percentage
of D8/17-positive B lymphocytes in PSRA patients ranged from 2.1% to 9.6%
with a mean (S.D.) 5.5% (2.7%). A control group of 22 unselected (eight females,
14 males) healthy volunteers was used to determine the normal expression of
D8/17. The percentage of D8/17-positive B cells had a normal distribution, with
range 1.0%–8.0% and mean (S.D.) 4.0% (2.2%). Two of seven PSRA patients
(patients 6 and 7) had elevated expression of D8/17 (>8.0%).
We conclude that arthritis secondary to streptococcal infection in our region of
the Netherlands is not accompanied by cardiac or neuropsychiatric involvement.
Only 29% of PSRA patients had an elevated percentage of D8/17-positive
B lymphocytes, which is in contrast with the 63%–100% in the ARF literature. The
fact that five of seven (71%) of our patients had a normal percentage of D8/17-
positive B lymphocytes may suggest non-susceptibility to developing ARF in the
majority of Dutch PSRA patients. Further prospective multicenter studies are
warranted to confirm these findings in larger patient populations.
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Table 1. Demographic and laboratory data of seven PSRA patients
Patient 1 2 3 4 5 6 7 Group
data:
Mean (SD)
Age (years) 54 18 32 32 31 19 37 32 (12)
Sex F F F M F F F F/M=6/1
Previous ARF - - - - - - -
Throat culture GAS GAS1 Neg Neg Neg GAS Neg 3/7 GAS
Number of arthritic joints 19 6 1 2 3 10 14 8 (7)
Fever + - - + + + - +/-=4/3
ESR (mm/hr) 73 13 22 84 59 90 69 59 (30)
CRP (mg/l) 44 3 9 96 40 69 68 47 (34)
D8/17 (%) 2.1 3.2 4.1 4.4 6.9 8.0 9.6 5.5 (2.7)
ASO (U/l) 1200 340 1200 1200 300 2400 300 990 (760)
AntiDNAse B (U/l) 2500 240 1600 500 400 6400 2000 1950 (2150)
ASO/AntiDNAse B ratio 0.48 1.42 0.75 2.40 0.75 0.38 0.15 0.90 (0.77)
Recovery (months) 6 2 3 4 4 2 5 3.7 (1.5)
Extra-articular phenomena * ** ***
PSRA=post-streptococcal-reactive arthritis; ARF=acute rheumatic fever; ESR=erythrocyte sedimentation
rate; CRP=C-reactive protein; ASO=antistreptolysine O; AntiDNAse B=antideoxyribonuclease B;
M=male; F=female; Neg=negative; GAS=group A streptococci; 1also positive for Haemophilus
influenzae
Extra-articular manifestations: *cholestatic hepatitis; **transient nodal escape, minor valve insufficiency
and uveitis; ***corticosteroid (topical)-responsive iritis and episcleritis
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Abstract
Objective: In tic disorder patients, previous studies have demonstrated increased
seroreactivity against crude neuronal antigen extracts. However, no molecular
characterization of the antigenic structures involved is available. The aim of this study
was to identify and characterize possibly involved target autoantigens.
Methods: Eighty-two patients with a tic disorder were compared with 43 healthy control
subjects, 15 patients with autistic disorder (AD), and 25 persons with obsessive-compulsive
disorder (OCD). In these subjects, seroreactivity against a protein extract from HTB-10
neuroblastoma cells was analyzed by using Western blot techniques. The most relevant
identified antigenic structure was subsequently isolated, and subjected to amino acid
sequencing.
Results: All subjects showed reactivity against a multitude of protein bands. Binding to a
protein with a molecular weight of 60 kD occurred significantly more frequently in patients
with a tic disorder (67.1%), than in patients with AD (40.0%), OCD patients (40.0%),
and healthy controls (41.9%). Sequence analysis identified this protein as a human 60
kD heat shock protein (hsp60). However, the involvement of other autoantigens with a
molecular weight of 60 kD cannot be excluded.
Conclusion: Hsp60, an antigenic structure that is not exclusive to neuronal tissue, may
be an important target auto antigen in tic disorders. These data lend further support to the
involvement of autoimmunity in tic disorders.
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Introduction
Over the past decade, several research reports (recently reviewed by Hoekstra et al.1)
have appeared, which suggested the presence of autoantibodies directed against
components of the central nervous system in the serum of patients with tic and
related disorders. This may indicate the involvement of autoimmunity in these
disorders. The studies involved used a crude antigen substrate, stemming from a
neuroblastoma cell line or human or animal brain tissue for detecting these
autoantibodies. By means of either immunofluorescence or enzyme-linked
immunosorbent assay (ELISA), differences in the presence or levels of antineuronal
binding between tic disorder patients and normal controls have, thus, repeatedly
been reported. Relatively high levels of antineuronal antibodies, however, have also
been found in sera of healthy control subjects. This raises doubts about the exclusive
neuronal nature of the epitopes concerned. In general, a major disadvantage of using
crude antigen extracts is the possible involvement of a multitude of different
antigens, which may include binding sites that are not specific for neuronal tissue.
Only a limited number of studies so far, were directed at identifying separate
neuronal antigens, by using Western blot techniques. Most of these studies detected
candidate antigenic structures, derived from either brain tissue, or a neuroblastoma
cell line, with an apparent molecular weight of 60 and/or 83 kD.2-8 Typically, in such
studies, significantly more patients with a tic disorder than healthy comparison
subjects were found to show seroreactivity against proteins of these molecular
weights. Until now, molecular characterization of these antigenic structures has not
been carried out, however.
In the present study, we intended to further elucidate the antigenic nature of
antineuronal antibodies in patients with a tic disorder, by using the immunoblot
technique to identify neuronal antigens (originating from the HTB-10 cell line, a
human neuroblastoma cell line) recognized by autoantibodies present in sera of
patients with a tic disorder, and by sequencing the most relevant antigenic
structure(s). Levels of autoantibodies against this HTB-10 cell line had previously
been shown to differentiate between patients with Tourette’s syndrome and healthy
control subjects in an ELISA assay.9
Methods
Subjects
Patients with a tic disorder were compared with three control groups: healthy
volunteers, and two disease control groups, that is, patients with autistic disorder
(AD) and patients with obsessive-compulsive disorder (OCD). Patients with a tic
disorder were required to fulfill the criteria for a definite tic disorder according to
the Tourette’s Syndrome Research Criteria.10 These criteria require observable tics
to be present during the clinical interview to allow for study entry. Patients with
AD were diagnosed in accordance with both the Autism Diagnostic Interview-
Revised11 and the Autism Diagnostic Observation Schedule-Generic criteria.12
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Participants with a diagnosis of OCD had to meet DSM-IV criteria for OCD.
Healthy volunteers could only participate in the study when they had never been
in contact with mental health services.
Excluded from the study were subjects with a history or family history of an
autoimmune disorder. Another exclusion criterion for the comparison groups,
including the patients with OCD, was a history or family history of tics. None of the
subjects who were willing to participate in the study fulfilled any of these exclusion
criteria.
The tic disorder patients and patients with OCD were recruited from the
outpatient clinic of the Child and Adolescent Psychiatry Center or from patients’
associations, whereas subjects with AD previously participated in other studies at
our center. The healthy volunteers were recruited from hospital staff or their
children. The aim and procedure of the study were fully explained to the subjects
before written consent was requested. If the subjects were under 18, the parents
were informed as well, and the written informed consent of the parents and the
subject's assent were obtained.
To assess tic severity, we used the Yale Global Tic Severity Scale,13 which
consists of separate scales for motor and vocal tics complemented with a separate
rating of impairment. Blood was sampled from the subjects within a week of the
psychiatric screening.
Eighty-two tic disorder patients entered the study (55 male, 27 female), ranging
in age from 6 to 63 years (mean=22.0, SD=15.4). These were not preselected
according to an association of symptom exacerbations with streptococcal infections.
Twenty of the 82 tic disorder patients demonstrated clinically relevant obsessions
and compulsions comorbid with the tics. However, none of the tic disorder patients
met DSM-IV criteria for AD or Asperger’s disorder. In addition, a total number of
15 patients with AD (14 boys, one girl) participated in the study, with an age range
from 8 to 16 years (mean=11.9, SD=2.7). The OCD comparison group consisted of
25 subjects (eight men, 17 women) and ranged in age from 10 to 54 years
(mean=30.3, SD=11.3). Finally, 43 healthy volunteers (26 male, 17 female) entered
the study, ranging in age from 5 to 67 years (mean=22.3, SD=16.9). Though there
was no significant age difference between the tic disorder patients and the healthy
comparison subjects (t-test), the age of the tic disorder patients was significantly
higher (t-test=2.5, df=95, p=0.014) than that of the patients with AD, and
significantly lower (t-test=-2.5, df=105, p=0.014) than that of the OCD patients.
The mean total Yale Global Tic Severity Scale score for the tic disorder patients
was 44.3 (SD=24.2, range=5-100), with a mean motor score of 13.8 (SD=4.9,
range=4-25), a mean vocal score of 8.7 (SD=6.4, range=0-25), and a mean
impairment score of 22.0 (SD=16.4, range=0-50). Thirty-six of the tic disorder
patients were taking psychotropic medication, that is, various antipsychotic agents
(N=25), clonidine (N=7), or antidepressive medication (N=4); 46 tic disorder
patients were free of medication.
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Culture of cell lines and isolation of cell protein extracts
The human neuroblastoma cell line HTB-10 (American Type Culture Collection,
Rockville, MD) was used for our experiments, with the larynx carcinoma cell line
Hep2 (American Type Culture Collection) serving as non-neuronal control cell
line. Cells were grown at 37° C in a 5% CO2 incubator, in tissue culture flasks
containing RPMI 1640 with 25 mM hepes and L-glutamine (Bio-Whittaker,
Europe) and 10% fetal calf serum, supplemented with 200 mM glutamine, 100
mM sodium pyruvate, 0.05 M Eagle's Basal Medium, 10 µg/ml gentamycine, and
2.12 µg/ml amphotericin B.
The cell lines were rinsed with Dulbecco’s Minimal Essential Medium
(DMEM) containing 4.5 g/l glucose and L-glutamine, then trypsinized with
DMEM containing 2 mM ethylene glycol-bis-(beta-aminoethyl ether)-N,N,N',N'-
tetracetic acid and 2 mM ethylenediamine tetraacetic acid, and subsequently
homogenized in 10 mM tris-HCl with 1.5 mM MgCl2, 10 mM NaCl and a cocktail
of protease inhibitors to a concentration of 20 000 cells per ml. The homogenate
was centrifuged at 800 rpm for 5 minutes. The supernatant was centrifuged at
12 000 rpm for 20 minutes. The resultant pellet was resuspended in 10 mM Tris
isolation buffer and stored at –80° C until use.
Western blot
A total of 0.36 mg of each protein extract was subjected to electrophoresis in
7.5% acrylamide gels (Biorad) and then transferred to nitrocellulose. The
nitrocellulose was blocked for 1.5 hours with phosphate-buffered saline
containing 4% milk and then exposed to serum (diluted 1:250 in 1% milk and
0.1% Tween 20) for 1 hour at room temperature. Sera were kept frozen at –80° C
for a maximum period of 3 years prior to analysis. The nitrocellulose was washed
and then exposed to the secondary antibody, horseradish peroxidase-conjugated
rabbit anti-human immunoglobulin G (IgG) (Dako P214), diluted 1:3500, for
1 hour at room temperature. After washing with phosphate-buffered saline, the
bound antibodies were visualized by using enhanced chemiluminescence reagents
(Roche). Estimation of molecular weights of the bands was based on the distance
migrated for molecular weight standards. This was performed by an examiner
(G.H.) who was blind to subject status.
Purification and N-terminal protein sequence analysis of a 60 kD
protein
In order to isolate and purify the protein band of a molecular weight of 60 kD, to
which most frequent antibody binding occurred in tic disorder patients, we
subjected the neuroblastoma protein extract to 7.5% sodium dodecylsulphate-
polyacrylamide gel electrophoresis. The gel was then stained with 0.1% Coomassie
Brilliant Blue (CBB-R250) in 45% methanol and 10% acetic acid for 30 minutes
at room temperature, and destained with 45% methanol and 10% acetic acid. The
60 kD protein band was cut from the gel and subjected to sequence analysis, by
performing phenylisothiocyanate degradation. A total number of 12 N-terminal
amino acid cycles was determined.
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Statistical analysis
Pairwise comparisons between tic disorder patients and the three control groups
were carried out by using chi-square analysis, with the dichotomous variable of
presence or absence of reactivity against the 60 kD protein. To rule out possible
medication and sex effects, we compared tic disorder patients with and without
medication, as well as male and female patients by means of chi-square analysis. We
used the t-test to investigate possible differences between tic disorder patients with
and without seroreactivity against the 60 kD protein, regarding age, and severity of
tics as measured by the motor, phonic, and total score on the Yale Global Tic
Severity Scale. Also, in each of the three comparison groups, the t-test was used to
test the significance of possible age differences between subjects with and without
seroreactivity against the 60 kD protein. Given the large range in age between and
within subject groups, we decided to also separately perform these analyses for
subjects below 17 and subjects of 17 years and older. Finally, group differences were
analyzed separately for children below 13, using chi-square. All tests of significance
used the 0.05 level of significance and were two-tailed.
Results
In Western blots, IgG in serum from both tic disorder patients and comparison
subjects reacted with a multitude of protein bands in the neuroblastoma cell
extract. By far the most frequently observed antibody-antigen interaction
occurred at a molecular weight of 60 kD. When using an antigen extract from the
HEP2 cell line, only very weak reactions against a protein band of 60 kD were
detected. Figure 1A shows some representative Western blots, demonstrating
presence or absence of seroreactivity against the 60 kD protein when using the
neuroblastoma cell line protein extract. Figure 1B shows binding of the same sera
against the HEP2 extract. In total, when using the HTB-10 cell line, binding of
serum IgG to the 60 kD band was detected in 55 of 82 (that is, 67.1%) patients
with a tic disorder, as opposed to 10 of 25 (40.0%) OCD patients, six of 15
(40.0%) patients with AD, and 18 of 43 (41.9%) healthy comparison subjects.
Table 1 contains the binding percentages across the subject groups as a whole as
well as separately for subjects below and above 17 years, and for children below
13. Regarding the whole group, the percentage of tic disorder patients who
showed reactivity against the 60 kD protein was significantly higher than this
percentage in healthy comparison subjects (chi-square=7.4, df=1, p=0.007),
patients with OCD (chi-square=5.9, df=1, p=0.015), and patients with AD
(chi-square=4.0, df=1, p=0.046). Also, when confining the comparisons to
subjects below 17, the percentage of tic disorder patients who showed reactivity
against the 60 kD protein was significantly higher than this percentage in healthy
comparison subjects (chi-square=5.8, df=1, p=0.016) and in patients with AD
(chi-square=6.0, df=1, p=0.015). In this age group, no comparisons with OCD
patients could be carried out, since only two OCD patients were below 17. Table
1 shows that group differences in binding percentages were similar in magnitude
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for the subjects above 17. However, these differences did not reach statistical
significance within this age group (chi-square analysis). Differences within
children below 13 between tic disorder patients and healthy controls
(chi-square=9.1, df=1, p=0.003), and between tic disorder patients and patients
with AD (chi-square=7.0, df=1, p=0.008) were both significant. Comparisons of
presence or absence of 60 kD seroreactivity between male and female tic disorder
patients, or between tic disorder patients with and without medication did not
reveal any significant differences, neither in the group as a whole, nor in patients
below or above 17 separately. Also, no significant differences were found
between tic disorder patients with and without seroreactivity against the 60 kD
protein regarding severity of tics as measured by the motor, phonic, and total scores
on the Yale Global Tic Severity Scale, neither in the group as a whole, nor in
patients below or above 17 separately. However, within the group as a whole, the
mean age of tic disorder patients with seroreactivity against the 60 kD protein
(mean=18.4 years) turned out to be significantly (t-test=-3.1, df=80, p=0.002) lower
than the age of tic disorder patients without this seroreactivity (mean=29.2 years).
Separate subgroup analyses for tic disorder patients below and above 17 with regard
to anti-60 kD reactivity related to age, only identified significant age differences
within the older subject group (mean age of 60 kD reacting tic disorder patients
within subjects above 17=32.3; mean age of 60 kD negative subjects within this age
group=44.4; t-test=-2.6; df=30; p=0.013), which was not observed in the group of
patients below 17. No age differences were found between subjects with and
without seroreactivity against the 60 kD protein in the three comparison groups,
neither in the group as a whole, nor in patients below or above 17 separately.
Sequence analysis of the aminoterminal region of the isolated 60 kD protein
yielded aminoacid sequences (Ala-Lys-Asp-Val-Lys-Phe-Gly-Ala-Asp-Ala-Arg-Ala)
that were 100% identical to the N-terminal sequence of the mature chain of a
human 60 kD heat shock protein (hsp60). This sequence applied to more than 90%
of proteins present that did not show N-terminal blocking.
Table 1. Percentages of seroreactivity against a protein band with a molecular weight
of 60 kD as detected by Western blot analysis using HTB-10 in the group as a whole,
as well as in patients categorized according to age.
Whole group* Subjects<13** Subjects<17** Subjects>16***
Tic disorder 67.1% (55/82) 80.8% (21/26) 74.0% (37/50) 56.3% (18/32)
AD 40.0% (6/15) 33.3% (3/9) 40.0% (6/15)
OCD 40.0% (10/25) 50.0% (1/2) 50.0% (1/2) 39.1% (9/23)
Healthy controls 41.9% (18/43) 35.3% (6/17) 46.2% (12/26) 35.3% (6/17)
AD=autistic disorder; OCD=obsessive-compulsive disorder
*Differences between tic disorder patients and AD, OCD as well as healthy controls are
significant.
**Differences between tic disorder patients and AD as well as healthy controls are ignificant.
***Differences between tic disorder patients and OCD as well as healthy controls do not
reach statistical significance.
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Discussion
This immunoblot study showed that autoantibodies present in serum of tic
disorder patients do not recognize a single major neuronal antigenic structure.
Rather, in each individual patient, binding occurs to a multitude of proteins.
Given this finding, previous studies3,4,9,14,15 which reported higher than usual
levels of antineuronal antibodies as measured by ELISA assay or immuno-
fluorescence, should be viewed with caution. In fact, the studies involved
simultaneously measured a plethora of antigen antibody interactions.
Still, our study confirms earlier reports2-4,7 about the relatively frequent
involvement of a target autoantigen with a molecular weight of 60 kD, present in
neuronal cells. Furthermore, reactivity to human basal ganglia antigens of the
same molecular weight have occurred in poststreptococcal acute disseminated
encephalomyelitis16 and Sydenham’s chorea.17 However, an earlier preliminary
claim of homology of a 60 kD neuronal antigenic structure, apparently involved
in tic disorders, with calpastatin,6 could not be confirmed by the results of our
sequence analysis. Instead, we identified the 60 kD protein as a human heat shock
protein.
Western blot analyses aim to identify possibly relevant antigenic structures and
do not quantify antibody levels. Antibodies to hsp60 are known to be present in
virtually all individuals.18 Apparently, our immunoblot assay only detects anti-
hsp60 binding above a certain threshold level. Also, the HTB-10 cell line may
Figure 1A. Representative Western
blots showing sera that
demonstrate reaction against
hsp60 (lanes A, C, G and K), and
other sera that do not show anti-
hsp60 binding (lanes B, D, E, H, I,
L), when using a protein extract
from HTB-10. Lane F does not
contain serum. Apart from present
or absent reaction against hsp60,
binding against several other
protein bands is clearly visible.
Especially lane H shows many
immunoreactive proteins, with yet
absent hsp60 binding.
Figure 1B. Autoantibody binding
patterns of the same sera against
the HEP2 protein extract, demon-
strating much weaker anti-hsp60
binding.
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theoretically contain more than one 60 kD protein, especially as far as such a
protein would show N-terminal blocking, which would not make it susceptible to
the sequence analysis. Reactions against such additional 60 kD proteins would
not be distinguishable from anti-hsp60 bindings on Western blots. Thus, though
our results strongly suggest elevated serum anti-hsp60 titers in tic disorder
patients, specific anti-hsp60 ELISA assays are needed to quantify this
autoantibody. Also, a 2-D gel electrophoresis may be used in future studies, to
demonstrate whether indeed only a single 60 kD protein would be involved. In
addition, it should be stressed that the presence of human hsp60 is by no means
confined to neuronal tissue. Indeed, hsp60 is ubiquitously present. It is found
intracellularly, and functions as a molecular chaperone protein involved in the
assembly and folding of proteins.19 In addition, hsp60 can be released into the
extracellular environment, and has been identified in the peripheral circulation of
normal individuals.20 Neuronal cells, including neuroblastoma cell lines, have
specifically been demonstrated to secrete hsp60 in response to toxic agents.21
Hsp60 is thus thought to serve also extracellularly a protective role, intended to
prevent cellular damage. Protection against cell death is of critical importance to
neuronal cells, given their lack of cell-dividing capabilities. Differences between
anti-hsp60 reactivity when using the neuronal cell line versus when using the
Hep2 cell line may be explained against the background of a more profound role
and, possibly, elevated quantity of hsp60 within neuronal tissue.
There is accumulating evidence that inappropriate reactivity to heat shock
proteins is involved in autoimmune disorders.22 Abnormal reactivity to hsp60 has
been most notably linked to rheumatic autoimmune diseases.23-25 For instance,
increased serum levels of antibodies to hsp60 have been found in children with
juvenile chronic arthritis.26 Also, the association between elevated anti-hsp60
levels and severe coronary heart disease and carotid atherosclerosis is well-
established.27
Given the high degree of antigenic homology between microbial (bacterial and
parasitic) and human hsp60, immunity to microbes may lead to harmful cross-
reactivity with human structures.28 Also, in patients with tic and related disorders,
an association of infections with symptom exacerbations has been suggested.29
Apart from induction through bacterial infections, genetic factors may well be
involved in increased anti-hsp60 antibody levels: a strong association between
IL-6-174 gene polymorphism and anti-hsp60 titers has recently been described.30
This fits remarkably well to the relevance of both genetic factors and
environmental factors in tic disorders. Thus, tic disorder patients with elevated
anti-hsp60 titers may well form a relatively homogeneous subgroup, useful for the
design of genetic studies.
Though we used a neuroblastoma cell line as antigenic substrate in our
experiment, it remains to be investigated whether any reactivity occurs at all
against hsp60 in neuronal tissue in vivo. One finding which favors true antibody-
antigen interactions in the central nervous system, relevant to the pathogenesis of
tic disorders, comes from a recently developed animal model31,32  in which the
transfer of antineuronal antibodies of children with Tourette’s syndrome to the
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striatum of rats induced stereotypic movements and utterances in these animals.
Future studies should investigate the pathophysiologic relevance, if any, of anti-
hsp60 interactions in the central nervous system.
An interesting feature of antibodies to hsp60 is their reported cross-reactivity
to pathogenetically relevant autoantigens in several disease states, including
Lyme's disease33 and rheumatoid arthritis.34 Thus, it may well be that our finding
of more frequent binding to hsp60 in tic disorder patients actually reflects
increased antibody binding to a disease-specific epitope that remains to be
identified.
In our study, increased detection of anti-hsp60 was confined to tic disorder
patients. The patients with AD and the OCD patients showed anti-hsp60
reactivity that was remarkably similar to the healthy comparison subjects. Still,
future studies that examine anti-hsp60 antibody levels in tic disorder patients,
may consider to include patients with schizophrenia, given some reports of the
latter patient’s increased anti-hsp60 seroreactivity.35-38 Other studies may want to
investigate the role of age, in combination with the duration of illness. While we
failed to systematically collect data regarding disease duration in the present study,
we did find an association between lower tic disorder patients’ age and
seroreactivity against hsp60. This was largely due to the lower mean age of adult
patients showing anti-hsp60 binding. We did not observe this age difference in
the pediatric patients, which makes this finding hard to interpret. The appearance
of the tics may have been induced by infections that are thought to evoke
antibodies that cross-react with human tissue. This might explain the apparently
increased levels of anti-hsp60 autoantibodies in younger patients, given these
patients’ shorter time frame since the first occurrence of the tics. Possibly,
children’s general tendency to show increased anti-hsp antibodies due to their
heightened frequency of infections, may initially obscure the disease duration
effect. In this respect, it is of interest to note that tics are also far more common
in children than in adults.39 Longitudinal studies, however, are needed to examine
the course and significance of alterations of anti-hsp60 autoantibody levels over
time, related to disease development. In addition, it would be of interest to study
autoantibody reactions at the onset of the disorder, since later autoantibody
repertoires can reflect responses to damaged tissues,40 and, thus, could be the
consequence rather than the cause of the underlying mechanism accounting for
the disease process. If, however, anti-hsp60 antibodies would indeed be involved
in the etiopathogenesis of tic disorders, such studies should find increased levels
of these antibodies early in the course of illness, rather than later.
In conclusion, the present finding of elevated anti-hsp60 reactivity in serum of
patients with a tic disorder adds to existing data, which may support the
involvement of autoimmunity in tic disorders. We are, however, far from
understanding the precise complex interplay between genetic and environmental
factors in tic and related neuropsychiatric disorders.
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Abstract
Objective: Increased levels of plasma kynurenine have been reported in tic disorder
patients, and this observation has been suggested to be indicative of immune
dysregulation in tic disorders. In the present study, we aimed to replicate this finding in a
large group of well-characterized tic disorder patients.
Methods: Plasma concentrations of tryptophan and kynurenine were determined in
Dutch patients with Tourette’s disorder (N=44), patients with chronic motor tic
disorder (N=15), and healthy volunteers (N=32). Correlations between Yale Global
Tic Severity Scale scores and the plasma levels were examined.
Results: Our results revealed no significant differences between patients and controls in
plasma tryptophan and kynurenine concentrations or in the kynurenine to tryptophan
ratio. Also, kynurenine did not correlate with indices of tic severity. A small, but
statistically significant negative relationship (r=-0.341; p=0.009) was found between
tryptophan levels and vocal, but not motor tic severity. These results indicate that the
metabolism of tryptophan through the kynurenine pathway is not altered in tic disorders.
Conclusion: Although it is unclear how much may be inferred about immune function
based on measurement of plasma kynurenine, the present results do not lend support to
hypothesized alterations in immune processes in tic disorder patients.
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Introduction
Tic disorders constitute a spectrum of complex neuropsychiatric disorders
characterized by the presence of diverse motor and/or vocal tics, often accompanied
by behavioral abnormalities.1,2 The pathogenesis of tic disorders is not well
understood. The possible involvement of immune dysfunction has attracted
considerable research attention and has been recently reviewed.3 In short, studies
have pointed to the relevance of overexpression of a B lymphocyte surface marker,
designated D8/17,4 to the possible role of antineuronal autoantibodies,5 and to an
association with antistreptococcal antibodies.6
In addition, investigators have reported on elevated levels of the tryptophan
metabolite kynurenine in Tourette’s disorder (TD) patients.7,8 This increase in
kynurenine has been suggested to be another indication of immune dysregulation in
tic disorders. Increased kynurenine levels are a well-known marker of immune
activation across a wide range of inflammatory conditions. This can be explained by
the effects of pro-inflammatory cytokines, most notably interferon-gamma, on
indoleamine 2,3-dioxygenase (IDO), which promotes the breakdown of tryptophan
to kynurenine.9 IDO is present in both brain and non-brain tissue, including lung,
kidney and circulating macrophages. Across a wide range of systemic immune
activation, it has been found that increases in cerebrospinal fluid levels of kynurenine
are substantially greater than increases in plasma levels.10 Still, plasma kynurenine has
also been shown to be increased through immune activation.11 The kynurenine to
tryptophan (K/T) ratio in plasma has been suggested to be a direct measure for
IDO activity, and has been found to correlate with neopterin, a well-known
marker of cellular immune activation.12 Finally, subsequent metabolites of the
kynurenine pathway are known to be neurotoxic, and may possibly be involved in
the pathogenesis of tics or associated symptoms.13,14 In the present study, we aimed
to replicate the finding of elevated plasma kynurenine, and to examine levels of
plasma tryptophan in a large series of tic disorder patients.
Methods
Subjects
Two groups of subjects were chosen for the study: healthy volunteers and
patients with a tic disorder according to DSM-IV criteria.15 The tic disorder
patients were recruited from the outpatient clinic of the Child and Adolescent
Psychiatry Center or from members of the TD patients’ association of the
Netherlands. The aim and procedures of the study were fully explained to the
subjects before written consent was requested. If the subjects were under 18, the
parents were informed and the written informed consent of the parents and the
subject’s assent were obtained.
Thirty-two age-matched healthy volunteers, recruited from hospital staff or
their children (17 men, 15 women; 5 to 53 years of age; mean age=18.9,
SD=12.4), and 59 tic disorder patients (41 men, 18 women; 6 to 53 years of age;
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mean age=17.3, SD=11.8) entered the study. Both study groups were free of
chronic illnesses known to affect the immune system. Forty-four of the tic
disorder patients met DSM-IV criteria for TD, the remaining 15 tic disorder
patients fulfilled DSM-IV criteria for chronic motor tic disorder (CMT). Tic
severity was assessed using the motor and vocal scores of the Yale Global Tic
Severity Scale.16 The sum of both scores was used as a measure of total tic
severity. The mean total tic severity for the tic disorder patients was 20.5
(SD=9.15, range=5–41), with a mean motor score of 12.7 (SD=4.73,
range=4-24), and a mean vocal score of 7.88 (SD=5.99, range=0–22). Table 1
shows data regarding age, sex, and tic severity scores across both groups of tic
disorder patients and healthy controls.
Twenty-seven of the patients were taking psychotropic medication, either
clonidine (N=5), various antipsychotic agents (N=21), or a selective serotonin
reuptake inhibitor (N=1); 32 were free of medication.
Table 1. Subject characteristics regarding age, sex, and tic severity scores across
the two tic disorder groups and the healthy controls.
Tourette’s disorder
N=44 (35 M, 9 F)
Chronic motor
tic disorder
N=15 (6 M, 9 F)
Healthy controls
N=32 (17 M, 15 F)
Mean (SD), range Mean (SD), range Mean (SD), range
Age 17.1 (11.5), 7-53 17.9 (12.8), 6-46 18.9 (12.4), 5-53
Motor tic score 13.0 (4.61), 4-24 11.7 (5.11), 5-20
Vocal tic score 10.6 (4.34), 3-22
Total tic score 23.6 (8.22), 9-41 11.7 (5.11), 5-20
M=male; F=female
Laboratory measures
Blood was sampled from all subjects during the morning, between 10 AM and
noon. This took place within 1 week of each patient’s psychiatric screening. All
tests were carried out using plasma samples which had been kept frozen at -80° C
for a maximum period of 3 years prior to analysis. Plasma tryptophan and
kynurenine were determined by high performance liquid chromatography using a
modification of the method of Widner et al.17 Briefly, 100 µl plasma samples were
deproteinized with 100 µl of 0.7 M perchloric acid after addition of 50 µl of 25%
ascorbic acid and 500 ng of the internal standard, 5-hydroxytryptophan.
Supernatants were directly injected on a C18 column (mobile phase 96%, pH 3.7,
1.5% acetic acid/4% methanol, 1 ml/min) and measured fluorometrically
(tryptophan, 285/345 nm excitation/emission wavelengths) and by ultraviolet
absorbance (kynurenine, 360 nm) with within-day and day-to-day coefficients of
variation of less than 7%.
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Statistical analysis
We used multiple analysis of variance (MANOVA) to test for differences in
plasma tryptophan and kynurenine concentrations between patients with TD,
patients with CMT, and comparison subjects, as well as between male and female
subjects and between patients with and without medication. With analysis of
variance (ANOVA), we investigated possible differences between the groups in
the K/T ratio, using post-hoc t-tests to separately compare the tic disorder
subgroups to the normal control group. In addition, Pearson’s correlation test
was used to assess the relationship between tryptophan and kynurenine across all
subjects, and between the laboratory measures and the total as well as motor and
vocal tic scores of the Yale Global Tic Severity Scale across the tic disorder
patients as a whole. Also, correlations of the test results with age in tic disorder
patients and controls were performed. All tests of significance used the 0.05 level
of significance and were two-tailed.
Results
MANOVA found no significant effect of diagnostic group when patients with
TD, patients with CMT, and healthy controls were compared with regard to
plasma tryptophan and kynurenine (F=1.60, p=0.212). Also, no effects of
medication status (F=0.346, p=0.709) or gender (F=0.387, p=0.681) were
observed. Table 2 shows mean values of tryptophan, kynurenine, and the K/T
ratio across the groups. In a separate ANOVA, no significant diagnostic group
effect was seen on the K/T ratio (F=2.82, p=0.065). Given the trend-level
significance seen in the group effect on the K/T ratio, we proceeded to separately
compare the tic disorder subgroups to the normal control group using post-hoc
t-tests (TD versus normal controls, t=-1.74, p=0.086; CMT versus normal
controls, t=0.809, p=0.423). No significant correlations were observed between
kynurenine and indices of tic severity (eg, r=0.024, p=0.857 regarding kynurenine
versus total tic severity). However, the K/T ratio showed a weak, but statistically
significant correlation with vocal (r=0.330, p=0.011), but not motor (r=0.150,
p=0.260) tic severity. In healthy controls, tryptophan values correlated weakly
with kynurenine values (r=0.372, p=0.036), which we did not find in the tic
disorder patients (r=0.151, p=0.254). Within the tic disorder patients, we found a
small, but statistically significant negative correlation between tryptophan
concentration and vocal (r=-0.341, p=0.009) as well as total tic severity (r=-0.311,
p=0.017). In contrast, we found no significant correlationship between
tryptophan and motor tic severity (r=-0.169, p=0.204). Finally, age appeared to
be positively correlated with tryptophan concentrations in the healthy controls
only (r=0.484, p=0.005). This relationship between age and tryptophan was not
observed in the tic disorder patients (r=0.080, p=0.546). In addition, across both
the healthy and the tic disorder group, age was not significantly correlated with
kynurenine (r=0.135, p=0.460, and r=-0.113, p=0.395, respectively).
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Table 2. Plasma concentrations of kynurenine and tryptophan, and the mean
kynurenine to tryptophan ratio in tic disorder patients and healthy controls. No
















Tryptophan (µg/ml) 11.3 (2.67) 12.1 (1.91) 11.7 (3.06)
Kynurenine/tryptophan
(x1000)
38.1 (12.8) 31.3 (9.13) 33.5 (8.50)
Discussion
Contrary to two previous reports,7,8 our study failed to find significant differences in
plasma kynurenine concentration between tic disorder patients and healthy compa-
rison subjects. Another indication that plasma kynurenine is not associated with tics,
was the absence of any tendency for kynurenine levels to correlate with indices of tic
severity. Although there was a trend toward a greater K/T ratio in the TD group
compared to the control group, this was not encountered at all in the CMT group.
In our study, individual kynurenine values varied substantially, and did not correlate
with tryptophan within the tic disorder patients. Apart from possible cytokine-
induced IDO activation, the activities of the liver tryptophan metabolising enzyme
tryptophan 2,3-dioxygenase18 and the kynurenine metabolizing enzymes kynureni-
nase and kynurenine hydroxylase19 are known to affect plasma kynurenine levels;
variation in these other enzymes may have obscured the effects of IDO activation.
Plasma tryptophan concentrations of the tic disorder patients in the present
study were not different from those of the healthy controls. This is in contrast with
two independent studies20,21 that had previously reported slightly, but significantly,
decreased serum tryptophan levels in tic disorder patients. However, the results of
our study may still support some association of tic disorders with alterations in
tryptophan, given the significant negative correlation of tryptophan levels with vocal
as well as total tic severity. In addition, tryptophan was not positively correlated with
age in the patients, in contrast with the situation in the controls. These two findings
are in accordance with previous studies. Comings20 also found an absent correlation
between age and tryptophan in tic disorder patients, whereas Lepage et al.22
demonstrated a steady increase of tryptophan levels throughout infancy,
childhood, and adolescence in healthy controls. Currently, we do not have an
explanation for this difference between tic disorder patients and healthy controls.
In conclusion, it appears that in our group of tic disorder patients the
metabolism of tryptophan through the kynurenine pathway is not altered. In
addition, changes in plasma tryptophan, if present, appear to be quite subtle.
Although it is unclear how much may be inferred about immune function based on
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measurement of plasma kynurenine, the results do not lend support to hypothesized
alterations in immune processes in tic disorders. Thus, while previous studies have
identified a number of possible interesting laboratory indicators of immune
dysfunctioning in tic disorder patients, it now appears unlikely that the
measurement of plasma kynurenine will provide confirming evidence of the
possible involvement of autoimmune phenomena in tic disorders.
Given the likelihood that immune mechanisms are operating in at most a
subset of tic disorder patients, future studies in this area may benefit from
focusing on those patients with abnormal immune indices and on those with
markedly elevated plasma kynurenine or K/T ratio.
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Abstract
Objective: Cross-sectional data and some case studies suggest a temporal relationship
between fluctuations in tic severity and preceding infections. The aim of the present study
was to examine this possible relationship in a prospective longitudinal design.
Methods: Two groups of tic disorder patients were included in this study, a pediatric
group between 7 and 15 years (N=20), and an adult group of 16 years and older
(N=41). During a 24 weeks’ period, participants were asked to weekly fill out self-
questionnaires regarding the presence of tic exacerbations and experience of common cold.
In addition, six throat swabs were taken at fixed intervals irrespective of symptoms, and
cultured for streptococci; also, three serial serum assessments of streptococcal antibodies
were performed.
Results: In the pediatric group, the self-report of a common cold was strongly
associated with an exacerbation in tic severity 4 weeks later (odds ratio=4.685,
p=0.001). In this group, no association between the self-report of a common cold and tic
exacerbations was found in other weeks. In the adult group, we found no association at
all between reports of common cold and tic exacerbations. Association with streptococcal
infections could not be determined due to the limited number of observed streptococcal
infections.
Conclusion: While it remains to be proven whether or not streptococcal infections are
associated with exacerbations in tic severity, this study points to a hitherto unknown
association of common viral infections with exacerbations in tic severity in children,
which may support the involvement of immune dysregulation in tic disorders.
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Introduction
Though the precise mechanism at a molecular level is unknown, a growing number
of studies suggest the involvement of autoimmunity in the pathogenesis of tic
disorders.1 A common feature of autoimmune disorders in general is their relapsing
course over time. Infections have been suggested to induce or reinforce auto-
immune reactions in genetically predisposed individuals, and may, thus, be
associated with exacerbations and remissions in autoimmune conditions.2
A pattern of fluctuations in symptom severity is also common in tic disorders.3
Some authors have suggested an association between infections with group A beta-
hemolytic streptococci and changes in tic severity in at least a subgroup of patients.4
This possible relationship has been exclusively based on cross-sectional data5-7 and
some case studies,8-11 however. In the present prospective longitudinal study, we
aimed to examine the possible temporal relationship between symptom
exacerbations and preceding infections in an unselected cohort of pediatric and adult
patients with a tic disorder.
Methods
Subjects
Participants were required to be at least 7 years old. Given the large range in age
of participating subjects, we decided to separately analyze patients below and
above 16 years old, that is, a pediatric group of patients between 7 and 15 years,
and an adult group of 16 years and older. All patients with a tic disorder could
only enter the study if they fulfilled the criteria for a definite tic disorder
according to the Tourette’s Syndrome Research Criteria.12 These criteria require
observable tics to be present during the clinical interview to allow for study entry.
Excluded from the study were subjects with a history or family history of an
autoimmune disorder. None of the subjects who were willing to participate in the
study fulfilled any of these exclusion criteria.
The tic disorder patients were recruited from the outpatient clinic of the Child
and Adolescent Psychiatry Center, Groningen, the Netherlands, or from the Dutch
Tourette’s syndrome patients’ association. The aim and procedure of the study
were fully explained to the subjects before written consent was requested. If the
subjects were under 18, the parents were informed as well, and the written
informed consent of the parents and the subject's assent were obtained. The
study was approved by the Dutch central medical-ethical committee. To assess tic
severity at study entry, we used the motor and vocal scores of the Yale Global Tic
Severity Scale.13 The sum of both scores was used as a measure of total tic
severity.
Twenty tic disorder patients entered the pediatric study group (14 boys, six girls),
ranging in age from 7 to 15 years (mean=12.3, SD=2.5). The adult group of tic
disorder patients consisted of 41 patients (25 men, 16 women) and ranged in age
between 16 and 64 years (mean=34.1, SD=15.3). The mean total tic severity score
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for the pediatric tic disorder patients at study entry was 18.6 (SD=10.0, range=8-50),
with a mean motor score of 12.5 (SD=5.2, range=6-25) and a mean vocal score of
6.1 (SD=6.4, range=0-25). For the adult tic disorder group, the mean total tic
severity score at study entry was 23.5 (SD=8.9, range=10-50), with a mean motor
score of 14.6 (SD=4.4, range=7-25), and a mean vocal score of 8.9 (SD=6.5,
range=0-25). The mean total, motor and vocal tic severity of the adult and pediatric
study group did not differ significantly (t-test). At study entry, 13 of the 20 (that is,
65%) pediatric tic disorder patients were taking psychotropic medication, that is, an
antipsychotic agent (N=8), clonidine (N=3), or a combination of an antipsychotic
agent and clonidine (N=2). In addition, 14 of the 41 (that is, 34%) of the adult
patients were on medication, being an antipsychotic agent (N=11) or an
antidepressive agent (N=3).
Procedure
During 24 consecutive weeks, each week, on a chosen fixed day of the week,
participants were asked to fill out a questionnaire. When participants were children,
parents were allowed to assist the children in filling out the questionnaire. On this
questionnaire, participants had to state whether or not they had experienced a
common cold over the past 7 days, as well as whether or not they had experienced
symptoms suggestive of a pharyngitis (i.e., a sore throat). Since common cold is such
a universal experience, we did not ask for specific symptoms suggestive of a
common cold, but simply asked for the presence or absence of a common cold
according to the patient’s opinion. In addition, they had to fill out whether the tic
severity over the past 7 days had stayed about the same, had decreased or increased
slightly, or had increased or decreased much, compared to the preceding period of
7 days. Finally, they were asked to record any change in psychotropic medication
regime. All questionnaires were to be mailed to us in stamped envelopes on a weekly
base.
During this 24 weeks’ study period, every 4 weeks, that is, at study entry (week 0),
and subsequently at week four, eight, 12, 16, and 20, throat specimens were taken,
which were cultured for streptococci. In addition, at three time points, at week four,
12, and 20, blood was drawn for assessing antistreptolysine O (ASO) titer and anti-
deoxyribonuclease B (antiDNAse B) titer. The whole study was performed in the
period between September 2001 and May 2002.
Definitions of infections and tic exacerbations
A two titerstep rise in either ASO or antiDNAse B or both was regarded as evidence
of an experienced streptococcal infection. To determine the precise time of the
actual infection, in case of such a two titerstep rise, we used information from the
questionnaires regarding symptoms suggestive of a pharyngitis (i.e. a sore throat). A
newly acquired positive throat culture, i.e., a positive throat culture that had not been
present in the preceding assessment, was considered a streptococcal colonization,
provided we did not detect a subsequent two titerstep rise in the levels of the
antistreptococcal antibodies. Positive throat cultures that were present at the first as
well as subsequent throat swabs were considered carrier states.
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Only those reports of common colds which had not been reported in the
preceding week, were considered a common cold in the analyses. When a common
cold had already been reported in the preceding week, a subsequent report of a
common cold was relabelled as “not a common cold”. When no information was
available regarding the preceding week (this was the case with regard to all first
questionnaires, as well as when participants had failed to return the questionnaire in
the preceding week), reports of a common cold on the questionnaires were removed
from the analyses, i.e., treated as missing values. Thus, only reports of newly
acquired common colds during the observation period were used in the statistical
analyses.
When participants filled out that their tic severity over the past 7 days had
increased much, compared to the preceding period of 7 days, this was considered a
tic exacerbation. All other answers to this topic were classified as “no tic
exacerbation.”
Statistical analysis
In both patient groups, we intended to determine a possible association of the self-
report of a common cold, and a streptococcal pharyngitis or colonization, respec-
tively, with an exacerbation of tic severity during the same week, as well as 1, 2, 3, 4,
5, and 6 weeks later. For this purpose, odds ratios were computed, including 95%
confidence intervals. Odds ratios were also computed with regard to a possible
association between a change in medication, and tic exacerbations. Two-tailed P
values less than 0.05 were considered significant.
Results
Response rate
The pediatric group returned a total number of 412 questionnaires, a response rate
of 85.8% returned questionnaires. The adult patient group returned a total number
of 731 questionnaires, an overall response rate of 74.3%. In contrast to the pediatric
group, in which all patients participated throughout the whole study period, six of 41
adult patients decided to withdraw from the study, all within the first 4 weeks, thus,
lowering the overall response rate. Without these six patients, the response rate in
the adult group was 84.5%. In addition, we collected a total number of 53 pediatric
serial sera for assessment of streptococcal antibodies (88.3% of planned
assessments; two of the children refused blood draws), as well as 111 serial adult sera
(90.2% of planned sera). Finally, we collected 116 serial pediatric throat swabs
(96.7% of planned swabs) as well as 217 serial throat swabs in the adult patient
group (88.2% of planned swabs).
Frequency of tic exacerbations
The pediatric patient group reported 55 tic exacerbations, this is 13.3% of all 413
weekly questionnaires, or a mean number of 3.2 exacerbations per child per 24
weeks, whereas the adult patient group reported 99 tic exacerbations, being 13.5% of
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731 questionnaires, or a mean number of 3.2 exacerbations per 24 weeks per adult
participant.
Frequency of reports of infections
In the pediatric group, 37 common colds were reported, this is 9.6% of valid cases,
or a mean number of 2.3 common colds per child per 24 weeks. In addition, in the
pediatric group, only one streptococcal infection as well as one single newly acquired
streptococcal colonization was detected. Two additional subjects in the pediatric
group turned out to be streptococcal carriers.
In the adult group, 58 common colds were reported, this is 8.4% of valid cases,
or a mean number of 2.2 common colds per adult participant per 24 weeks. In the
adult group, no evidence of a streptococcal infection was detected. A new
streptococcal colonization during the study period happened in two adult patients,
whereas we found one adult streptococcal carrier state.
Changes in medication
In the pediatric group, participants reported 35 times a change in use of
psychotropic medication, or in 8.8% of valid cases. In the adult group, this was
reported 75 times, or in 10.6% of valid cases. In both the pediatric and the adult
patient group, no statistically significant relationship was found between change in
medication use and report of a tic exacerbation during the same week, or 1, 2, 3, 4, 5,
or 6 weeks later.
Association between tic exacerbations and infections
In the pediatric group, self-report of a common cold was strongly associated with an
exacerbation in tic severity 4 weeks later (table 1). When no common cold was
reported, tic severity 4 weeks later was reported “much increased” in 11.2% of cases,
whereas the report of a newly acquired common cold led to a “much increased” tic
severity 4 weeks later in 37.0% of cases, yielding an odds ratio of 4.685. No
statistically significant associations were found between common cold and tic
exacerbations in the same week, or 1, 2, 3, 5, or 6 weeks later (table 1). In the adult
patient group, no statistically significant associations were observed between reports
of a common cold and tic exacerbations in the same week or subsequent weeks
(table 2). Given the low number of observed streptococcal infections (N=1 in the
pediatric group versus N=0 in the adult group) or colonizations (N=1 in the
pediatric group versus N=2 in the adult group), we were not able to determine
associations between streptococcal pharyngitis or colonization and subsequent tic
exacerbations.
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Table 1. Odds ratios, including 95% confidence intervals and
significance levels regarding the association between the self-
report of a common cold and tic exacerbations in the same








Same week 0.550 (0.162-1.860) .301
1 week later 2.219 (0.886-5.554) .107
2 weeks later 0.876 (0.248-3.092) .835
3 weeks later 1.684 (0.593-4.783) .348
4 weeks later 4.685 (1.954-11.23) .001
5 weeks later 0.402 (0.092-1.765) .176
6 weeks later 0.768 (0.218-2.708) .673
Table 2. Odds ratios, including 95% confidence intervals and
significance levels regarding the association between the self-
report of a common cold and tic exacerbations in the same








Same week 1.964 (0.995-3.876) .065
1 week later 1.267 (0.571-2.808) .569
2 weeks later 1.406 (0.599-3.304) .448
3 weeks later 1.989 (0.936-4.229) .089
4 weeks later 0.934 (0.352-2.477) .890
5 weeks later 0.983 (0.369-2.623) .973
6 weeks later 1.491 (0.624-3.563) .385
Discussion
Although the first notion of a possible link between infection and tic disorders dates
back to 1929,14 this is the first study that examined the association between
exacerbations in tic severity and preceding infections in a prospective longitudinal
design. In the pediatric patients, we found a strong association between self-reports
of a common cold and a subsequent exacerbation in tic severity 4 weeks later. It is
improbable that this is due to a nonspecific stress reaction, since we did not find an
association with tic exacerbations in other weeks, including the week in which the
common cold was newly reported. The usual duration of cold symptoms in children
is 10 to 14 days,15 thus, the cold has already entirely disappeared by the time of the
tic exacerbation, 4 weeks later. In contrast, we did not encounter this association in
the adult patients. Only a trend regarding the occurrence of tic exacerbations 3
weeks after the cold may be noticeable in adults. Apparently, children and adults
differ with regard to the impact of infections on changes in tic severity. While
differences between children and adults are well-known with regard to both the
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immunological response to infections and the maturity of the nervous system, at
present, we do not have a plausible explanation for the different impact of upper
respiratory infections on children and adults with a tic disorder. Future studies
should focus on the immunological pathways that may be involved. Also,
speculations about why the time frame between the upper respiratory infection and
the subsequent exacerbation in tic severity appears to be 4 weeks, will have to await
such studies. Currently, we know of one additional study16 that pointed to the
relevance of common colds in obsessive-compulsive and tic disorders. In that study,
the presence of common cold at the time of onset of obsessive-compulsive disorder
and tic symptoms appeared to be associated with sudden, rather than insidious onset
of symptoms.
Prior studies pointed to a possible association between tic disorders and
streptococcal infections, as was suggested by increased serum levels of
antistreptococcal antibodies in unselected patients with a tic disorder.5-7 Though that
approach bears the risk of circular reasoning, other authors preferred to preselect
patients based on working criteria for pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections (PANDAS).17 Indeed, a number
of prospectively identified PANDAS cases have recently been presented.8 Thus,
there is some indication that streptococcal infections may be associated with tics. We
intended to address this issue in the present study, but identified only one
streptococcal infection in the pediatric cohort versus none in the adult patients
group over a period of 16 weeks. This frequency of streptococcal infections in our
patient groups is in accordance with a reported annual incidence of group A
streptococcal throat infections of 36 per 1000 in the general population.18 In
contrast, a previous study19 prospectively identified 35 streptococcal infections, albeit
with a somewhat less stringent definition, during 8 months in 37 children fulfilling
PANDAS criteria, despite use of penicillin during 4 of these 8 months. That finding
suggests the possibility that children with tics and related disorders would be more
susceptible to streptococcal infections. Also, the studies of Muller5,6 and Cardona7
would be in accordance with a possibly more frequent incidence of streptococcal
infections in tic disorder patients. We were not able to address the issue whether or
not streptococcal infections are associated with subsequent exacerbations in tic
severity. However, the data of the present study do not appear to support a more
frequent occurrence of streptococcal infections in tic disorder patients, compared to
the general population. Thus, given the relatively low incidence of streptococcal
infections, their role in clinical practice appears to be rather limited.
In contrast, common colds are fairly frequent, with an annual incidence of
around four colds per year in teenagers and adults, which center around the winter
season in temperate climates.15 Thus, the present study’s reported frequency of
slightly more than two colds per individual during the 24 weeks’ study period in the
fall and winter period, fits well to established epidemiological figures.15 Common
cold is almost exclusively a viral disease.20 Viral infections are well known to trigger
autoimmune conditions,21-24 though the precise mechanism of induction of
autoimmunity by viral infections is largely unknown. Since common colds can be
caused by a plethora of viral species, future studies should try to identify which
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viruses may be associated with tic exacerbations in children, and how these may
influence antineuronal antibody levels.25 Also, it would be of interest to prospectively
study the role of infections regarding the onset of tic disorders, eg in young children
with one or both parents and/or siblings affected by tics.
In the present study, we exclusively relied on subjective self-questionnaires for
both detecting tic exacerbations as well as common colds. Thus, future studies
should try to objectively determine exacerbations in tic severity, using established
rating instruments,3 preferably with at least weekly assessments of tic severity. In
addition, such studies may want to objectively document symptoms of common
cold. However, the excellent response rates in our study over a period of 24 weeks
surely is an indicator of the high motivation of participants, and thus, of the
reliability of the present data.
In conclusion, the present finding that common cold appears to be associated
with children’s exacerbations in tic severity 4 weeks later, adds to the growing
literature that indicates the possible involvement of the immune system in tic
disorders.1 In addition, this finding underlines the unique possibilities of tic disorders
to study the complex interplay between immune factors, brain functioning and
behavior.
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Abstract
Objective: Clinical experience suggests an association between stressful life events and
fluctuations in symptom severity of tic disorder patients. The aim of the present study was to
examine this possible relationship in a prospective longitudinal design.
Methods: Two groups of tic disorder patients were included in this study, a pediatric
group between 7 and 16 years (N=25; 24 of whom completed the study) and an adult
group of 18 years and older (N=32; 28 of whom completed the study and reported at
least one life event). During a 12 weeks’ period, participants were asked to weekly fill
out self-questionnaires regarding the occurrence of small life events and self-rating of tic
severity.
Results: In the adult group as a whole, we found a weak but statistically significant
correlation between negative small life events and tic severity during the same week
(r=0.268, p<0.001). However, only a minority of individual pediatric (21%) and adult
patients (18%) demonstrated significant relationships between the frequency of small life
events and tic severity in the same week or 1 week later, with undesirable small life
events positively associated with tic severity in some patients, and negatively associated
with tic severity in other patients.
Conclusion: Contrary to traditional views, in general, life events do not account for
changes in tic severity. Only in a minority of tic disorder patients, fluctuations in
symptom severity appear to be associated with possibly stressful small life events.
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Introduction
Symptoms of tic disorders typically show a pattern of waxing and waning severity
over the course of time.1 Clinical experience suggests that this fluctuation in
symptom severity may be related to stressful life events, such as interpersonal
conflicts, financial problems, and problems associated with work. There is a
surprising lack of research with regard to the role of stress in tic disorders. One
study, involving children and adolescents with Tourette’s disorder, identified
events causing anxiety, emotional trauma, and social gatherings to be associated
with an increase in tics.2 That study was based on the subjective experience of
patients in a cross-sectional retrospective questionnaire. Previously, in a similar
approach, involving a larger series of patients, Shapiro and coworkers3 had
identified that, according to the patients’ own impression, tics tend to increase
with certain environmental factors, such as anxiety and agitation, and tend to
decrease with other factors, most notably nonanxious absorption in a task and the
presence of strangers. In addition, a recent study investigated the role of
psychosocial stress at two timepoints separated by 4 months in a cohort of
children and adolescents with Tourette’s disorder and/or obsessive-compulsive
disorder.4 It demonstrated that these patients experienced significantly more
psychosocial stress than did age-matched healthy controls. Moreover, that study
found that symptom severity correlated with severity of experienced daily life
stressors, but not with indices of major life events. No other prospective,
longitudinal data are available with regard to a possible association of stressful life
events and tic symptom fluctuations.
Evidence for links between psychosocial stress and symptom fluctuations has
repeatedly been found for a broad range of disorders, particularly infectious5,6 and
autoimmune conditions.7 The best predictors of changes in symptom severity
have consistently been relatively frequent small irritants of daily life, generally
referred to as daily hassles.8 Examples include arguments with friends, being
criticized, having problems with (school)work, and being confronted with
unexpected financial burdens.
The Inventory of Small Life Events (ISLE) is one well-known and well-validated
diary type scale in which the occurrence of such concrete small life events can be
scored.9 It covers events in major areas of life, that is, family, work, leisure,
household, financial state, health/illness, nonfamily relations, crime/criminal activity,
education, religion, and transportation. A children’s version, the Small Events
Inventory-Child reports is also available.10
We used these scales in a pediatric and adult cohort of tic disorder patients to
investigate the possible relationship between weekly reports of small life events and
self-ratings of tic severity in a prospective longitudinal design, over a period of 12
weeks. Our hypothesis was that there would be a correlation between small stressful
life events and changes in tic severity over time.
Chapter 9  Small life events  108
Methods
Subjects
Two groups of tic disorder patients were included in this study, that is, a pediatric
group of patients between 7 and 16 years, and an adult group of 18 years and
older. All patients with a tic disorder could only enter the study if they fulfilled
the criteria for a definite tic disorder according to the Tourette’s Syndrome
Research Criteria.11 These criteria require observable tics to be present during the
clinical interview to allow for study entry, ensuring the inclusion of patients
objectively demonstrating tics. Excluded from the study were subjects with a
known IQ below 70. None of the subjects who were willing to participate in the
study fulfilled this exclusion criterion. Presence of comorbid diagnoses, which we
did not record systematically, was no ground for exclusion.
The tic disorder patients were recruited from the outpatient clinic of the Child
and Adolescent Psychiatry Center, Groningen, the Netherlands, or from the Dutch
Tourette’s syndrome patients’ association. Subjects were initially recruited by letters
sent to a number of patients with a known clinical diagnosis of a tic disorder at
our center, and to members of the patients’ association. From our child and
adolescent psychiatry center, 35% of approached patients were initially interested
to participate. The aim and procedure of the study were fully explained to the
subjects before written consent was requested. If the subjects were under 18, the
parents were informed as well, and the written informed consent of the parents
and the subject's assent were obtained. Patients were informed that we intended
to study the relationship between small life events and changes in tic severity over
time. However, we did not explicitly reveal the specific study hypothesis. The
study was approved by the Dutch central medical-ethical committee. To assess tic
severity at study entry, we used the motor and vocal scores of the Yale Global Tic
Severity Scale, which records tic severity over the past week.12 The sum of both
scores was used as a measure of total tic severity. We decided not to use the
impairment rating of the Yale Global Tic Severity Scale, in order to minimize
possible confounding with stress ratings, since the impairment ratings may
partially reflect perceived psychosocial stress. Diagnostic assessment and rating of
tic severity was performed by one of the authors, either P.J.H. or M.P.S., who are
both experienced in the diagnosis of tic disorders.
Twenty-five tic disorder patients entered the pediatric study group, 17 from the
patients’ association, and eight from our outpatient center. All patients from the
patients’ association had in the past been referred to a mental health service. The
adult group of tic disorder patients consisted of 32 patients, 24 from the patients’
association, and eight from our outpatient center. Again, all patients from the
patients’ association had in the past been referred to a mental health service. Table 1
shows demographic data, tic severity, and medication status at study entry of both
patient groups.
Chapter 9 109
Table 1. Patient characteristics regarding tic severity, age, gender, and





Symptom severity Mean SD (range) Mean SD (range)
YGTSS motor tics 12.6 5.7 (4-25) 14.4 3.8 (9-25)
YGTSS vocal tics 5.6 5.8 (0-25) 9.0 6.4 (0-25)
YGTSS total score 18.2 9.1 (8-50) 23.4 8.4 (10-50)
Age 13.0 2.7 (7-16) 36.1 14.6 (18-64)
Gender N % N %
male 19/25 76.0 20/32 62.5
female 6/25 24.0 12/32 37.5
Medication status
none 11/25 44.0 18/32 56.3
clonidine 3/25 12.0 0/32 0
clonidine+neuroleptic 2/25 8.0 0/32 0
neuroleptic 9/25 36.0 11/32 34.4
AD 0/25 0 3/32 9.4
YGTSS= Yale Global Tic Severity Scale; AD=antidepressive agent
Procedure
During 12 consecutive weeks, each week, on a chosen fixed day of the week,
participants were asked to fill out a questionnaire. When participants were children,
parents were allowed to assist the children in filling out the questionnaire. However,
parents and children were instructed that the child’s judgement should form the
basis of the scores. On this questionnaire, both pediatric and adult participants were
asked to weekly rate the severity of their tics on a 10-point scale in which one
represents no tics, two represents minimal tics, and 10 represents the worst-ever tics.
In addition, for pediatric patients, the questionnaire contained a Dutch translation of
the Small Events Inventory-Child Reports.10 This scale contains 41 different
everyday events that are meaningful indicators of the level of stress in the child’s life,
as well as indicators of positive transactions between the child and the social world.
There are 29 desirable items on the scale, whereas the remaining 12 items are
undesirable events. Respondents were asked to indicate whether each event
happened once, twice, three times, more than three times, or not at all during the
preceding week. The weekly questionnaire of the adult participants contained a
Dutch translation of the undesirable items of the ISLE,9 a total of 46 possible
negative events covering all major domains of everyday life. The reason we did not
include positive events in the adult ISLE is, that we wanted to keep the list short, in
order to increase response rates and reliability, since the adult ISLE contains far
more items than the pediatric version. Like the pediatric patients, adult respondents
were asked to indicate whether each event happened once, twice, three times, more
than three times, or not at all during the preceding week. Finally, both pediatric and
adult patients were asked to record any change in psychotropic medication regime.
We did not ask for reasons of change in medication. All questionnaires were to be
mailed to us in stamped envelopes on a weekly base.
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Statistical analysis
For the pediatric group, weekly scores of desirable events and undesirable events,
respectively, were computed by adding up all reported frequencies, with a
response of “more than three times” counted as 4 times. The same was done with
regard to weekly scores of undesirable small life events for the adult patients. For
each individual participant, Pearson’s correlation coefficients were computed
between weekly scores of events and weekly ratings of tic severity. In addition, we
computed Pearson’s correlation coefficients between weekly scores of events and
weekly ratings of tic severity for the pediatric and adult group as a whole. For the
latter analyses, we used z-scores of tic severity and small life events scores. These
z-scores were based on each individual’s ratings across the 12 weeks’ study
period. Also, we performed the same correlation analyses between tic severity and
life events score of the preceding week. To investigate whether there is an
association between the initial level of tic severity, as rated by the clinician, and
frequency of small life events, we computed Pearson’s correlation coefficients
between Yale Global Tic Severity Scale measures and first week small life events
scores, in both the pediatric and the adult group. Also, in both study groups, we
looked for an overall relationship between the patients’ average number of
negative and, in the case of the pediatric patients, also positive life events, and the
average subjective tic severity over the study period, again using Pearson’s
correlation coefficients. In addition, Pearson’s correlation coefficients were
computed for both patient groups between the total Yale Global Tic Severity
Scale baseline scores, and the subjective tic severity ratings from the same week,
to get preliminary data on the subjective ratings’ validity. Finally, to rule out
medication effects, in both the pediatric and adult patient group, we used the
paired-sample t-test to test for possible differences in subjective tic severity in the
week in which the medication was changed, and subjective tic severity 1, 2, 3, and
4 weeks later. Patients were only part of the analyses when they participated for
more than 2 weeks, and reported at least one small life event during the study
period. Two-tailed P values less than 0.05 were considered significant.
Results
Response rate
The pediatric group returned a total number of 241 questionnaires, a response rate
of 80.3% returned questionnaires. One pediatric patient decided to withdraw from
the study after 1 week. Without this patient, the response rate was 83.3%. The adult
patient group returned a total number of 317 questionnaires, an overall response rate
of 82.6%. One adult patient decided to withdraw after 1 study week, another adult
patient stopped after 2 weeks. Without these patients, the response rate of the adult
patient group was 87.2%. Finally, the response rate of the 28 adult patients who
were part of the statistical analyses was 86.3% (two adult patients did not report a
single negative life event over the entire study period, and were removed from the
analyses).
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Subjective tic severity ratings
The mean subjective tic severity for the pediatric group was 5.1 (SD=2.4,
range=1-10). For the pediatric group, the mean difference between the highest and
lowest subjective tic severity rating for each individual over the 12 weeks’ period was
4.0 (SD=1.4, range=1-8). The mean subjective tic severity for the adult group was
6.0 (SD=1.9, range=1-10). For the adult group, the mean difference between the
highest and lowest subjective tic severity rating for each individual over the 12
weeks’ period was 3.5 (SD=1.6, range=0-7). Finally, we identified significant
correlations between the total Yale Global Tic Severity Scale baseline scores and the
subjective tic severity ratings from the same week, in both the pediatric (r=0.599,
p=0.002) and the adult patients (r=0.503, p=0.006).
Small life events scores
The mean weekly rating of desirable small life events in the pediatric group was 32.2
(SD=18.2, range=0-81), whereas the mean weekly rating of undesirable small life
events in the pediatric group was 2.9 (SD=3.9, range=0-20). In the pediatric group,
the mean difference between the highest and lowest weekly desirable small life
events frequency rating for each individual over the 12 weeks’ period was 31.3
(SD=16.1 range=5-70), versus a mean difference between the highest and lowest
weekly undesirable small life events frequency of 7.3 (SD=4.5, range=2-20). The
first week desirable life events score demonstrated a significant inverse correlation
with the baseline vocal (r=-0.437, p=0.029), and total tic score (r=-0.447, p=0.025),
but not motor tic score (r=-0.342, p=0.095). No such significant or nearly significant
correlations were found between first week negative life events scores and baseline
indices of tic severity.
In the adult group, the mean weekly rating of undesirable small life events was
6.6 (SD=7.8, range=0-78). Two adult patients did not report a single undesirable
small life event over the entire study period, two other subjects participated for no
more than 2 weeks. One of these last subjects reported a high number of
undesirable life events regarding this single week. Without these four subjects, the
mean weekly rating of undesirable small life events in the adult group was 6.9
(SD=6.7, range=0-35). For the adult group without the aforementioned four
subjects, the mean difference between the highest and lowest weekly undesirable
small life events frequency rating for each individual over the 12 weeks’ period was
11.9 (SD=7.8, range=2-35). In the adult group, no significant or nearly significant
correlations were found between first week negative life events scores and baseline
indices of tic severity.
Changes in medication
In the pediatric group, participants reported 19 times a change in their use of
psychotropic medication, or in 8.1% of all weekly ratings. In the adult group, this
was reported 38 times, or in 12.6% of all weekly ratings. In both the pediatric and
the adult patient group, no statistically significant relationship was found between
subjective tic severity in the week in which the medication was changed and
subjective tic severity 1, 2, 3, and 4 weeks later (paired sample t-tests).
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Association between subjective tic severity and small life events
Of 24 pediatric patients who returned more than two questionnaires, 19 (or, 79%)
did not show any statistically significant correlation between weekly ratings of tic
severity and weekly frequencies of desirable small life events or weekly ratings of
undesirable life events during the same week or 1 week earlier. Of the remaining five
pediatric patients (21% of the total group), two showed a significant relationship
between tic severity and positive events during the same week, albeit in opposite
directions (r=-0.723, p=0.008; and r=0.781, p=0.022), one patient showed a
negative relationship between 1 week-lagged positive events and tic severity
(r=-0.535, p=0.022), and another patient showed a significant positive relationship
between 1 week-lagged negative events and tic severity (r=0.607, p=0.048). Finally,
one pediatric patient showed a positive correlation between positive life events and
tic severity during the same week (r=0.720, p=0.044), as well as a negative
correlation between tic severity and 1 week-lagged negative life events (r=-0.811,
p=0.027). In the pediatric group as a whole, no statistically significant correlation
was found between weekly ratings of tic severity and weekly frequencies of desirable
small life events or weekly ratings of undesirable life events. Also, no statistically
significant correlation was found between weekly ratings of tic severity and weekly
frequencies of desirable small life events or weekly ratings of undesirable life events
1 week earlier. Finally, no overall relationship was identified between the pediatric
patients’ average subjective tic severity over the study period, and their average
number of encountered negative (r=0.229, p=0.282) and positive small life events
(r=0.099, p=0.645).
Of the 28 adult patients who participated in the study for longer than 2 weeks
and who reported at least one undesirable life event over the 12 weeks’ study period,
23 (or, 82%) did not show any statistically significant correlation between weekly
ratings of tic severity and weekly frequencies of undesirable small life events during
the same week or 1 week earlier. Of the remaining five adult patients (18% of the
total group), only one subject showed a significant relationship between tic severity
and undesirable life events during the same week (r=0.818, p=0.001). This same
patient also showed a significant positive correlation between tic severity and 1
week-lagged negative life events (r=0.781, p=0.005). Figure 1 shows the course of tic
severity and number of negative small life events of this particular patient. The four
remaining patients all showed a significant correlation between tic severity and 1
week-lagged negative small life events, with two patients demonstrating a negative
correlation (r=-.796, p=0.006; and r=-0.843, p=0.002) and two patients showing a
positive correlation (r=0.964, p=0.036; and r=0.605, p=0.049). In the adult group as
a whole, we found a small, but statistically significant correlation between negative
small life events and tic severity during the same week (r=0.268, p<0.001). In the
adult group as a whole, no statistically significant correlation was found between
weekly ratings of tic severity and weekly frequencies of undesirable life events
1 week earlier. Finally, no overall relationship was identified between the adults
patients’ average subjective tic severity over the study period, and their average
number of encountered negative small life events (r=-0.284, p=0.143). Table 2 gives
a summary of the main study findings.
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Table 2. Summary of study findings with regard to subjects who participated for






N % N %










Weekly number of positive events 32.2 18.2 (0-81) n.a.










none 19/24 79.2 23/28 82.1
only with negative events 1/24 4.2 5/28 17.9
only with positive events 3/24 12.5 n.a.
both with negative and positive events 1/24 4.2 n.a.
Associations within whole group r p r p
negative events n.s. .2681 .001
positive events n.s. n.a.
n.a.=not available, n.s.=not significant; 1was found with regard to association between tic
severity and number of negative small life events within the same week.
Discussion
Tics have traditionally been considered stress-sensitive phenomena.13 Indeed, in the
adult group, but not in the pediatric study group, we found a weak but statistically
significant correlation between negative small life events and changes in tic severity.
The results of correlation analyses within individuals, however, indicate that only in a
small minority of around 20% of cases, fluctuations in tic severity may be related to
stressful small life events. Moreover, in those individuals whose tics appear to be
associated with the frequency of reported small life events, the direction of the












Figure 1. Course of tic severity
and number of experienced
negative small life events in an
individual adult patient who
showed a significant  relation-
ship between tic severity and
undesirable life events during
the same week (r=0.818,
p=0.001) and between tic se-
verity and 1 week-lagged ne-
gative life events (r=0.781,
p=0.005).
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patients whose tics deteriorated in association with desirable life events, and other
patients in whom undesirable small life events were associated with decrease in tic
severity. We also, however, identified individual associations the other way around.
Thus, there does not appear to be a general pattern of how stressful life events may
be associated with fluctuations in tic severity. This is in accordance with the reports
of Silva et al.2 who also found that tics could decrease in response to a particular
environmental factor in some individual patients, which could lead to an increase in
tics in other patients. Examples of these ambiguous environmental factors included
social gatherings, a doctor’s office visit, and reading for pleasure. However, it should
be stressed that only in the pediatric group we investigated the role of positive
events.
In the present study, we focused on weekly changes in tic severity versus changes
in the weekly frequencies of small life events. Indeed, the patients in this study
showed rather large weekly fluctuations in self-reported tic severity. Still, in general,
the frequency of reported life events, which showed similarly large weekly
fluctuations, do not appear to account for the reported changes in tic severity.
Despite the apparently limited role of small life events with regard to weekly
fluctuations in tic severity, certain psychologically relevant environmental factors,
especially anxiety-producing events may still be associated with short term increases
in tic severity, which may only last minutes to hours and may not influence tic
severity across the better part of a week. Future studies should specifically address
that issue using prospective designs.
Other environmental factors may play a more profound role, presumably
common infections.14 It would be of interest to determine whether individual
patients can be identified according to a unique responsiveness to environmental
factors, such as life events or streptococcal infections.15 Also, it would be of
interest to study biological substrates of stress influences, including cortisol and
the role of the hypothalamic-pituitary-adrenal axis.16
In future designs, frequency of small life events may be measured simultaneously
with perceived stress,17 since individuals may differ with respect to the impact of
small life events. The recent study by the Yale group4 demonstrated that patients
with Tourette’s disorder, compared with unaffected controls, greatly differed with
regard to reported cross-sectional levels of perceived stress, including perceived
severity of stress associated with everyday problems. Patients were not found to
differ significantly from controls, however, with regard to the number of
experienced life events, as long as discrete events were concerned. While we did not
obtain weekly small life events scores from healthy controls, we did not generally
encounter significant correlations between the frequency of small life events and
baseline tic severity as rated by the clinician. Taken together, the findings of Findley
et al.4 and the present study suggest that tic disorder patients may not differ from
unaffected controls with regard to the probability of having encountered life events,
but with regard to the levels of experienced stress associated with them.
Findley et al.4 found a significant longitudinal relationship between experienced
severity of stress associated with daily life hassles and symptom severity. According
to the present study, life events per se are in general not associated with changes in
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tic severity. However, it may well be that tic disorder patients are more sensitive to
stress associated with daily hassles and that the findings of the study of Findley et al.4
may in fact reflect this as a consequence, rather than as a cause of changes in tic
severity over time. We intended to study the impact of daily life events on tic
severity, while trying to rule out the confounding influence of heightened sensitivity
to life events, and thus only assessed the frequency of concrete events which all were
in principle observable. Unfortunately, direct comparisons of reported small life
events scores of the present study, as yielded by the ISLE with previously reported
frequencies in other patient groups18 are hampered by differences in selection of
ISLE items and ways of obtaining scores (telephone ratings versus use of self-
questionnaires). Thus, future studies should use well-matched control subjects to
investigate the issue of frequency of encountered life events and levels of perceived
stress associated with them.
Limitations of the study
The relationship between psychosocial stress and tic severity is an important issue,
that very few studies have addressed so far. It should be stressed that the present
study served primarily exploratory purposes and that it has several limitations, which
should be considered in future studies. First, we obtained only a single mean score
for baseline tic severity at enrollment. Future studies may consider to use a washout
period during which a few weeks of tic fluctuations could be recorded. This might
better ground a subsequent response to life events in terms of magnitude. In
addition, we failed to investigate the role of major life events,19 such as breaking up
intimate relationships or death of beloved ones. However, the results of the study of
Findley et al.4 seem to indicate a more significant role for psychosocial stress
associated with small events than with less frequent major events. Furthermore, in
this study, we exclusively relied on subjective self-questionnaires. These correlated
modestly with Yale Global Tic Severity Scale scores, what should be viewed,
however, against the background that participants subjectively rated their tics
according to their individually experienced range of tic severity, rather than
according to the overall range of tic severity of tic disorder patients in general.
Future studies, though, should try to objectively determine fluctuations in tic
severity, using established rating instruments. However, the excellent response rates
in our study over a period of 12 weeks surely is an indicator of the high motivation
of participants, and thus, of the reliability of the present data.
In conclusion, this study regarding the association between small life events and
fluctuations in tic severity confirms the clinical impression that stressful life events
may lead to changes in tic severity in individual patients. However, a more important
conclusion is, that for the majority of patients this does not appear to be the case.
Thus, clinicians should be cautious with simple psychological explanations for
exacerbations in symptom severity of tic disorder patients.
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Abstract
Objective: Case studies and a placebo-controlled study previously suggested the
effectiveness of immunomodulatory therapy in those patients with tic or related disorders
whose symptoms show a relationship with streptococcal infections. No data are available
on the effectiveness of intravenous immunoglobulins (IVIG) on tic severity in unselected
tic disorder patients.
Methods: Thirty tic disorder patients were randomized to IVIG (1 g/kg on two
consecutive days; mean age of subjects=28.71, range=14-53) or placebo (mean age of
subjects=30.73, range=14-63). Symptom rating occurred at baseline and at week two,
four, six, 10, and 14 post-treatment, after which blinding was broken.
Results: We observed no significant differences between both treatment groups
regarding post-treatment changes in tic severity. Severity of obsessions and compulsions,
which was in the subclinical range at base line, decreased significantly in the IVIG
group compared to the placebo group at week six (p=0.02). Then, there was a 32.3%
improvement in the IVIG group compared to base line level. Though this improvement
was maintained over the following 8 weeks, no statistically significant differences between
the IVIG and the placebo group with regard to improvements in obsessions and
compulsions were detected at subsequent assessments. IVIG treatment was associated
with significantly more side-effects than placebo, most notably headache.




Tic disorders, formerly thought as having a psychogenic cause,1 are now generally
regarded neurobiological disorders with a strong genetic component.2 These
disorders are characterized by the presence of recurrent sudden movements and/or
utterances, frequently accompanied by associated behavioral difficulties, such as
hyperactivity/impulsivity, attentional problems, emotional lability, rage attacks, and
obsessive-compulsive symptoms.3 Though symptoms may improve after the onset
of puberty,4 a considerable number of patients suffer lifelong from this debilitating
symptomatology. Intriguing recent research findings support the possible
involvement of autoimmunity in tic disorders.5 Infections are thought to induce
symptom exacerbations,6 possibly through the involvement of antineuronal
autoantibodies.7 The relationship between infections and symptom fluctuations is
most evident in cases fulfilling criteria for pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections (PANDAS),8 but may also apply
to a broader range of tic disorder patients, as recently discussed.5 The relevance of
immunological factors may have important treatment implications. Indeed, some
published case studies reported the successful application of immunomodulatory
therapies in patients with tic disorders, mostly reported in cases fulfilling PANDAS
criteria. These included immunosuppression with corticosteroids,9-11 therapeutic
plasma exchange,12,13 and intravenously administered immunoglobulins (IVIG).13-15
Only a single placebo-controlled study is available with regard to immune-based
treatments.16 That study pointed to the effectiveness of both plasma exchange and
IVIG in pediatric tic and obsessive-compulsive disorder patients who all met
PANDAS criteria,8 compared to a placebo condition. Interestingly, a single course
of plasma exchange or IVIG resulted in positive effects that were still present at 1
year after treatment. Treatment with IVIG resulted in significant improvements in
obsessive-compulsive symptoms, anxiety, and depression. However, the IVIG
group did not show significant improvement in tic severity. Since the study of
Perlmutter et al.16 included two different disorders, that is, obsessive-compulsive
disorder (OCD) and/or tic disorders, the number of patients with tics in that study
was rather low (eight children with tics in the placebo group versus four in the IVIG
group). In addition, given the PANDAS criteria that subjects had to meet, which
require evidence of an association between streptococcal infection and onset or
exacerbation of signs and symptoms, the patients who were enrolled in the study
may well not be representative of tic disorder patients in general. In other words,
whether IVIG benefits tic severity in unselected patients with a tic disorder has not
been addressed. This is an important issue, given the possible involvement of
immune factors across tic disorder patients who were not specifically preselected
using PANDAS.6,17 Meanwhile, the imposing results of the single placebo-
controlled study,16 as well as the published highly successful case reports,13-15
information which is readily accessible to a lay public via the internet, has
occasionally led to considerable pressure inflicted on clinicians by tic disorder
patients or their parents to apply one of the immunomodulatory treatment options.
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Also, many clinicians themselves wonder if they should refer their patients with tic
or related disorders to such treatment modalities, especially given the paucity of
currently available treatment possibilities, which consist largely of the use of
antipsychotic agents, that are purely symptomatic and may have troublesome side-
effects. This led us to conduct the present double-blind study in which we
compared the therapeutic effect of a single course of IVIG with a placebo condition
in a group of unselected patients with a chronic tic disorder. We used changes in tic
severity as the primary endpoint of the study. In addition, we assessed changes in
obsessive-compulsive symptoms.
Contrary to the study of Perlmutter et al.,16 who studied children aged 5-14 years,
we decided to enroll patients of 14 years and older, including adult patients.
Spontaneous, long lasting remissions in tic severity are far less likely to occur in
older patients, especially adults, than in prepubertal children.18 Thus, development
of effective treatment options is most urgently needed for those older patients, who
continue to show bothersome tics. We hypothesized that IVIG treatment would be




Patients with a tic disorder of 14 years or older were recruited from two sources,
that is, from members of the Tourette’s syndrome patients’ association in the
Netherlands and from patients who had been referred to the outpatient clinic of the
Child and Adolescent Psychiatry Center in Groningen, the Netherlands. Patients of
both groups received a written invitation to participate in the study. This letter
provided information about the aims and background of the study. A total number
of 64 patients (21 from our outpatient clinic and 43 from the patients’ association)
were initially interested to participate and were assessed for study eligibility by the
first author. Eligibility criteria included fulfillment of the research criteria for a
definite tic disorder according to the Tourette’s Syndrome Classification Study
Group19 (implying that observable tics have to be present during the clinical
interview to allow for study entry) and presence of tics severe enough to cause
significant distress and interference with the patient’s functioning in at least two
spheres (home, school, work, social relationships). This tic severity requirement
was based on the subjective experience of patients and not on a formal tic rating
cutoff. In addition, the presence of a tic disorder had to be the primary problem.
Though none of the patients met PANDAS criteria,8 these were not used as an
exclusion criterion. Excluded from the study were subjects with total IgA
deficiency and anti-IgA antibodies, given the risk of anaphylactic reactions caused by
IgE class anti-IgA antibodies reacting with IgA in the IVIG preparation. Therefore,
all patients were screened with regard to IgA deficiency. This was detected in none
of the subjects who were willing to participate. The aim and procedure of the study
were fully explained to the subjects before written consent was requested. If the
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subjects were under 18, the parents were informed as well, and the written
informed consent of the parents and the subject's assent were obtained. The
study was approved by the Dutch central medical-ethical committee (The Hague,
the Netherlands) and was in accordance with the Helsinki Declaration of 1975, as
revised in 1983. Thirty-four patients did not meet inclusion criteria or were
unwilling to give final consent; the remaining 30 patients (eight from our
outpatient clinic and 22 from the patients’ association) were subjected to
randomization. All patients from the patients’ association had in the past been
referred to a mental health service. Thus, all participating patients can be
regarded as referred patients.
Treatment
The 30 tic disorder patients were en bloc randomized to IVIG or placebo with
stratification by sex and age (above and below 18 years). Treatment of all patients
was subsequently scheduled within a period of 14 weeks onward. Patients
allocated IVIG treatment received 1 gram per kilogram immmunoglobulins
(Gammagard, Baxter, the Netherlands) daily for two consecutive days.
Gammagard is a sterile, freeze-dried preparation of at least 90% IgG, purified
from large pools of human plasma, stemming from at least 1 000 donors. The
placebo infusion consisted of an equal volume of 5% albumin solution in the
same vehicle prepared by the manufacturer of the immunoglobulins, which was
also administered daily for two consecutive days. Investigators, nurses, and
patients were unaware of the treatment assignments.
All treatments took place at the day care facility of the University Hospital
Groningen, the Netherlands. After an initial dose of 0.5 mg per kilogram per
minute over a period of 30 minutes, the infusions were administered at a rate of 3
mg per kilogram per minute over a period of 5 to 6 hours. Vital signs, including
blood pressure, were monitored throughout the infusion.
The first investigator, who performed all pre- and post-treatment psychiatric
assessments, was kept unaware of the occurrence of side-effects, which might
have revealed the active treatment. Patients were explicitly asked, not to discuss
these with the first investigator at all assessments. Mild side-effects were to be
treated symptomatically. Acetaminophen was to be used in the case of headache,
flu-like symptoms, and fever, whereas mild adverse reactions (simple urticaria)
were to be treated symptomatically with antihistamines. Treatment-resistant
headache, flu-like symptoms, or fever would lead to a maximum 24-hour
interruption of study medication. Repeated adverse events would cause
discontinuation of treatment. Side-effects were recorded by each patient on a
form containing possible IVIG-associated side-effects.
Throughout the trial, patients were free to continue or adjust any
neuropsychiatric medication, as appropriate according to their physicians, with
no limits on the permissible dose adjustment. This was done for ethical reasons,
given the unproven effectiveness of IVIG.
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Evaluation
Changes in tic severity as assessed by the Yale Global Tic Severity Scale20 were
the primary endpoint of the study. This scale provides an evaluation of the
number, frequency, intensity, complexity, and interference of motor and phonic
symptoms, based on direct examination and historical data from multiple
informants. In addition, we assessed post-treatment changes in severity of
obsessions and compulsions.
Standardized ratings of neuropsychiatric signs and symptoms were obtained
for each patient at baseline. These consisted of the Yale Global Tic Severity Scale
(of which we only used the sum of the motor and vocal tic score), the Yale-
Brown Obsessive Compulsive Scale,21,22 or the children’s version23 for subjects
below 16 years, and the clinical global impression scale of symptom change with
regard to tic severity.24 For the statistical analyses with the latter scale, we decided
to combine the categories “very much improved” and “much improved” to the
outcome “treatment response” and to label all other categories, that is, “minimally
improved”, “no change”, “minimally worse”, “much worse”, and “very much
worse” to one category, “no treatment response”. Evaluations of severity of
neuropsychiatric signs and symptoms were scheduled at week two, four, six, 10,
and 14 after treatment. Serum creatinine was measured at baseline and on day
three. After the final evaluation of the last patient, the IVIG/placebo masking
was broken en bloc. Results were analyzed on the basis of intention to treat.
Patients were not asked which treatment they thought they had received.
Statistical analysis
To measure differences between groups at baseline and subsequent assessments
after treatment, we used repeated-measures analysis of variance (ANOVA) on each
of the neuropsychiatric ratings by use of the SPSS statistical program. Differences in
outcome of the clinical global impression scale of symptom change between both
treatment groups were tested by chi-square analysis. Chi-square analysis was also
used to test for differences in the occurrence of side-effects. Differences in baseline
severity between both treatment groups were assessed by the Mann-Whitney U test.
All tests of significance used the 0.05 level of significance and were two-tailed.
Results
Patient characteristics
One scheduled patient chose to withdraw from the trial before treatment. This
subject had been randomized to receive IVIG. Thus, 14 patients received IVIG and
15 patients placebo. Patient characteristics of the two randomized groups are shown
in table 1. Both groups were comparable in age, sex, tic disorder diagnosis, and use
of psychotropic medication. At baseline, tic severity and severity of obsessions and
compulsions did not differ significantly. None of the patients fully met DSM-IV
criteria for OCD; severity of obsessions and compulsions was in the subclinical
range. No patients were lost on follow-up.
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Mean range Mean range
Age 28.71 14-53 30.73 14-63
Gender N % N %
male 9/14 64.3 9/15 60.0
female 5/14 35.7 6/15 40.0
Medication status
none 6/14 42.9 7/15 46.7
neuroleptic 3/14 21.4 7/15 46.7
neuroleptic+AO 2/14 14.3 0/15 0.0
AO 3/14 21.4 1/15 6.7
Symptom severity Mean SD Mean SD
YGTSS 25.0 9.6 25.5 8.9
YBOCS









TD 13/14 92.9 13/15 86.7
CMT 1/14 7.1 2/15 13.3
IVIG=intravenous immunoglobulins; AO=anti-obsessional agent; YGTSS=
sum of motor and vocal score on Yale Global Tic Severity Scale;
YBOCS=score on Yale-Brown Obsessive Compulsive Scale, or children’s
version for subjects below 16 years; TD=Tourette’s disorder; CMT=chronic
motor tic disorder;
Treatment response
No significant differences were observed between both treatment groups with
regard to post-treatment changes in tic severity (table 2). In both the IVIG group
and the placebo group, post-treatment ratings of tic severity were slightly lower
compared to baseline, that is, between 2.4% and 19.6% for the IVIG group and
4.7% and 16.5% for the placebo group, depending on the post-treatment week.
Regarding changes in severity of obsessions and compulsions, a significant
difference between both treatment groups was only observed at week six
(repeated measure ANOVA; F=5.7; p=0.02). At that time point, there was a
32.3% improvement in the IVIG group compared to the base line level. In
contrast, in the placebo group the improvement at week six was 3.6% compared
to baseline. Though improvement in obsessions and compulsions was
maintained over the following 8 weeks (table 2), no statistically significant
differences between the IVIG and the placebo group with regard to
improvements in obsessions and compulsions were detected at subsequent
assessments.
Treatment response, as determined by the clinical global impression scale of
symptom change ranged between 6.7% and 33.3% in both treatment groups at the
different post-treatment time points. Chi-square analysis did not reveal differences
in number of responders between treatment groups (table 2). Four patients
recorded changes in the use of psychotropic medication during the trial. Two
patients stopped their haloperidol medication, which they both had used in a dose
of once daily 1 mg. One other patient started to use haloperidol, also in a dose of 1
mg daily. The final patient who recorded medication changes had lowered his
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risperidone medication by 1 mg, while at the same time increasing his haloperidol
dose by 1 mg. All patients who changed their medication fell in the placebo group.
The changes in psychotropic medication did not lead to the category “treatment
response” in all four cases, however.
Table 2. Mean symptom severity at baseline and at different post-
treat-ment points, compared to baseline, as well as percentages of
treatment responders.*
Rating Baseline Week 2 Week 4
IG Pl IG Pl p IG Pl p
YGTSS 25.0 25.5 22.9 22.5 .77 24.4 21.3 .17
YBOCS 10.2 5.6 6.1 4.5 .11 9.2 3.7 .50
% responders 7.1 33.3 .08 7.1 33.3 .08
Rating Week 6 Week 10 Week 14
IG Pl p IG Pl p IG Pl p
YGTSS 21.1 22.4 .77 22.1 24.3 .40 20.1 24.3 .18
YBOCS 6.9 5.4 .02 6.4 4.6 .13 6.7 4.5 .11
% responders 14.3 26.7 .41 21.4 13.3 .56 28.6 6.7 .12
IG=IVIG (intravenous immunoglobulins); Pl=placebo; YGTSS=sum of motor
and vocal score of Yale Global Tic Severity Scale (range=0-50); YBOCS=score
on Yale-Brown Obsessive Compulsive Scale, or children’s version for subjects
below 16 years (range=0-40)
*Treatment response was based on the presence or absence of a “very much” or
“much improvement” rating according to the clinical global impression scale of
symptom change, with regard to tic severity. P values represent significance
levels of repeated-measures analyses of variance with regard to differences in
treatment response between patients who received IVIG treatment and patients
who received placebo, and significance levels of chi-square analyses regarding
differences in percentages of treatment responders between treatment groups,
respectively.
Side-effects of treatment
Mild-to-moderate side-effects were reported by four patients receiving placebo
(27%) versus 13 of 14 patients receiving IVIG (93%). Table 3 shows the most
frequently observed side-effects. Most side-effects tended to occur during the
second day of the infusion. The use of acetaminophen was greater in the IVIG-
group than in the placebo-group (71% versus 27%; Pearson’s chi-square=5.8,
p=0.016). Antihistamines for treating adverse reactions were used in three patients
(21%), all belonging to the IVIG-group. Severe treatment-resistant headache led to a
24-hour interruption of medication on the second day in one patient, which implied
that the rest of the dose was given on a third day. This patient belonged to the
IVIG-group. Due to treatment-resistant difficulty in breathing, one patient, who
belonged to the IVIG-group, discontinued treatment on the second day of the
infusion. This patient had received 1 g/kg IVIG on the first day, as scheduled, and
had finished 12.5% of the planned amount of IVIG on the second day. The first
investigator, who performed all pre- and post-treatment psychiatric assessments,
never became aware of the occurrence of adverse events before deblinding.
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Table 3. Occurrence of mild-to-moderate side-
effects in both treatment groups. P values represent






N % N % P
Any side-effects 13 93 4 27 <.001
Chills 6 43 1 7 .023
Headache 11 79 4 27 .005
Fever 5 36 0 0 .011
Vomiting 4 29 0 0 .026
Nausea 7 50 1 7 .009
Dizziness 3 21 0 0 .058
Discussion
This is the first double-blind placebo-controlled study in which the effect of
IVIG is examined in unselected chronic tic disorder patients, either Tourette’s
disorder or chronic motor tic disorder, two etiologically closely related
disorders.25 According to our data, IVIG does not appear to be an effective
treatment with regard to reducing tic severity in these patients. One major
difference with the earlier study of Perlmutter et al.16 is our use of a patient
group, whose main feature was the presence of tics, while the study of Perlmutter
et al.16 involved children who did or did not have tics, and whose primary
problems were in the field of obsessions and compulsions and emotional
problems, including anxiety and depressive symptoms. A second major
difference is that our patients did not meet PANDAS criteria contrary to the
study of Perlmutter et al.16 Finally, the present study involved adolescent and
adult patients, as opposed to the pediatric patients in the study of Perlmutter and
colleagues.16 Still, regarding effect on tic severity, our results are in accordance
with the latter study,16 which, also, did not show improvement in tic severity after
IVIG.
Apart from the possibility that IVIG may have no effect on tics, a number of
other factors may explain the lack of treatment response in the present study.
First, patients in our study had experienced many years of disease, which may be
associated with non-reversible damage to relevant neuronal circuits. Further-
more, patients were not preselected with regard to a presumed autoimmune
etiology, based on either clinical criteria8 or laboratory parameters.26 The present
study cannot rule out that highly selected patients may still profit from treatment
with IVIG. Moreover, the patients had access to psychotropic medication both
prior to and during the trial, and thus form a treated patient population. This
makes it more difficult to detect a positive effect from a new treatment, which
increases the risk of a type II error. Another risk for a type II error may be the
relatively low number of patients in each treatment arm. Finally, we used only a
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single IVIG dose, as did Perlmutter and coworkers,16 whereas many IVIG
treatment protocols use repeated, often monthly IVIG applications over time.27
It may still be that multiple IVIG doses doses over a longer period of time
appear to demonstrate efficacy in lessening of tic severity. However, the present
available data from both our and Perlmutter’s study16 do not lend support to the
application of IVIG in tic disorder patients.
Though we studied patients with a primary diagnosis of a tic disorder, we did
find a significant effect regarding improvement of obsessive-compulsive
symptoms in the IVIG group. At week six post-treatment, ratings of obsessions
and compulsions had been decreased by 32% in the IVIG group. While this
improvement was maintained over the following 8 weeks, differences between
the IVIG and the placebo group with regard to improvements in obsessions and
compulsions did not reach statistical significance at subsequent assessments.
Also in the study of Perlmutter et al.,16 IVIG appeared to benefit severity of
obsessions and compulsions. Thus, there is some indication that IVIG may improve
obsessions and compulsions. Still, the present results regarding possible
effectiveness of IVIG for symptoms of OCD should be viewed with much caution,
given the fact that obsessions and compulsions were by no means the patients’ main
symptoms. In fact, baseline ratings for OCD symptoms were rather low in our
study and were in the subclinical range. Thus, observed improvements should not
be considered clinically significant. In addition, the between-group difference in
improvement of OCD symptoms at week six post-treatment may have been
primarily related to a floor effect, due to the very low YBOCS baseline ratings in the
placebo group. Future studies should specifically study the effect of IVIG in
patients with different subtypes of OCD, eg pediatric onset versus adult onset
OCD, OCD with tics versus OCD without tics, and OCD with and without
poststreptococcal exacerbations.
Contrary to Perlmutter et al.,16 we found a relatively high placebo response in our
study, with 33% of patients in the placebo group being much or very much
improved at 2 weeks post-treatment. While we do not have an explanation for the
striking lack of placebo effect in the study of Perlmutter et al.,16 the sizeable placebo
response that we encountered, may well explain some of the successes of the case
studies which reported improvement after immune-based therapy,13-15 as well as
some of the effect of the plasma exchange in the study of Perlmutter et al.,16 which
was not placebo-controlled. Thus, future studies should use blinded and well-
controlled designs.
In conclusion, based on the present results, we cannot recommend IVIG
treatment for reducing tic severity. Moreover, at present, the use of IVIG in OCD
patients should be confined to placebo-controlled research protocols.
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Abstract
Tourette’s syndrome is a childhood-onset neuropsychiatric disorder characterized by the
presence of both multiple motor and vocal tics. While the pathogenesis at a molecular
and cellular level remains unknown, structural and functional neuroimaging studies
point to the involvement of the basal ganglia and related cortico-striato-thalamo-cortical
circuits as the neuroanatomical site for Tourette’s syndrome. Moreover, Tourette’s
syndrome has a strong genetic component and considerable progress has been made in
understanding the mode of transmissioin and in identifying potential genomic loci.
Summaries of recent findings in these areas will be reviewed, followed by a critical
overview of findings both supporting and challenging the proposed autoimmune
hypothesis of Tourette’s syndrome. We conclude that Tourette’s syndrome is a




A tic is an involuntary, sudden, rapid, recurrent, nonrhythmic, stereotyped motor
movement or vocalization.1 Thus, a distinction is made between motor and vocal
tics. Tics are rather common in school age children, but are more often than not
transient phenomena.2 They may, however, follow a chronic course, and can be
present lifelong in some persons.3 The best studied tic disorder is Tourette’s
syndrome (TS), defined in the latest edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV TR)1 by the presence of both multiple
motor tics and one or more vocal tics throughout a period of more than 1 year,
during which period there was never a tic-free period of more than three
consecutive months. Closely related,4 are a number of other tic disorders as
defined in DSM-IV TR, most notably chronic motor tic disorder and chronic
vocal tic disorder, in which only one type of tic is present, either solely motor
movements or vocalizations, respectively.
While tic disorders were once regarded as psychogenic conditions,5 twin and
family studies now indisputably point to a major genetic contribution in these
disorders. Neurobiological research has revealed a number of possible alterations
and there is some indication that immune dysregulation may be involved in the
pathogenesis of tic disorders. Briefly, some of the immune research suggests that
infections may induce or reinforce tics and associated features in susceptible
individuals, through the possible involvement of abnormal humoral immune
responses directed against self-tissue antigens. After outlining the main clinical
features of TS and summarizing the research in the areas of genetics,
neurochemistry and neuroimaging, we will present an overview of findings
supporting, as well as challenging the immune hypothesis of tic disorders.
Clinical features
Tics vary greatly between and within individuals. Most motor tics are brief,
sudden and meaningless muscle movements, such as eye blinking, nose twitching,
or shoulder shrugging, referred to as simple motor tics. In contrast, complex
motor tics appear more purposeful and involve several muscle groups. Examples
include touching other people or objects, retracing steps when walking, and
various complex hand gestures. Similarly, vocal tics may be subdivided into
simple and complex tics, ranging from meaningless sounds as throat clearing,
sniffing, and barking to the sudden utterance of words, phrases, and full
sentences which may include echolalia and coprolalia.
Tic intensity can vary substantially, ranging from barely visible or audible tics
to extremely forceful or loud expressions. Quite often, tics are mild, in which case
they may hardly attract attention from others and may not interfere with everyday
life at all. However, powerful and frequent tics may severely interfere with
everyday activities, including speech, driving, and walking. In exceptional cases,
tics may lead to physical injury, including joint dislocation and other tissue
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damage. Patients who display more severe or complex tics may be stigmatized as
a result of the unusual, inappropriate, and bizarre character of their tics.
Most patients do not experience their tics as entirely beyond their control.6
Many individuals describe premonitory urges preceding their tics,7 feelings that
are momentarily relieved by the performance of tics and may be temporarily
ignored by suppressing the tics. Furthermore, tics tend to occur in bouts
alternated with relatively tic-free periods within the course of a day.8
The median age of onset of tics is 7 years.9 Onset before the age of two and
after the age of 12 is highly unusual. In general, tics do not start abruptly in an
individual’s life. More typical is a gradual initial course, in which weeks with mild
tics alternate with tic-free periods. Over time, tics may either disappear
spontaneously, or may gradually become more frequent and prominent. Initial
tics almost invariably involve the face; most frequently, eye blinking forms the
first tic symptom. In the following months to years, tics may spread to other
body parts and may become more complex and forceful. Vocal tics tend to begin
several years after the first motor tics have appeared. They commonly start as
meaningless simple sounds, but may be supplemented by more complex
vocalizations later on. Especially in children, tics tend to vary substantially over
time in their location, frequency, and forcefulness and may typically follow a
waxing and waning course with regard to overall severity.10 This changing pattern
tends to become less varied by the early adult years, concomitant with an overall
trend of diminishing tic severity11 with regard to both intensity and frequency.
Still, a significant minority of patients may continue to demonstrate bothersome
tics in their adult years.
A recent large epidemiological study reported transient tics to be present in up
to 5% of school age children and reported a prevalence of TS in school age
children of about 0.6%, with males found to be more frequently affected than
females.2 This prevalence of 0.6% is higher than those reported in previous
studies.12
A final important feature of tic disorders is their association with a wide range
of comorbid behavioral abnormalities, which in certain individuals may be more
clinically relevant than the tics themselves. Most studies have reported increased
frequencies of hyperactivity, impulsivity, attentional impairments, obsessive-
compulsive features, and difficulties regarding social functioning in tic disorder
patients, when examined on a group basis.13-15
Neuroanatomy
Currently, the pathogenesis of tic disorders at a molecular and cellular level is
unknown. Also, there is no definite evidence of the neuroanatomical substrate of
tics. The basal ganglia play an established role in other movement disorders
including Huntington’s disease,16 Parkinson’s disease,17 and encephalitis
lethargica,18 and thus form an attractive candidate site for involvement in tic
disorders. Moreover, based on the phenomenology and natural history of tic
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disorders, cortico-striato-thalamo-cortical (CSTC) circuits have been suggested to
be involved in tic disorders.19 At least five functionally and anatomically distinct
CSTC circuits have been identified, which subserve sensorimotor, motor,
oculomotor, cognitive, and limbic processes (recently reviewed by Mink20). A
failure to inhibit specific CSTC subsets has been hypothesized to be involved in
tic and related disorders and may be directly linked to specific types of tics, given
the somatotopical organization of these CSTC circuits. For example, facial tics
could be associated with a failure of inhibition of CSTC circuits that receive
topographical projections from the orofacial regions of the (pre)motor cortex.
Similarly, oculomotor CSTC circuits may be involved in eye movement tics,
whereas the limbic circuit may be associated with vocalizations and comorbid
obsessive-compulsive disorder (OCD) and externalizing behavior problems.20
The possible involvement of the basal ganglia and related cortical structures in
tic disorders is supported by recent large-scale structural magnetic resonance
imaging (MRI) studies involving both children and adults with TS. These have
identified basal ganglia and cortical volume differences between TS patients and
healthy controls.21,22 Previously reported findings23-25 of a lack or an inversion of
normal basal ganglia volume left-right asymmetry could not be replicated.22
However, across both children and adults with TS, volumes of the caudate
nucleus were found to be significantly reduced.22 Previously, in a study involving
monozygotic twins both affected with TS, the caudate nucleus was also
consistently found to be smaller in the more severely affected co-twin,26 which
points to the non-genetic nature of the identified caudate volume reduction. The
most prominent feature of the recent large scale studies,21-22 though, were
strikingly different findings between children and adults with TS. In accordance
with previous work,24 adults with TS were found to have reduced lenticular nuclei
volumes, which was not observed in children with TS.22,25 Similar remarkable
differences between children and adults with TS were reported with regard to
cortical volumes.21 Prefrontal and orbital frontal cortical volumes were enlarged
in children with TS, but decreased in adult patients, compared to healthy controls.
Finally, in a functional MRI study in which adult patients were asked to suppress
their tics, prefrontal areas were found to be strongly activated.6
Taken together, the structural MRI studies certainly support the involvement
of the basal ganglia and interconnected cortical structures, even though the
identified volume differences may not necessarily be directly related to the
pathophysiology of TS.27 When considering the opposing direction of some of
the neuroimaging findings in children and adults with TS, it should be
remembered that adults who continue to show tics do not represent the typical
course of tic disorders. Rather, the majority of TS cases have shown complete
remission by the early adult years. Thus, adults with tics may form a subgroup
that is unsuccessful in finding compensatory pathways to the tics. Accordingly,
identified volume changes in children with TS may actually reflect such
compensatory pathways, that the adults with tics would not be expected to
display. In other words, volume changes may point to the plasticity of the brain in
response to compensating for the presence of tics, rather than form a direct
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expression of the pathogenesis of tics. Above all, these findings point to the
importance of longitudinal MRI studies that could study volumes of relevant
brain structures in relation to the onset, changing severity pattern, and possible
remission of the tics over the course of time.27
Finally, in general, findings of positron-emission tomography (PET) and
single-photon emission-computed tomography (SPECT) studies are also in
accordance with the involvement of the basal ganglia in TS. Both reduced glucose
utilization in the ventral striatum28-30 as well as reduced blood flow in the globus
pallidus and putamen31 or the entire basal ganglia32,33 has been reported. In
addition, a recent PET study34 compared regional cerebral glucose metabolic rates
between TS patients and controls and found altered limbic-motor interactions in
TS, again pointing to the relevance of the CSTC circuits. Functional connections
between the motor and lateral orbitofrontal circuits were identified in both
patients and controls; however, a reversal in the pattern of these interactions
differentiated TS patients and controls. In TS patients, activity in the motor and
lateral orbitofrontal circuits appeared to be positively correlated, whereas in
healthy controls, increased activity in motor circuits appeared to be associated
with relative inactivity in lateral orbitofrontal circuits.34
Neurochemistry and psychopharmacology
Without doubt, altered neurotransmission is involved in the pathophysiology of
tics. Central neurotransmitters serve the major goal of communication within the
brain, through binding to specific receptors. Several well-established research
findings strongly suggest disturbances within the dopaminergic system in TS.
First, dopamine receptor blocking pharmacological agents constitute the most
effective tic suppressing medication.35 Moreover, agents which increase central
dopaminergic activity such as L-dopa36 and CNS stimulants37 may induce or
exacerbate tics. Indeed, in five monozygotic twin pairs with TS, SPECT findings
suggested increased dopamine receptor capacity in the caudate nucleus of the
more severely affected co-twin,38 possibly explaining the beneficial effect of
dopamine antagonists in tic disorders.35 In addition, a recent PET study
demonstrated increased intrasynaptic dopamine levels in the putamen of TS
patients after amphetamine challenge, which the authors linked to possible
abnormal dopamine transporter regulation in TS.39 The latter observation can be
taken to suggest that in TS patients, dopamine neurons may release larger than
normal amounts of the transmitter when activated, possibly resulting in loss of
control of motor functions, and the emergence of tics. A recently reported animal
model does tend to support a role for hyperactivation of the dopaminergic
system. Transgenic mice expressing a neuropotentiating protein within a cortical-
limbic subset of dopamine D1-receptor-expressing neurons were shown to
demonstrate tic-like behavior.40
A postmortem brain study has reported that neuronal dopamine uptake sites
were significantly increased in number in the caudate and the putamen, compared
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to control values. This was suggested to indicate enhanced dopamine innervation
within the striatum.41 However, other postmortem brain studies have not found
differences in a range of presynaptic dopaminergic markers,42,43 and a large study
of cerebrospinal fluid neurochemicals did not find altered levels of the principle
dopamine metabolite homovanillic acid.44 In addition, a PET imaging study of a
presynaptic marker of dopaminergic neurons in the striatum did not find
differences between TS and healthy controls.45
Limited additional neurochemical data are available which are suggestive of
alterations of other neurotransmitter systems, including the noradrenergic
system,44 endogenous opioid peptides,46 the serotonergic system,43 and the
glutamatergic system.43 The report of altered glutamatergic neurochemistry in the
medial globus pallidus is of interest as it is consistent with imaging studies
indicating alterations in the pallidum.
Genetics
TS has a strong genetic background (recently reviewed by Pauls47). In a twin
study, in which at least one co-twin had TS, it has been demonstrated that
monozygotic twins are more often concordant for the presence of TS (53%) or
any tics (77%) than dizygotic twins (8% concordant for TS, and 23% for any
tics).48 Thus, genetic factors play a profound role, but the phenotype may be
variable and may not be confined to full-blown TS. Indeed, family studies have
shown that family members of a proband with tics are much more likely to have
tics, compared to persons in the general population.49,50 Several independent
family segregation analyses have reported that the mode of vertical transmission
of TS fitted best to a mode of inheritance involving a single autosomal dominant
locus with varying penetrance;50-52 more recent studies though, have indicated that
the genetic transmission is probably more complex.53,54
Subsequent classic multigenerational parametric linkage studies were
unsuccessful in finding the presumed major TS locus, after having excluded more
than 95% of the genome.47,55 These linkage studies had been carried out under
the assumption that TS is a homogeneous disorder in which a major dominant
gene would be involved and that the presumed TS phenotype would include
chronic motor tics. Obviously, these assumptions were challenged by the negative
results of the linkage studies. In addition, there is still debate about the exact
nature and range of the putative TS phenotype. According to some authors, this
may include forms of OCD56 and attention deficit/hyperactivity disorder
(ADHD).57
Meanwhile, new strategies have been enlisted in the search for the genes
involved in TS, including the investigation of a number of candidate genes and
regions. Candidate genes included the dopamine58 and adrenergic59 receptor
genes, the dopamine60 and serotonin transporter61 genes, the catechol-o-
methyltransferase gene,62,63 and the human leukocyte antigen locus.64 To date, the
candidate gene studies have been negative. Related studies have chosen candidate
Chapter 11  Do immune factors really matter?136
regions based on identified chromosomal abnormalities in individual patients;
however, involvement of the candidate region could either not be confirmed,65-66
or still awaits confirmation (a novel gene by a breakpoint in 7q31;67 and the
contactin-associated protein 2 gene by the breakpoint at 7q35-7q3668). A recent
study described a TS patient with a 18q21-q22 inversion, whereby the
rearrangement was fine-mapped to within 1 Mb of a 7;18 translocation
(breakpoint at 18q22) present in a previously independently described TS
pedigree69 in which that translocation co-segregated with TS and related problems
in that individual’s family. Interestingly, fine-mapping in the recent case report
identified no structurally disrupted transcripts, but, instead, found evidence for
epigenetic abnormalities. These consisted of functional dysregulations of one or
more genes in the region, in the form of a significant increase in replication
asynchrony in the patient compared to controls, with the inverted chromosome
showing delayed replication timing across at least a 500-kb interval.70 This finding
makes the 18q22 region an interesting candidate region, and, moreover, points to
a novel mechanism for neuropsychiatric pathogenesis, resulting from balanced
autosomal gene rearrangements.
As a third genetic strategy, a number of non-parametric full genome scans
have been carried out that used either affected sib-pairs,71 multigenerational
families,72 or a case control design in an isolated Afrikaner population.73,74
Although some genome regions have been implicated by these studies, only the
possible involvement of the 11q23 region73,74 has been confirmed in an
independent study that involved a large French Canadian family.75 This makes the
11q23 region probably the most interesting candidate genome area at present. A
recent genome scan76 used a more homogeneous subgroup of patients with
selection based on the presence of hoarding obsessions and compulsions and
found evidence that loci on 4q, 5q and 17q might be associated with this TS
subtype. Only the 4q locus was near a region of potential involvement identified
in the previously conducted sib-pair genome scan of unselected TS patients.71 In
conclusion, while the concept of one single major TS gene now appears
untenable, considerable progress has been made in the search for the genetic
background of TS. Although a number of candidate regions have been identified,
most of these await confirmation. Moreover, the regions of interest will still need
to be fine-mapped before anything specific can be said about TS genetics at a
gene level.
Notwithstanding the clear involvement of genetic factors in TS, the
non-100% concordance rates for TS in monozygotic twins48 also point to the
involvement of non-genetic elements. Indeed, a number of environmental factors
have been identified. These include adverse prenatal events, as evidenced by the
lower birth weight in the more severely affected co-twin of monozygotic twin
pairs with TS77 and a reported association of maternal stress and severe nausea
and vomiting during pregnancy with later tic severity in the off-spring.78 Also,
stressful life events have been linked to fluctuations in tic severity to some
extent.79 Finally, there has been quite some interest recently in the possible
adverse consequences of certain infections, both with respect to tic induction and
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tic exacerbations. We will review this possible relationship in the following
sections.
Possible role of infections in tic disorders
In the mid-1990s, several case studies entered the literature in which children
were described who suddenly demonstrated severe forms of tics and obsessive-
compulsive symptoms, which the authors linked to signs and symptoms of
streptococcal infections.80-82 Confronted with a failure of conventional treatment
approaches, authors described the successful application of immune-based
treatments in some of these cases, consisting of therapeutic plasma exchange,80-82
intravenously administered immunoglobulins,82-84 or simple use of antibiotics82 to
treat the infectious process. Such treatment modalities had not been previously
employed in child psychiatry. In some cases, streptococcal reinfections were
associated with the reinduction of neuropsychiatric symptoms.85 Also, there was
the notion that patients with Sydenham’s chorea, which has a well-established
link to group A streptococcal infections, often show behavioral symptoms,
including obsessions, compulsions, and emotional lability.86 Finally, a study had
suggested the presence of autoantibodies reacting with brain tissue in patients
with tics and/or OCD.87 All in all, these observations led researchers at the
National Institute of Mental Health to formulate clinical criteria for a putative
subgroup of children with OCD or TS in whom symptom exacerbations were
abrupt, dramatic, and temporally related to group A beta-hemolytic streptococcal
infections. The subgroup was designated by the euphonious acronym PANDAS
(pediatric autoimmune neuropsychiatric disorders associated with streptococcal
infections).85,88 PANDAS inclusion criteria were outlined, that require the
presence of OCD and/or tic disorder, pre-pubertal symptom onset, sudden onset
or episodic course of symptoms, temporal association between streptococcal
infections and neuropsychiatric symptom exacerbations, and associated
neurological abnormalities.
The concept of PANDAS strongly centers on Sydenham’s chorea as a putative
disease model, including the suggested pathogenic role of autoantibodies that cross-
react with brain antigens as a hypothesized consequence of structural homology with
streptococcal antigens.89 Introduction of the concept of PANDAS has certainly
done much to stimulate research and clinical interest in the potential relevance of
immune factors in tic and related disorders. Concerns regarding the validity of
PANDAS have been raised, however.90-93 These include criticism about the
vagueness92,93 of some of the criteria for PANDAS. For example, when should an
exacerbation be considered abrupt? Or what time frame exactly constitutes a
temporal relationship between group A beta-hemolytic streptococcal infections and
symptom exacerbations? Also, concerns regarding diagnostic criteria for a
streptococcal infection have been raised.90,91 Should a positive throat swab, without
raised antistreptococcal antibody levels or symptoms suggestive of pharyngitis94
really be considered a streptococcal infection? As an example, in a recent study,95
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investigators claimed to have prospectively identified a number of PANDAS cases,
without, however, having obtained serological evidence in the majority of putative
cases.
In addition to the questions regarding criteria, we have three more fundamental
concerns regarding the concept of PANDAS. First, in our opinion, it is far too early
to call tic and related disorders “autoimmune”, even when and if there is an
established association with infections. As will be discussed in a later section,
proving the involvement of autoimmunity in a neuropsychiatric disorder is a
formidable challenge and requires much more than showing a connection with
infection.
Second, studies on PANDAS bear the very real risk of circular reasoning: what
you include, is what you find. In our opinion, research that attempts to define the
extent of immune involvement in neuropsychiatric disorders should preclude the a
priori selection of cases that, by definition, demonstrate a temporal relationship with
streptococcal infections. Moreover, in a previous review,92 we pointed to the fact
that, so far, no laboratory markers for immune dysregulation have been identified in
PANDAS cases that have not also been described in unselected tic disorder patients.
Therefore, we strongly argue for the use of unselected tic disorder patients in future
studies on the extent of involvement of immune factors in tic disorders. This is not
to reject the possibility that careful longitudinal studies of extreme phenotypes (eg
those patients with the most elevated antibody titers or those with the most marked
exacerbations) might also provide a useful approach.
A third concern is that the required association with streptococcal infections in
PANDAS seriously hampers unbiased investigation of other possibly involved
infections in tic disorders. As an example, Allen82 described case studies associated
with viral infections. In addition, two TS cases associated with mycoplasma
infections have recently been described.96 Also, in a 6 month longitudinal study with
unselected tic disorder patients, our group recently identified a highly significant
association between the occurrence of a common cold and a subsequent
exacerbation in tic severity in pediatric patients 4 weeks later, after symptoms of the
cold had long disappeared. 97 The involvement of streptococcal infections in our
study could be ruled out, given the finding of negative throat swabs and absent rise
of streptococcal antibody levels in our study participants. Previously, Cardona98 had
reported a more frequent history of upper respiratory tract infections in tic disorder
patients than in healthy controls subjects. Also of interest is a recent study that
pointed to the importance of common colds at the time of onset of OCD and tic
symptoms.99 Thus, infections other than streptococcal infections may well be
involved in tic disorders; these may include relatively common viral infections.
It is remarkable that four studies that did not preselect tic disorder according
to PANDAS criteria probably found the best available evidence for an
association of tic disorders with streptococcal infections,98,100-102 even when the
exact nature of this possible association remains unclear. In essence, these studies
reported markedly increased serum levels of antistreptococcal antibodies in a
cross-sectional single time point design. Interestingly, Cardona98 found that levels
of antistreptolysin O correlated with severity of the tics, whereas the recent study
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of Church and coworkers102 identified an intriguing association between raised
antistreptolysin O titers and presence of antibasal ganglia antibodies, as assessed
by Western blotting and indirect immunofluorescence in unselected TS subjects.
The cross-sectional design makes these findings extremely hard to interpret,
especially since antibody levels in these subjects were not assessed at the time of
the first appearance of their tics, nor at a time of symptom exacerbation, but
rather at an arbitrary point in time. Are patients with tics more likely to encounter
streptococcal infections? Or does their immune system differently respond to
streptococci, which may include a more prolonged humoral response? We really
need longitudinal data to answer these and other questions. In contrast, several
US studies failed to find increased single time point levels of antistreptococcal
antibodies in tic disorder subjects.103-106 Thus, even though some data may
support an association between streptococcal infections and tic disorders, at
present the association does not appear to be universally present, but may be
confined to certain geographical areas. The potential importance of the topic lies
partially in the possible relevance to treatment: the use of antibiotics to treat the
underlying infections has received limited attention so far,94 but is certainly a
topic that deserves further consideration.
In conclusion, some evidence is available about a possible association of
streptococcal infections with tic disorders. Little can be said, however, about the
nature of this association. Moreover, there is also some indication about the
possible involvement of non-streptococcal infections, including common viral
infections, in exacerbations of tic disorders. With much interest we await the
outcome of the ongoing longitudinal studies on this topic.
B lymphocyte surface marker D8/17
Besides a possible association of tic disorders with infections, a number of
laboratory findings have been reported in tic disorders that may support the
involvement of immune dysregulation. We will first review a line of research
which focuses on overexpression of a B lymphocyte surface marker, designated
D8/17, a putative marker of susceptibility to rheumatic fever, and then
summarize the findings regarding assessment of autoantibodies against neuronal
tissue. The monoclonal antibody against the D8/17-epitope is a mouse
monoclonal IgM antibody that was originally prepared from fusions of spleen cells
from mice that had repeatedly been immunized with isolated human B lymphocytes
obtained from rheumatic fever or rheumatic heart disease patients.107 D8/17-specific
monoclonal antibody has been reported to bind with a small percentage of
B lymphocytes in normal controls (averaging 5-7%), but in rheumatic fever the
percentage of D8/17 positive B lymphocytes was found to be much higher (33.5%
in average).107 It was proposed that an individual could be classified as D8/17-
positive when the percentage of D8/17-positive B lymphocytes exceeded the mean
plus one standard deviation of that of healthy controls (that is, 12%). An individual’s
D8/17-positivity has been reported to be a susceptibility marker for rheumatic fever,
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a well-known complication of infections with group A beta-hemolytic streptococci,
with 60%-100% of rheumatic fever subjects reported to be D8/17-positive.108
In 1997, the first two reports on D8/17 in tic disorders appeared in the
literature.88,109 Results of these studies were quite remarkable: when subjects were
categorized as either D8/17-positive or D8/17-negative according to the
previously established cutoff of more than 12% D8/17-positive B lymphocytes,
D8/17-positivity appeared almost diagnostic for the presence of a tic disorder or
OCD. In one study,109 100% of patients (either having childhood-onset OCD or
TS) appeared to be D8/17-positive versus less than 5% of healthy controls,
whereas the other study88 reported 85% of patients fulfilling PANDAS criteria to
be D8/17-positive versus 17% of healthy controls. Subsequently, an association
of D8/17-positivity was also reported with other psychiatric disorders, including
autistic disorder,110 trichotillomania,111 and anorexia nervosa.112
Although these D8/17 findings are intriguing, the method with which they
were obtained has serious flaws. In all studies mentioned so far, D8/17 expression
on B cells had been assessed by indirect immunofluorescence whereby individual
B cells were visually categorized as either D8/17-positive or D8/17-negative and
counted manually by fluorescence microscopy. Three studies have used the more
objective method of flow cytometry113-115 and also found group differences between
patients with a tic disorder and/or OCD and healthy controls. However, our group
made use of a control IgM monoclonal antibody in addition to the antibody directed
against the D8/17 epitope.114 For this purpose, we used MOC32, an IgM
monoclonal antibody that is directed against a neuroendocrine antigen of epithelial
origin of small cell lung cancer cells. Upon re-examination of our data, it now
appears likely that we did not detect D8/17 overexpression on B cells in tic disorder
patients compared to healthy controls, but, rather, increased expression of receptors
for the constant parts of IgM molecules (Fc-µ) on B cells. Thus, this appears to
suggest that tic disorder patients do not express a specific susceptibility marker for
experiencing autoimmune sequelae in the aftermath of streptococcal infections.
Instead, the evidence may be indicative of a generalized increased immune activity.
Whatever is measured when assessing D8/17 B cell overexpression, we and
other centers encountered major reproducibility problems in subsequent studies,
which were often not published. The D8/17-specific antibody appeared to
gradually lose its patient-control discriminating abilities in the course of months
(unpublished observations from our laboratory). In addition, there appeared to be
major differences between different antibody batches, an experience we share
with others in the field.116 At present, the molecular nature of the D8/17 epitope
is unknown. Many centers have stopped using this antibody, given the failure to
replicate group differences.117 Finally, a recently published study failed to find an
association between D8/17-positivity and the presence of tics or OCD in a
community sample.118 Thus, a line of research that seemed quite promising at the
outset, now appears to be floundering due to lack of progress in characterizing
the presumed susceptibility marker. It is possible that previous positive reports
were due to an unspecific increase of the number of Fc-µ receptors on B cells, a
possibility that certainly deserves further study.
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Antineuronal autoantibodies
The presence of autoantibodies reacting with parts of the brain that are thought
to be involved in tic disorders, is potentially a strong line of evidence in favor of
the autoimmune hypothesis of tic disorders. In a previous review, we summarized
the work carried out in this area.92 In short, two studies assessed autoantibody
binding to human caudate tissue with an indirect immunofluorescence technique
in patients with tics and/or OCD,87,109 as previously applied in patients with
Sydenham’s chorea.119 Results in both studies were similar: positive staining was
reported in 44%-50% of tic disorder patients versus 21%-24% of healthy
controls. Subsequent studies, using enzyme-linked immunosorbent assays against
either an immortalized neuronal cell line,120,121 human basal ganglia,104 or rat
brain,103 in general, confirmed the increased levels of serum antineuronal
antibodies in TS patients.
Some support for the direct involvement of antineuronal autoantibodies in the
disease process stems from two different research findings. First, intravenously
administered immunoglobulins and therapeutic plasma exchange were reported
to be highly effective treatments in cases fulfilling PANDAS criteria.122 These
treatment modalities are thought to block or remove the antineuronal
autoantibodies, respectively. As yet, this finding still awaits confirmation. A
second pillar possibly supporting a pathogenic role of antineuronal antibodies is
formed by two studies in which animal models were developed to study whether
serum or purified IgG from patients with TS can induce tic-like behavior in
rats.123,124 In these studies, serum or IgG was microinfused through cannulas
placed in regions of the neostriatum known to induce stereotypies, after which
the rats were observed for development of movements or utterances. Hallett et
al.123 infused dilute serum from five TS patients with high antibody titers against
human neuroblastoma bilaterally into the ventral striatal region of the rat. Results
showed a significant increase in tic-like behaviors (eg, licks and forepaw shakes)
and episodic utterances in rats infused with TS sera, which was not observed
when sera from healthy controls were microinfused. Taylor et al.124 infused serum
from 12 TS patients with high antibody titers against rat striatum bilaterally into a
different brain area, the ventrolateral striatal region. Results showed a significant
increase of high titer-induced oral stereotypies over a 5 days’ period of
observation. These intriguing results were not confirmed in a recent study in
which Loiselle and coworkers microinfused serum from five TS children with
high antibody titers against human postmortem putamen bilaterally into the
ventral and ventrolateral striatum. In that study, no rat was reported to develop
any audible abnormality and there was no significant increase in stereotypic
behaviors.93 At our center, we also infused TS sera into rat brains at the same
coordinates used in the Hallett and Taylor protocols, but did not identify any
differences in tic-like behavior compared to rats that had been microinfused with
sera from healthy controls (unpublished results). We have no explanation for
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these conflicting results across different centers. Future studies might profit from
across-center sharing of reference sera that had been previously demonstrated to
induce tics.
It should be noted that, as yet, no single neuronal antigenic structure has been
identified as target for the putative antineuronal antibodies. Only a limited
number of studies have aimed to identify separate neuronal antigens, by using
Western blot techniques. Most of these studies detected candidate antigenic
structures, derived from either brain tissue or a neuroblastoma cell line, with an
apparent molecular weight of 60 and/or 83 kD.102,104,121,125 In another Western
blot study, our group recently detected, in line with existing studies, more
frequent seroreactivity in tic disorder patients against a 60 kD protein band from
a neuronal cell line compared to healthy controls, patients with autistic disorder,
and patients with OCD.126 Subsequent sequence analysis identified this 60 kD
band as the human 60 kD heat shock protein. This protein is by no means
confined to neuronal tissue; on the contrary, the human 60 kD heat shock
protein is considered to be ubiquitous.127
Although involvement of specific neuronal antigens cannot be ruled out, the
results of our study indicate that autoantibody binding to tissue of neuronal origin
does not necessarily have to be confined to exclusively neuronal epitopes. This
may as well explain the findings of antineuronal antibodies in sera of healthy
controls, as reported in earlier studies.87,109 Though we could not directly link the
presence of autoantibodies to the pathogenesis of tic disorders, our findings are
still likely to support the involvement of immune factors in tic disorders.
Inappropriate reactivity to heat shock proteins in humans may be understood,
given the high degree of antigenic homology between microbial and human
hsp60, which may lead to harmful cross-reactivity with human structures.128 There
is well-established evidence that inappropriate reactivity to heat shock proteins is
involved in autoimmune disorders,129 including rheumatic autoimmune
diseases,130,131 severe coronary heart disease, and carotid atherosclerosis.132 Also,
increased anti-hsp60 binding may be due to frequently encountered infections.
In conclusion, the assessment of serum autoantibodies has appeared to be a
fruitful research area in tic disorders. However, this area is very much a
work-in-progress, especially with regard to characterizing antigenic structures at a
molecular level and elucidating the pathogenic relevance of the antibody-antigen
interactions in animal models.
Conclusions
Considerable progress has been made over the last decade with regard to the
neurobiology of TS. Convincing evidence indicates that the basal ganglia and
related cortico-striato-thalamo-cortical circuits are likely to be involved in both
the tics and related behavioral abnormalities. Some intriguing, though quite
preliminary neurochemical data are available that appear to indicate differences in
specific neurotransmitter systems. Much progress has also been made in the field
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of genetics. While independent twin and family studies had indicated the genetic
background of TS and related disorders some time ago, now a number of genetic
linkage and association studies have provided the first candidate loci on the
human genome.
Apart from genetic findings, a number of environmental factors have been
implicated in the pathogenesis and pathophysiology of TS, most notably adverse
perinatal events and infections. Most research in this latter area has used
Sydenham’s chorea as a medical model, and thus has largely focused on the role
of streptococcal infections and assessment of cross-reacting antibodies against
human brain regions. Evidence for the relevance of this model for TS is still
scarce, however, and is entirely based on cross-sectional studies. However,
nonspecific immune activation may play a more profound role. This hypothesis is
based on our findings of possibly increased receptors for the Fc-fragment of IgM
on B lymphocytes, the notion of a temporal association of common viral upper
respiratory infections with exacerbations of tic severity, and increased anti-hsp60
autoantibody binding in tic disorders. These findings all point to a rather general
activation of the immune system that may be associated with tic disorders. Thus,
even though the precise mechanism is largely unknown, at present, the available
evidence does indeed seem to suggest that immune factors do appear to matter in
at least some individuals with tic disorders. Ongoing large-scale longitudinal
studies will have to provide definite answers to this intriguing topic.
Several lines of evidence suggest that TS is likely to be a heterogeneous
disorder, meaning that different pathways may lead to the disorder. Thus,
clinically relevant subgroups may emerge. For example, neuroimaging studies
suggest that adults who continue to demonstrate tics may have unique
neuroimaging findings which are often opposite from what has been found in
pediatric patients. Neurotransmitter abnormalities may give clues for subgroups
in which a certain neurotransmitter system may or may not be involved. To
illustrate this, dopamine antagonists do not appear to have effect on tics in a
significant minority of patients. Similarly, autoimmunity may be involved in only a
subgroup of patients. Future genetic linkage and association studies may give
better results when homogeneous subgroups are used, based on either clinical
features or biological markers. Also, combining different research tools, eg
neuroimaging with immune factors, may prove fruitful. Giedd et al.81 described
an interesting case study in which enlargement of basal ganglia volumes decreased
dramatically in response to therapeutic plasma exchange. Peterson and
colleagues105 studied the relationships between antistreptococcal antibody titers
and basal ganglia volumes in a cross-sectional design. Interestingly, higher
antibody titers in subjects with ADHD or OCD were associated with larger
volumes of the putamen and globus pallidus nuclei; surprisingly, higher titers
were not seen in tic disorder patients. In another example of combining research
approaches, the National Institute of Mental Health group assessed first-degree
relatives of 54 children fulfilling criteria for PANDAS for the presence of a tic
disorder.133 Results were remarkably similar to those of family studies using non-
PANDAS tic disorder probands. Integrating neuroimaging, neurochemistry,
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genetics, and neuroimmunology may prove to be an especially powerful
approach. Ultimately, however, identifying the involvement of major genes will
allow for more definite studies of gene-environment interactions, both through
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To classify a disease as autoimmune, one must show that an adaptive immune
response to a self-antigen causes the observed pathology. One mechanism of
autoimmunity is through autoantibody binding to autoantigens. Do the results of
the experiments described in this thesis provide confirming evidence to classify
Tourette’s syndrome as an autoimmune disease? The answer should be, at the
most, not yet. In tic disorder patients, we did detect increased frequency in serum
of autoantibodies directed against autoantigens, but did, as yet, not establish a
role for the autoantibody-autoantigen interaction in the disease process. Also, we
identified differences between tic disorder patients and healthy controls with
regard to B lymphocyte surface antigens, but do not know the functional
significance of this finding. Moreover, we provided evidence for an association
between common, viral upper respiratory infections and subsequent
exacerbations of tic severity in children, but have no clue with regard to the
immunological pathway that may be involved. Infections are known to induce
flare-ups in certain autoimmune conditions, such as Wegener’s granulomatosis.1
As outlined in chapter 11, our findings are best summarized as pointing to a
rather general activation of the immune system in patients with a tic disorder.
Thus, even though the precise mechanism is largely unknown, at present, the
available evidence from our experiments and those of others does seem to
suggest that immune factors appear to be involved in tic disorders. Two findings
in the present thesis do not provide evidence for the involvement of the immune
system in tic disorders. First, we found no indication that the metabolism of
tryptophan through the kynurenine pathway would be altered in tic disorder
patients. Thus, these results could not confirm a more than usual activation of
indoleamine 2,3-dioxygenase through pro-inflammatory cytokines, which would
promote the breakdown of tryptophan to kynurenine. Furthermore, intravenously
administered immunoglobulins did not appear to be an effective treatment in
patients with a tic disorder. Positive results would have been an indirect clue to a
possible pathogenic role of autoantibodies in tic disorders. Our longitudinal study
regarding the role of psychosocial stress, however, is well compatible with the
autoimmune hypothesis of Tourette’s syndrome. The results of this study indicate
that in about 20% of individuals with a tic disorder, the changing tic severity over
time appears to be associated with small life events. In many autoimmune
conditions, psychosocial stress may adversely influence disease severity.2
What type of studies do we need to get more definite answers to the
presumed involvement of autoimmunity in tic disorders? Relevant antigenic
structures should be characterized at a molecular level. This regards both putative
susceptibility markers on B lymphocytes and autoantigenic targets of
autoantibodies with relevance for the pathogenesis of Tourette’s syndrome.
Results could lead to the development of animal models in which the functional
significance of identified immune alterations could be investigated in vivo. In
addition, longitudinal studies should study the involvement of immune factors,
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including B lymphocyte subsets, autoantibody-autoantigen interactions, and
intercurrent infections in relation to the onset, changing severity pattern, and
possible remission of the tics over the course of time. Finally, identification of
major genes involved in Tourette’s syndrome would greatly enhance such studies.
Concluding remarks156
References
1. Pinching, A.J., Rees, A.J., Russell,
B.A., Lockwood, C.M., Mitchison,
R.S., and Peters, D.K.: Relapses in
Wegener’s granulomatosis: the role
of infection. BMJ 1980, 281:836-838.
2. O'Leary A.: Stress, emotion and





Gilles de la Tourette’s syndrome is a childhood-onset neuropsychiatric disorder
characterized by the presence of both multiple muscle movements and
vocalizations, referred to as motor and vocal tics. Some research findings suggest
a central role for the involvement of autoimmunity in the pathogenesis of tic
disorders. These seem to suggest that infections may induce or reinforce tics and
associated features in susceptible individuals, possibly through the involvement of
abnormal humoral immune responses directed against self-tissue antigens. This
possible role of immune dysregulations in the pathogenesis of tic disorders is the
topic of the present thesis.
In chapter 1, we provide a review of research findings which may support the
involvement of autoimmunity in childhood-onset tic disorders, in particular the
presence of antineuronal autoantibodies, D8/17 B lymphocyte overexpression, a
marker of chorea associated with streptococcal infection, and possible beneficial
effects of immunomodulatory intervention. One of the most controversial areas
in this field is the validity of the proposed PANDAS concept. Some researchers
have delineated a putatively unique subgroup of patients from the spectrum of
illness encompassing Tourette’s syndrome and obsessive-compulsive disorder
(OCD), whose tics and obsessive-compulsive symptoms are shown to arise in
response to beta-hemolytic streptococcal infections. They designated it by the
term pediatric autoimmune neuropsychiatric disorders associated with
streptococcal infections (PANDAS). Herein we, additionally, present pros and
cons concerning the concept of PANDAS. Finally, recommendations for future
research directions are given.
Chapter 2 describes a study in which we investigated social and behavioral
problems related to attention deficit/hyperactivity disorder (ADHD), severity of
obsessions and compulsions, and tic severity in children with a tic disorder. Parents
of 58 clinically referred children with a tic disorder with and without different forms
of ADHD filled out the Child Behavior Checklist (CBCL) and the Children’s Social
Behavior Questionnaire, a novel parent questionnaire covering a broad range of
behavior problems as seen in children with milder variants of pervasive
developmental disorders. Comparisons were made between tic disorder patients
with primarily hyperactive-impulsive ADHD, tic disorder patients with primarily
inattentive ADHD, and tic disorder patients without ADHD. Also, part
correlations of subscale scores of the questionnaires with measures of ADHD
severity, severity of obsessions and compulsions, and tic severity, respectively, were
executed, while controlling for the predictive value of the other two measures on the
outcome of the questionnaires. Results indicated that tic disorder patients with
primarily hyperactive-impulsive ADHD had the highest scores on the parent
questionnaires, tic disorder patients with primarily inattentive ADHD medium
scores, and tic disorder patients without ADHD the lowest. On a considerable
number of subscales, significant part correlations with ADHD severity, but not tic
severity were obtained. Severity of obsessions and compulsions was independently
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correlated with the CBCL subscale thought problems, but not with most other
subscales. There was no significant correlation between tic severity and ADHD
severity. In conclusion, in patients with a tic disorder it is the presence and severity
of ADHD that is the main predictor of associated behavior and social problems.
The purpose of the study described in chapter 3 was to assess D8/17
expression on B lymphocytes of tic disorder patients by using an objective
method in which no operator variability was involved. Elevated D8/17
expression on B lymphocytes is a known susceptibility marker of rheumatic fever.
Previous studies had also reported increased D8/17 expression on B lymphocytes
of patients with tic disorders. In our study, D8/17 expression on B lymphocytes
was assessed with flow cytometry by using an IgM monoclonal D8/17-specific
antibody in an unselected group of Dutch patients with tic disorders (N=33) and
healthy volunteers (N=20). Binding of this monoclonal antibody was compared
with binding of an irrelevant IgM monoclonal antibody and the shift in mean
fluorescence intensity of the D8/17-specific antibody compared to that of the
irrelevant IgM monoclonal antibody was used as a measure of D8/17
overexpression. For the patients, Yale Global Tic Severity Scale scores were used
to assess disease severity. We found that D8/17 overexpression in the patient
group (mean=16.8 arbitrary units, SD=30.5) was significantly higher than in the
control group (median=3.2, SD=3.0). A significant minority of the patients
(N=13, 39.4%), however, had levels of D8/17 overexpression within the range of
that of the healthy comparison subjects. Flow cytometric analysis did not indicate
a separate subpopulation of D8/17 positive B cells. These data confirm the utility
of D8/17 B cell overexpression as a peripheral blood marker in patients with tic
disorders and are compatible with a streptococcus-related pathogenesis for at
least a subgroup of patients with tic disorders.
However, in chapter 4, we present a reanalysis and reinterpretation of the
results of the preceding study. At reanalysis of the data, there appeared to be an
unexpected, close correlationship between the mean fluorescence intensity
produced by the irrelevant IgM, MOC32, and that by the D8/17-specific IgM, in
both patients and controls. This could suggest that, at least in part, we did not
detect D8/17 overexpression on B cells in tic disorder patients compared to healthy
controls, but rather, increased expression of receptors for the constant parts of IgM
molecules (Fc-µ) on B cells, so explaining increased binding of both the D8/17-
specific monoclonal antibody and the irrelevant monoclonal antibody (MOC32),
possibly due to a more general state of immune activation.
Chapter 5 contains the results of a study on D8/17 B lymphocyte expression in a
small group of Dutch patients with post-streptococcal reactive arthritis. Only 29%
of patients appeared to have an elevated percentage of D8/17 positive
B lymphocytes, which is in contrast with the 63%-100% in the acute rheumatic fever
literature. This may suggest non-susceptiblity to developing acute rheumatic fever in
the majority of Dutch post-streptococcal reactive arthritis patients.
In tic disorders, increased seroreactivity against neuronal antigens had been
demonstrated, without performing molecular characterization of antigens. In
chapter 6, unselected patients with a tic disorder were compared with healthy
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controls, patients with autistic disorder (AD), and persons with OCD. Seroreactivity
against neuroblastoma cells was analyzed by Western blot. Binding to a 60 kD
protein occurred significantly more frequently in tic disorder patients (67.1%) than
in AD patients (40.0%), OCD patients (40.0%), and controls (41.9%). Sequence
analysis identified this as a heat shock protein, a protein not exclusive to neuronal
tissue. This may support the involvement of autoimmunity in tic disorders.
Increased levels of plasma kynurenine have been reported in tic disorder
patients and this observation has been suggested to be indicative of immune
dysregulation in tic disorders. In chapter 7, we aimed to replicate this finding in a
large group of well-characterized tic disorder patients. Plasma concentrations of
tryptophan and kynurenine were determined in Dutch patients with Tourette’s
disorder (N=44), patients with chronic motor tic disorder (N=15), and healthy
volunteers (N=32). Correlations between Yale Global Tic Severity Scale scores
and the plasma levels were examined. Our results revealed no significant
differences between patients and controls in plasma tryptophan and kynurenine
concentrations or in the kynurenine to tryptophan ratio. Also, kynurenine did not
correlate with indices of tic severity. A small, but statistically significant negative
relationship (r=-0.341; p=0.009) was found between tryptophan levels and vocal,
but not motor tic severity. These results indicate that the metabolism of
tryptophan through the kynurenine pathway is not altered in tic disorders.
Although it is unclear how much may be inferred about immune function based
on measurement of plasma kynurenine, the results do not lend support to
hypothesized alterations in immune processes in tic disorder patients.
Cross-sectional data and some case studies suggest a temporal relationship
between fluctuations in tic severity and preceding infections. The aim of the study
described in chapter 8 was to examine this possible relationship in a prospective
longitudinal design. Two groups of tic disorder patients were included in this
study, a pediatric group between 7 and 15 years (N=20) and an adult group of 16
years and older (N=41). During a 24 weeks’ period, participants were asked to
weekly fill out self-questionnaires regarding the presence of tic exacerbations and
experience of common cold. In addition, six throat swabs were taken at fixed
intervals irrespective of symptoms, and cultured for streptococci; also, three serial
serum assessments of streptococcal antibodies were performed. In the pediatric
group, the self-report of a common cold was strongly associated with an
exacerbation in tic severity 4 weeks later (odds ratio=4.685, p=0.001). In this
group, no association between the self-report of a common cold and tic
exacerbations was found in other weeks. In the adult group, we found no
association at all between reports of common cold and tic exacerbations.
Association with streptococcal infections could not be determined due to the
limited number of observed streptococcal infections. In conclusion, while it
remains to be proven whether or not streptococcal infections are associated with
exacerbations in tic severity, this study points to a hitherto unknown association
of common viral infections with exacerbations in tic severity in children, which
may support the involvement of immune dysregulation in tic disorders.
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Clinical experience suggests an association between stressful life events and
fluctuations in symptom severity of tic disorder patients. The aim of the study in
chapter 9 was to examine this possible relationship in a prospective longitudinal
design. Two groups of tic disorder patients were included in this study, a pediatric
group between 7 and 16 years (N=25; 24 of whom completed the study) and an
adult group of 18 years and older (N=32; 28 of whom completed the study, and
reported at least one life event). During a 12 weeks’ period, participants were
asked to weekly fill out self-questionnaires regarding the occurrence of small life
events and self-rating of tic severity. In the adult group as a whole, we found a
weak but statistically significant correlation between negative small life events and
tic severity during the same week (r=0.268, p<0.001). However, only a minority
of individual pediatric (21%) and adult patients (18%) demonstrated significant
relationships between the frequency of small life events and tic severity in the
same week or 1 week later, with undesirable small life events positively associated
with tic severity in some patients and negatively associated with tic severity in
other patients. We concluded that, contrary to traditional views, in general, life
events do not account for changes in tic severity. Only in a minority of tic
disorder patients, fluctuations in symptom severity appear to be associated with
possibly stressful small life events.
Chapter 10 describes the results of a double-blind placebo-controlled study
regarding the efficacy of intravenously administered immunoglobulins (IVIG) in
patients with a tic disorder. Case studies and a placebo-controlled study had
previously suggested the effectiveness of immunomodulatory therapy in those
patients with tic or related disorders whose symptoms show a relationship with
streptococcal infections. No studies had been conducted on the effectiveness of
IVIG on tic severity in unselected tic disorder patients. In our study, 30 tic
disorder patients were randomized to IVIG (1 g/kg on two consecutive days) or
placebo. Symptom rating occurred at baseline and at week two, four, six, 10, and
14 post-treatment, after which blinding was broken. We observed no significant
differences between both treatment groups regarding post-treatment changes in
tic severity. Severity of obsessions and compulsions, which was in the subclinical
range at base line, decreased significantly in the IVIG group compared to the
placebo group at week six (p=0.02). Then, there was a 32.3% improvement in the
IVIG group compared to base line level. Though this improvement was
maintained over the following 8 weeks, no statistically significant differences
between the IVIG and the placebo group with regard to improvements in
obsessions and compulsions were detected at subsequent assessments. Thus,
based on these results, IVIG cannot be recommended in tic disorders.
In chapter 11, we present an overall discussion with regard to the relevance of
immune factors in tic disorders, taking into account the various results of the
experiments described in this thesis. In this chapter, we start with a general
overview of the neurobiology of Tourette’s syndrome with regard to
neuroimaging, neurochemistry and genetics. While the pathogenesis at a
molecular and cellular level remains unknown, structural and functional
neuroimaging studies point to the involvement of the basal ganglia and related
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cortico-striato-thalamo-cortical circuits as the neuroanatomical site for Tourette’s
syndrome. Evidence is also available for abnormalities within the dopaminergic
neurotransmitter system. Moreover, Tourette’s syndrome has a strong genetic
background, and considerable progress has been made in identifying possibly
involved genomic loci. We conclude that Tourette’s syndrome is a heterogeneous




Samenvatting in het Nederlands
Ticstoornissen waaronder het syndroom van Gilles de la Tourette worden
gekenmerkt door herhaald optredende onwillekeurige spierbewegingen en
geluiden, zogenaamde motorische en vocale tics. Tics beginnen over het
algemeen op de kinderleeftijd, gemiddeld op het zevende levensjaar. We weten
niet precies waardoor tics ontstaan. Wel weten we dat erfelijke factoren in sterke
mate betrokken zijn. Daarnaast zijn er aanwijzingen dat infecties gepaard gaand
met keelpijn, veroorzaakt door een bepaalde bacterie (de streptokok) een rol
zouden kunnen spelen in het ontstaan of het verergeren van tics. Sommige
bevindingen lijken erop te wijzen dat auto-immuniteit hierbij betrokken is. Men
spreekt van auto-immuniteit als de normale afweer van het lichaam zich niet meer
uitsluitend richt op ziekte-indringers, zoals bacteriën en virussen, maar ook op
onderdelen van het eigen lichaam. In het geval van ticstoornissen wordt er daarbij
gedacht aan afweerreacties tegen bepaalde hersengebieden die vervolgens tot tics
aanleiding zouden kunnen geven. Hierbij spelen mogelijk auto-antilichamen een
rol. Dit zijn stoffen die zich richten tegen lichaamseigen bestanddelen en soms
schade kunnen veroorzaken.
In hoofdstuk 1 geven we een algemeen overzicht van bestaande
onderzoeksbevindingen die zouden kunnen passen bij de betrokkenheid van
auto-immuniteit bij ticstoornissen. We gaan hierbij allereerst in op onderzoeken
die wijzen op de aanwezigheid van auto-antilichamen tegen hersenweefsel in het
bloed van mensen met tics. Daarna beschrijven we onderzoeken die hebben
gekeken naar de verhoogde aanwezigheid van een bepaald eiwit op bepaalde bij
de afweer betrokken witte bloedlichaampjes, namelijk het eiwit D8/17 op
B-lymfocyten (bloedcellen die bij de afweer tegen bacteriën betrokken zijn).
Eerder was verhoogde aanwezigheid van D8/17 op B-lymfocyten gezien bij
patiënten met acuut reuma, een ziektebeeld als gevolg van auto-immuun reacties
in aansluiting aan een streptokokkeninfectie, een infectie die normaal alleen
gekenmerkt wordt door keelpijn. Verhoogde aanwezigheid van D8/17 op
B-lymfocyten bij patiënten met tics zou dus een indirecte aanwijzing voor auto-
immuniteit in aansluiting aan een streptokokkeninfectie kunnen zijn. Verder
geven we een overzicht van onderzoeken waarin gerapporteerd is over het
mogelijk gunstige effect van behandelingen die ingrijpen op het immuunsysteem
bij personen met tics.
Hoofdstuk 2 beschrijft een onderzoek dat geen betrekking heeft op de rol van
auto-immuniteit. Daarentegen bespreken we een studie naar de aanwezigheid van
gedragsproblemen en problemen in de omgang met andere kinderen bij patiënten
met tics met en zonder aandachtstekortstoornis met hyperactiviteit (ADHD).
Hierbij werd aan de hand van oudervragenlijsten die onder andere sociaal gedrag
meten (bijvoorbeeld hoe kinderen bij hun gedrag wel of niet rekening houden
met anderen), gekeken of er verschillen bestaan ten opzichte van leeftijdsgenoten
zonder tics en of die verschillen meer met de tics samenhangen of meer met de
ernst van de ADHD. Het onderzoek laat zien dat de gedrags- en sociale
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problemen bij kinderen met tics voornamelijk in verband staan met ADHD en
niet met tics als zodanig. De belangrijkste conclusie van dit deel van het
onderzoek is, dat niet het hebben van tics, maar de eventuele bijkomende ADHD
gepaard gaat met problemen in het begrijpen en toepassen van sociale informatie.
Het onderzoek in hoofdstuk 3 is het eerste onderzoek op het terrein van de
immunologie binnen dit proefschrift. We hebben de mate van aanwezigheid van
het eerder vermelde D8/17 eiwit op B-lymfocyten gemeten bij zowel patiënten
met tics als bij gezonde proefpersonen. In vergelijking met eerdere onderzoeken
hebben we hierbij een nieuwe, sterk verbeterde methode gebruikt. Eerdere
studies hadden gebruik gemaakt van subjectieve handmatige tellingen van cellen,
terwijl wij een objectieve, volledig geautomatiseerde meting toepasten. In ons
onderzoek vonden we inderdaad aanwijzingen voor een grotere aanwezigheid van
het eiwit D8/17 op B-lymfocyten bij de meeste patiënten met tics in vergelijking
met de gezonde proefpersonen. De precieze betekenis van deze bevinding is
onduidelijk. Het wijst mogelijk op een betrokkenheid van het afweersysteem bij
de aanwezigheid van tics.
In hoofdstuk 4 geven we echter een alternatieve interpretatie van de
bevindingen van het onderzoek van hoofdstuk 3. Mogelijk is bij patiënten met
tics niet zozeer het oppervlakte eiwit D8/17 in verhoogde mate aanwezig op
B-lymfocyten, maar receptoren die een bepaald type antilichamen in het algemeen
binden. Met een antilichaam dat aan D8/17 bindt, proberen we een beeld te
krijgen van de hoeveelheid D8/17 aan de buitenkant van de B-lymfocyt; dat
antichaam bindt echter ook aan het betreffende type receptoren die eveneens aan
de buitenkant van B-lymfocyten aanwezig zijn en die bij activatie van de
B-lymfocyt in sterkere mate aanwezig kunnen zijn. De verhoogde binding bij
patiënten met tics zou kunnen wijzen op algemene activatie van het
immuunsysteem. We weten dus niet precies wat gemeten wordt bij onze
meetmethode gericht op de mate van aanwezigheid van D8/17.
De boven aangegeven meetmethode om de hoeveelheid D8/17 aan de
buitenkant van B-lymfocyten te meten hebben we in hoofdstuk 5 ook toegepast bij
een andere groep patiënten, namelijk patiënten met gewrichtsontstekingen in
aansluiting aan een streptokokkeninfectie. Bij dit ziektebeeld wordt aangenomen
dat auto-immuniteit waarschijnlijk een rol speelt. Het bleek echter dat maar een
minderheid van de patiënten een verhoogde mate van D8/17 op de B-lymfocyten
had (dan wel een verhoogde mate van de eerder genoemde receptoren). Kennelijk
is de betrokkenheid van het afweersysteem bij deze gewrichtsontstekingen anders
dan mogelijk bij tics het geval is.
Verder keken we in het onderzoek dat beschreven staat in hoofdstuk 6 in het
bloed naar auto-antichamen tegen hersenweefsel. We vonden dat personen met
tics vaker reageerden met een bepaald eiwit dat ook, maar niet alleen, in de
hersenen voorkomt. Dit eiwit is een zogenaamd heat-shock eiwit. Dit eiwit maakt
ook deel uit van veel bacteriën en virussen. Mogelijk wijzen onze bevindingen
erop dat infecties een rol spelen bij tics. Ook is het aanwezig zijn van de auto-
antilichamen een aanwijzing voor het betrokken zijn van auto-immuniteit bij
ticstoornissen.
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In hoofdstuk 7 staat onderzoek beschreven naar de stof kynurenine in het bloed
bij personen met tics vergeleken met gezonde personen. Verhoogde concentraties
kynurenine wijzen mogelijk op betrokkenheid van de afweer. In dit opzicht
vonden we echter geen verschillen tussen personen met tics en gezonde
personen.
In het onderzoek in hoofdstuk 8 vroegen we patiënten met tics gedurende een
half jaar om elke week schriftelijk aan ons door te geven, hoe het met de ernst
van de tics stond in vergelijking met een week eerder en ook of er sprake was van
een doorgemaakte verkoudheid. Er bleek, althans bij kinderen, een duidelijk
verband tussen het doormaken van een verkoudheid en een daaropvolgende
verergering van de tics precies vier weken later. Kennelijk is het doormaken van
een verkoudheid een belangrijke risicofactor voor een verergering van de tics vier
weken later. Bij volwassenen kwam dit verband er niet uit, al waren er ook in deze
groep aanwijzingen voor een verband, maar dan drie weken later. Ook deze
bevindingen wijzen, net als de bevinding van hoofdstuk 6, op de rol die infecties
spelen bij tics. Uit ons onderzoek blijkt bovendien dat het in tegenstelling tot wat
eerder werd verondersteld, in dit verband zeker niet om uitsluitend
streptokokkeninfecties gaat. Verkoudheden worden juist bijna altijd door virussen
veroorzaakt.
Ook keken we, in hoofdstuk 9, in wekelijkse vragenlijsten naar een verband met
stress en verergeringen van de tics. Hieruit is gebleken dat maar bij 20% van de
personen met tics er een verband was tussen doorgemaakte stressvolle
gebeurtenissen en wisselingen in ernst van de tics. Bij de rest van de personen
was dat verband er niet. Kennelijk speelt stress maar bij een minderheid van de
mensen met tics een rol in het erger worden van de tics. Overigens kunnen
stressvolle gebeurtenissen soms ook een rol spelen bij een verergering van auto-
immuunziekten.
Tot slot onderzochten we zoals beschreven staat in hoofdstuk 10, in hoeverre
het via een infuus toedienen van immuunglobulinen een goede behandeling zou
zijn voor de tics. Hiertoe hebben veertien mensen via het infuus gedurende twee
dagen een nepmiddel (placebo) gekregen en vijftien mensen de echte
immuunglobulinen. Helaas bleek dat het niets uitmaakte of er nu het placebo
middel of de immuunglobulinen gegeven werden. De tics bleven gemiddeld gelijk
in ernst. Wel was het zo dat de dwangklachten gemiddeld een lichte afname
vertoonden bij degenen die de immuunglobulinen hadden gekregen. De conclusie
moet echter zijn dat immuunglobulinen geen goede behandeling zijn bij het
syndroom van Gilles de la Tourette.
In hoofdstuk 11 hebben we in een overzichtsartikel onze bevindingen en die
van anderen samengevat om een voorlopig slotantwoord te vinden op de vraag in
hoeverre auto-immuniteit en infecties betrokken zijn bij ticstoornissen. Onze
belangrijkste conclusie luidt dat het te vroeg is om te concluderen dat het
syndroom van Gilles de la Tourette een auto-immuunziekte is, maar dat er wel





Het is als een groot voorrecht te beschouwen, in de gelegenheid gesteld te
worden wetenschappelijk onderzoek te verrichten. Veel dank ben ik daarom in
de eerste plaats verschuldigd aan mijn eerste promotor Ruud Minderaa die de
voorwaarden en ruimte hiervoor gecreëerd heeft. Een grote kwaliteit van
Ruud is dat hij medewerkers los van formele hiërarchische posities weet te
benaderen. Hierdoor werd de samenwerking vanaf het eerste begin
gekenmerkt door een sfeer van vertrouwen en gelijkwaardigheid. Heel erg
getroffen heb ik het daarnaast met de begeleiding vanuit de klinische
immunologie. De kinder- en jeugdpsychiatrie is misschien niet het meest voor
de hand liggende specialisme om een samenwerking met de immunologie te
zoeken. Toen ik echter op een dag bij Piet Limburg aanklopte met de vraag of
de D8/17 test in zijn laboratorium uitgevoerd kon worden, kwam hij
weliswaar met een aantal (terecht) kritische vragen, maar was hij zonder
formaliteiten bereid de eerste metingen te verrichten. Piet stond aan de basis
van de laboratoriumtechnieken die geleid hebben tot de hoofdstukken 3 tot en
met 6. De uitvoering van de proeven lag in de vertrouwde handen van Johan
Bijzet en Gerda Horst. Johan en Gerda waren altijd hulpvaardig, snel,
enthousiast en nauwkeurig. Bovendien zijn ze gewoon erg aardig! Bijzonder
prettig vond ik daarnaast de begeleiding door Cees Kallenberg, mijn tweede
promotor. Cees gaf me het gevoel niet te hoeven twijfelen aan de haalbaarheid
van het project en was daarnaast altijd heel goed bereikbaar voor kleine of
grote vragen. Hij heeft bovendien alle hobbels weggenomen bij het opzetten
van het IVIG onderzoek dat beschreven staat in hoofdstuk 10. Verder begrijp
ik nog steeds niet waar Cees de tijd vandaan haalt om steevast zo snel en
nauwkeurig op de manuscripten te reageren.
Ook begeleiders buiten de promotiecommissie zijn in belangrijke mate bij
het promotietraject betrokken geweest. Erg prettig vond ik de samenwerking
met Jaap Korf en de mensen op de zevende verdieping van het grote
psychiatrie gebouw. Mijn speciale dank gaat daarbij uit naar Willy Krop. De
kynurenine- en tryptofaanmetingen van hoofdstuk 7 zijn op het laboratorium
van George Anderson verricht. Ik heb de samenwerking met hem als erg
prettig en inspirerend ervaren. Door de hulp van Willem Manson kon ik ten
behoeve van hoofdstuk 8 zonder problemen in korte tijd enige honderden
keelswabs laten bepalen. Bovendien introduceerde hij me op het
streeklaboratorium, waar de antistreptokokkentiters bepaald zijn. Zeer goede
ervaringen had ik verder met Ido Kema en zijn laboratoriummedewerkers.
Menno Oosterhoff heeft me door zijn rijke klinische inzichten warm gemaakt
voor het syndroom van Gilles de la Tourette. Ook de contacten rond het
onderzoek met Hans den Boer waren altijd uiterst aangenaam. Via Hans
kwam ik in contact met Marjan Nielen. Marjan en ik hebben op een heel
constructieve en gezellige manier samen in korte tijd veel OCD patiënten aan
de verschillende onderzoeken laten meedoen. De leden van de
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beoordelingscommissie bedank ik voor het nauwkeurig doornemen van het
manuscript.
Veel dank ben ik verder verschuldigd aan het personeel van het
dagcentrum interne geneeskunde en kindergeneeskunde van het AZG voor de
zorgvuldige, flexibele en prettige wijze waarop het IVIG onderzoek van
hoofdstuk 10 verlopen is. Diverse onderzoeken hebben ook veel baat gehad
bij de geweldige inzet van de medewerkers van het priklab van de
gynaecologie van het AZG en van het huisartsenlaboratorium in Utrecht. Bij
Kiki Bugter en Elly Harmannij klopte ik nooit tevergeefs aan, met welke
kwestie ik ook zat. Heel veel dank! Koos Brander wist in situaties van
tijdsnood zonder problemen grote hoeveelheden post de deur uit te krijgen.
Nathalie Blokzijl en Neeltje Valkhof dank ik voor het invoeren van gegevens
in de SPSS bestanden. Financieel werd het onderzoek mogelijk gemaakt door
bijdragen van het AZG, de medische faculteit, de PCK en van Baxter. Vooral
Rob de With van Baxter wil ik dank zeggen voor zijn zeer gewaardeerde inzet
voor het IVIG onderzoek in goede samenwerking met Gea Olsder van de
apotheek van het AZG.
Een met recht onmisbare bijdrage hebben de deelnemers aan de
onderzoeken geleverd. De fantastische en trouwe inzet bij de diverse
onderzoeken en de prettige wijze van samenwerking behoren tot mijn
blijvende herinneringen aan het promotietraject. Bij de werving van de
patiënten heeft de Stichting Gilles de la Tourette een cruciale rol gespeeld.
Bijzondere dank gaat uit naar Gijs Slootweg voor de verzending van enorme
hoeveelheden oproepen onder grote tijdsdruk.
Hoewel het onderzoek op diverse plekken plaatsvond, bleef toch het
academisch centrum voor kinder- en jeugdpsychiatrie mijn vertrouwde
thuisbasis. Ik had en heb daar altijd een geweldige tijd, dankzij een aantal zeer
gewaardeerde collega’s, in een aantal gevallen leidend tot ‘iets wat een aanzet
zou kunnen zijn tot een beginnende vriendschap’. In de eerste plaats denk ik
hierbij aan mijn geweldige paranimfen Barbara van den Hoofdakker en Pieter
Troost, die zowel binnen als buiten de werkvloer veel voor mij betekenen.
Erik Mulder hielp menig probleem uit de wereld en was altijd in voor een kop
koffie. Ik had me geen betere buurman op de kinder- en jeugdpsychiatrie
kunnen wensen! Veel steun en gezelligheid kreeg ik ook van Mark-Peter
Steenhuis, Lianne van der Veen en Natasja van Lang. Sommige van de
collega’s hebben ook een actieve bijdrage aan het onderzoek geleverd. Pieter
Troost heeft in het kader van het D8/17 onderzoek diverse patiënten
gediagnosticeerd, zowel in Groningen als in Utrecht. Mark-Peter Steenhuis
heb ik bereid gevonden om meer dan eens de trein van 6.18 uur naar Utrecht
te nemen, om daar in korte tijd een grote hoeveelheid patiënten te zien. Ook
dank ik de collega’s van mijn huidige werkplek, de volwassen psychiatrie van
het AZG, voor alle steun en belangstelling tijdens de laatste fase van het
werken aan het proefschrift.
Veel heb ik daarnaast ook te danken aan vrienden. Ik wil met name Onno
de Klerk noemen voor zijn niet aflatende steun en belangstelling. Ook mijn
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naaste familie, vader Jan, mijn zussen Rina en Gerry en broer Eelco waren
altijd erg geïnteresseerd en betrokken. Eindelijk is het proefschrift dan af! Ik
ben er dankbaar voor dat ik mijn moeder nog heb kunnen vertellen dat ik een
mooi onderwerp voor het promotietraject te pakken had, met alle vertrouwen
in een goede afloop.
Andrea heeft, zoals dat heet, alle pieken en dalen van het onderzoek van
nabij meegemaakt. Haar rol was echter veel groter dan een van emotionele
steun. Zonder dat ze het zelf altijd door had, heeft ze mij op een aantal uiterst
cruciale punten in het onderzoek op de juiste aanpak gewezen. Verder was het
mij alleen nooit gelukt, het boekje zo mooi vorm te geven. Heel veel dank
voor dit alles! Ik hoop dat ik ook iets kan betekenen voor haar eigen
proefschrift.
